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ABSTRACT 
Tuberculosis (TB) causes disease worldwide and multi-drug resistance is rising. 
Matrix metalloproteinases (MMPs) cause immunopathological lung matrix 
destruction, which results in transmission, morbidity and mortality. Collagen is the 
primary structural fibril of the lung and I primarily studied two collagenases: secreted 
MMP-8, and membrane bound MMP-14, and also the stromelysin MMP-10, which 
activates not only MMP-8 but another collagenase MMP-1. 
 
 Human monocyte and macrophages were stimulated with Mtb H37Rv, BCG, ESAT-
6 peptides or Conditioned Media from Mtb infected monocytes (CoMTb). MMP 
concentrations were measured by Luminex bead array and ELISA.  Gene expression 
was quantified by RT-PCR. Immunohistochemistry was performed on biopsies. Flow 
cytometry quantified MMP-14 expression. Fluorescent microscopy detected MMP-14 
and monocyte driven fluorescent collagen degradation. Monocyte migration was 
measured by the agarose spot assay.  
 
MMP-8 was increased in the plasma in TB compared to both respiratory 
symptomatics and controls (both p<0.001).  MMP-10 was increased in the 
respiratory secretions of patients with TB compared to controls (p<0.05). Mtb drove 
up to a 31.5 fold increase in MMP-10 secretion from macrophages (both p<0.001). 
Mtb caused 3.5 fold more MMP-10 secretion from macrophages than BCG (p<0.001) 
and a specific peptide from ESAT-6 drove MMP-10 secretion from macrophages. In 
induced sputum, MMP-14 mRNA was increased 3.3-fold in TB compared to controls 
and positively correlated with infiltration on chest radiograph (both p<0.05). 
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Macrophages of TB granulomas in biopsies stained strongly positive for MMP-14. 
Mtb increased monocyte MMP-14 surface expression 31.7-fold (p<0.05) and CoMTb 
17.5-fold (p<0.01). Mtb infected monocytes degraded collagen, with co-localised 
MMP-14 surface expression.  Monocytes migrated to the edge of CoMTb 
impregnated agarose drops, expressing MMP-14 on migration. Inhibition of  MMP-14 
activity with a neutralising antibody, decreased Mtb driven collagen degradation by 
73% (p< 0.001) and CoMTb driven monocyte migration by 44% (p<0.001).  
 
These data shows that, MMP-1, -8, -10 and -14 cause immunopathology and 
regulate leukocyte migration in TB. 
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1. INTRODUCTION 
1.1 The Global Tuberculosis Epidemic 
 
Tuberculosis (TB) is the second biggest killer among infectious diseases. The 
causative agent is Mycobacterium tuberculosis (Mtb). In 2011 it caused 8.7 million 
new cases and 1.4 million deaths worldwide.  This includes 310,000 cases of 
multidrug resistant TB (MDR-TB) and 84 countries reported extensively drug 
resistant TB (XDR-TB) [1]. Of great concern are the reports of “totally drug resistant 
TB” in Iran, India and South Africa [2-4]. In the UK there were 8693 new cases in 
2011, with MDR cases rising from 0.6% in 2000 to 1.6% [5].  
 
The majority of all TB occurs in low and middle income countries in Africa, Asia, 
Eastern Europe and Central/ South America [1]. In these resource challenged 
settings, it is difficult to implement the long treatment regimes. These stand at a 
recommended 6 months for drug sensitive and 18 - 24 months for drug resistant TB 
[6]. Treating drug resistant TB is expensive and complicated, involving drugs with 
serious side effects and limited efficacy [7]. Therefore there is an urgent need for 
new drugs which shorten treatment duration for both drug sensitive and resistant TB.  
 
To develop new therapeutic approaches it is critical to understand underlying 
mechanisms of disease. Tissue destruction is characteristic of tuberculosis and is a 
consequence of immunopathology driven by the host response to Mtb. Within the 
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lungs pulmonary extracellular matrix (ECM) breakdown causes cavitation, which 
leads to morbidity, mortality and increased transmission. Research within our group 
and in my thesis has focussed on the roles of a group of enzymes known as matrix 
metalloproteinases (MMPs) in tissue destruction and immunopathology in TB.  
 
1.2 The Pathogen 
 
Mycobacterium tuberculosis (Mtb) was identified as the causative agent of 
tuberculosis in 1882 by the German scientist Robert Koch. It is a member of the 
Mycobacterium tuberculosis complex of organisms which cause human disease and 
bovine tuberculosis. This also includes Mycobacterium africanum, Mycobacterium 
bovis, Mycobacterium microti, and Mycobacterium canetti. Mtb is an obligate 
intracellular pathogen and humans are the main host. It is an aerobic bacteria that 
replicates more easily in the lungs apices, potentially because oxygen content is high. 
Therefore most cases of TB are pulmonary, although it infects and causes disease in 
any organ. It has a characteristic mycolic acid rich cell wall which renders it resistant 
to decolourisation after staining or „acid fast‟. It divides extremely slowly once every 
15-20 hours which is the reason for the long duration of antimicrobial therapy 
required  [8]. 
 
 
Mtb has evolved mechanisms to evade intracellular killing including preventing 
phagosome maturation and acidification and inhibiting apoptosis while promoting 
necrosis. These have been important to the success of the organism [9]. 
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1.3 The Host Immune Response  
1.3.1 Innate immune response 
 
Mtb is inhaled and phagocytosed by alveolar macrophages, dendritic cells, 
neutrophils and monocytes. A range of mycobacterial antigens activate these cells to 
produce cytokines and chemokines which play important roles in enabling the 
immune system to control infection [10, 11]. Tumour necrosis factor alpha (TNFα) is 
a key cytokine for macrophage activation and the control of acute Mtb infection. Mtb 
infection is rapidly lethal with an associated high bacterial burden in TNFα deficient 
mice [12]. Interleukin 12 (IL-12) is vital to the subsequent adaptive immune response 
by driving T helper 1 (TH1) cells to produce interferon gamma (IFNϒ).  IL-12 
deficient mice show an increased bacterial burden and reduced survival [13]. 
Humans with mutations in the IL-12 gene or IL-12 receptor gene show a reduced 
IFNϒ response and increased susceptibility to non tuberculous mycobacterial 
infections [14].                            
 
1.3.2 Adaptive immune response 
 
The onset of adaptive cell mediated immunity is delayed in humans to approximately 
42 days after infection. Infected dendritic cells migrate to draining lymph nodes, and 
present mycobacterial antigens to naive T-cells. These differentiate into Mtb antigen 
specific TH1 cells which migrate to the site of infection in the lungs. The TH1 cells 
are further activated by IL-12 secreted by macrophages and produce IFNϒ.  IFNϒ  is 
a vital cytokine for activating macrophage killing mechanisms and controlling 
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infection [10, 11]. IFNϒ deficient mice are highly susceptible to Mtb infection [15] and 
humans with mutations in the IFNϒ or IFNϒ receptor genes develop severe 
mycobacterial infections [14].  
 
It is at this stage that the classical histopathological hallmark of tuberculosis forms. 
The granuloma has traditionally been considered to be a feature of the adaptive 
immune response. It has a central core of necrotic cells, surrounded by 
macrophages that have transformed into epithelioid cells, multinucleate giant cells 
and foam cells surrounded by a rim of T cells. Many other cell types including 
neutrophils, B cells, natural killer cells and fibroblasts are present and adjacent lung 
epithelial cells also participate in the immune response [16]. 
 
1.3.3 Progression to latent or active tuberculosis  
 
This initial infection is known as „primary tuberculosis‟ and after the onset of the 
adaptive immune response described above many humans will control but not 
eliminate the mycobacterial infection. These persons have latent TB and are 
asymptomatic and non-infectious. It is estimated that one third of the world‟s 
population harbours latent TB. In these individuals a Ghon complex can be identified 
in the lungs at post mortem with a subpleural calcified/ fibrotic focus of infection (the 
Ghon focus) and an associated lymph node. The status of the bacteria within 
macrophages in the Ghon complex during latency is unclear though they remain 
viable [9, 11].  
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Reactivation of latent TB to cause active symptomatic disease („post primary  
tuberculosis‟ ) is highest in the first 9 years after infection especially in the 16-35 year 
age group with a strong tuberculin skin test response [17].  The reason for 
reactivation is generally considered to be waning immunity though the only clearly 
established examples are T helper cell defects in Human Immunodeficiency Virus 
(HIV) positive individuals and therapeutic neutralisation of TNFα with monoclonal 
antibodies . In some humans the initial immune response does not achieve control 
and acute active tuberculosis („primary progressive tuberculosis‟) ensues straight 
away.  This is more common in infants [11].  
 
In both TB due to reactivation or acute active disease the innate and adaptive 
immune responses will continue responding to the multiplying Mtb, and play an 
important role in causing the clinical presentation of disease [10, 11].  
 
A final necessary step for any microbe is to infect a new host. In active TB the Mtb 
bacilli achieve airborne transmission in respiratory droplets generated by coughing, 
which are then inhaled by the new host [11].  Cavity formation within the lungs 
greatly increases infectivity [18]. 
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1.4 The Clinical Disease 
1.4.1 Presentation 
 
The symptoms are those due to the systemic inflammatory response including fever, 
night sweats and weight loss and those due to localised inflammation in the lung 
including productive cough, haemoptysis, dyspnoea and chest pain [8].  
1.4.2 Diagnosis 
 
Microscopy for acid-fast bacilli (AFB) in  a sputum smear is the most widely used 
diagnostic method but sensitivity varies from 34–80% [19]. It is not specific as it does 
not distinguish Mtb from non-tuberculous mycobacteria. Sputum culture is much 
more sensitive and the current WHO recommendations are a liquid culture system 
which provides results within 4 to 13 days, including susceptibility testing to first line 
drugs. [20]. The Mtb gene amplification test (GeneXpert MTB/RIF) diagnoses 
pulmonary TB using sputum samples with a turnaround time of just 2 hours. It 
simultaneously gives a result for rifampicin resistance which is a surrogate marker 
for multidrug resistance [20, 21]. Much effort has been invested in identifying 
biomarkers that would be amenable to a simple dipstick test, providing an immediate 
result. Improving TB diagnostics remains a significant challenge and is a goal of the 
WHO STOP TB Strategy [22].  
 
Though not diagnostic in themselves, radiographic findings are often highly 
characteristic, with disease preponderance at the lung apices or the apical segments 
 18 
 
of the lower lobes. One series showed upper lobe infiltration in 86% and cavitation in 
55% of cases of newly diagnosed TB on chest radiograph [23].  
 
1.4.3 Antimicrobial therapy and drug resistance 
 
 Standard treatment for drug sensitive pulmonary tuberculosis is a 6 month regime 
consisting of 2 months of rifampicin, isoniazid, pyrazinamide and ethambutol 
followed by 4 months of rifampicin and isoniazid [6].  MDR-TB is defined as 
resistance to at least rifampicin and isoniazid, XDR-TB as resistance to rifampicin 
and isoniazid, any fluoroquinolone and one of the three injectable drugs, 
capreomycin, kanamycin and amikacin [1].  
 
The reasons for the emergence of drug resistance are multi-factorial. The duration of 
the treatment regime, even for drug sensitive disease, is prolonged at 6 months. In 
resource poor countries, where TB is endemic, health policies, regulation and 
enforcement can be weak. This results in antituberculous drugs being obtained 
without prescription, incorrect prescribing and poor adherence to treatment. The HIV 
epidemic may have contributed to the development of drug resistance by 
problematic drug interactions, reduced adherence due to a large number of 
medications and malabsorption. It has also resulted in an increased pool of 
individuals who are likely to progress to active TB after the initial infection rather than 
achieve control [7]. The consequences of drug resistance in resource poor settings 
with a high prevalence of HIV infection are catastrophic. In a rural area of South 
Africa sputum culture and drug sensitivity testing showed XDR-TB in 53 of 
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15patients. All of these patients were HIV positive and 52 of 53 died with a median 
duration of 16 days, well before they had even been diagnosed as having drug 
resistant disease [24]. 
 
The recommended treatment for MDR-TB is pyrazinamide with four second line 
drugs including a fluoroquinolone, an injectable agent, ethionamide or prothionamide 
and either cycloserine or para-aminosalicylic acid. Twenty months of therapy is 
advised. The treatment of XDR-TB is even more complex with individual tailoring. 
These drugs have unpleasant and serious side effects which make tolerance a 
problem [6].  
 
Identifying effective regimens of a shorter duration using existing drugs, and also 
producing agents with new mechanisms of action is therefore a priority. The REMox 
and OFLOTUB III trials compare the standard 6 month regimen to a 4 month 
regimen with moxifloxacin or gatifloxacin added. Bedaquiline (TMC207) is a 
mycobacterial ATP synthase inhibitor and Delamanid (OPC-67683) a nitroimidazole 
which inhibits mycolic acid synthesis. Both have been shown to improve sputum 
culture conversion at 8 weeks and are being considered for multidrug resistant 
disease [25].  
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1.5 The Negative Sequelae of Lung Damage 
As this research pertains to tissue destruction in TB, it is important to discuss the 
background evidence which shows that pulmonary cavitation is deleterious.  
1.5.1 Transmission 
 
Analysis of a large cohort of smear positive TB cases and their contacts showed that 
intravenous drug use, cavitatory disease on chest radiograph and a young age were 
significantly associated with generating secondary active TB cases including 
microepidemics (≥ 2 cases of active TB caused by the same index case) and 
potentially many more cases of latent TB [26]. In one particularly well investigated 
outbreak an index case with cavitatory pulmonary TB had 97 regular contacts at a 
public house he frequented. Using chest radiographs, tuberculin skin testing and 
DNA fingerprinting on isolates it was shown that in 6 months he had apparently 
infected 42% of these contacts with 14 cases of active TB (11 of the culture isolates 
underwent DNA fingerprinting and all had same chromosomal DNA restriction 
pattern as the index case) and 27 cases of latent TB [18].  
 
A key factor leading to the high infectivity of cavitatory TB is the high bacterial 
burden within a space which communicates directly with a bronchus [27]. A study 
measured pre-treatment sputum time to positivity (TTP) in pulmonary TB patients 
with a range of disease patterns. The BacT/ALERT 3D Mycobacteria detection liquid 
culture system was used, which is a semi quantitative measure of bacterial load with 
an inverse relationship between TTP and colony forming units. The presence of 
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cavitation on chest radiograph was associated with a significantly shorter TTP of 6.6 
days median, compared to 15.4 days if cavities were not present. In a subgroup 
analysis using CT chest, those who had 4-6 cavities had a significantly shorter TTP 
of 5.15 days median compared to 14 days in those with 1-3 cavities [28].  
 
A potential reason for this high bacterial burden was demonstrated by 
immunohistochemical analysis of resected lung in patients with treatment refractory 
TB.  Cross sections showed numerous mononuclear cells at the luminal surface of 
cavities with large numbers of intracellular bacilli present when compared to 
enclosed granuloma. These mononuclear cells stained CD68 positive indicating that 
they were macrophages. CD3, CD4, and CD8 T cells were scarce at the luminal 
surface of cavities in comparison to enclosed granuloma where T cells and 
macrophages co-localised. The absence of T cell-macrophage interaction at the 
luminal surface of the cavity surface may result in impaired mycobacterial killing by 
macrophages [29].   
1.5.2 Morbidity and mortality 
 
The presence of extensive tissue destruction and cavitatory disease causes 
increased morbidity both during active infection and after resolution. In a group who 
underwent surgical treatment for tuberculosis related haemoptysis, cavitation on 
chest radiograph was present in 100% of massive haemoptysis cases and 92% of 
major haemoptysis cases, compared to only 21% of minor haemoptysis cases [30]. 
In an endemic area without surgical treatment or percutaneous embolisation, 
massive haemoptysis is difficult to control and can have a mortality rate approaching 
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50% [31]. The haemoptysis occurs because of a Rasmussen‟s aneurysm which is a 
bronchial artery aneurysm which forms within or next to the cavity [32].  
 
Analysis of a large cohort of patients with lung tissue destruction secondary to 
previous TB showed an average forced expiratory volume 49% predicted and forced 
vital capacity  61% predicted with an obstructive pattern in 76.8%. These findings are 
probably a consequence of fibrosis causing airways stenosis and poor compliance 
with distal airway collapse. Treatment with inhaled bronchodilators and 
corticosteroids lead to only small improvements in spirometry. Patients experienced 
acute exacerbations of their obstructive airways disease requiring emergency 
department attendance [33]. 
Unsurprisingly cavitatory disease is also a risk factor for mortality. An analysis of 
predictors of poor outcome in HIV negative patients treated for XDR-TB was 
performed where poor outcome included death in its definition. Cavitatory disease 
was an independent risk factor poor outcome. In the poor outcome group 79% had 
cavitatory disease on chest radiograph compared to 54% in the favourable outcome 
group [34]. 
1.5.3 Treatment failure and drug resistance 
 
Cavitatory disease is associated with slower response to treatment and an increased 
risk of treatment failure and relapse. A study of patients with pulmonary TB receiving 
directly observed therapy used weekly smear and a liquid mycobacterial sputum 
culture to enable accurate assessment of time to negativity. In patients with 
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cavitatory disease on chest radiograph the time to smear negativity was 48 days 
median, compared to 20 days in those without cavitatory disease. Culture time to 
negativity was 49 days median compared to 12. The use of culture was important as 
smear positivity may be caused by dead bacilli [35]. In a large cohort of HIV negative 
patients being treated for  fully sensitive Mtb, treatment failure or relapse occurred in 
9.5% of those with cavitatory disease on chest radiograph compared to 3.6% of 
those without cavitatory disease [36]. These findings may be due to the high 
bacterial burden present in cavitatory disease [28]  and subtherapeutic drug 
penetration into the damaged and fibrotic tissue of the cavity wall [27]. 
 
There is interesting evidence from studies using resected tuberculous cavities that 
cavitatory disease promotes the emergence of drug resistance mutations. 
Resistance occurs because of spontaneous chromosomal mutations at a rate of 10-6  
to 10-8 mycobacterial replications, therefore the high the mycobacterial load seen  
within cavities, has greater potential to drive resistance [37]. Again subtherapeutic 
drug penetration into the damaged and fibrotic tissue of the cavity wall may play a 
role [27]. In paired sputum and resected cavity tissue cultures in patients who 
underwent adjunctive surgical resection for MDR/XDR TB, additional drug resistance 
was found in the cavity in 37% of cases [38]. In an analysis of resected lung in 
patients with treatment refractory TB, sequence analyses revealed heterogeneity in 
the drug resistance patterns among Mtb isolates from different lung lesions in the 
same case. The additional mutations were seen in Mtb cultured from cavity surfaces 
where bacilli were numerous [29].  
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1.6 Tissue Destruction in Tuberculosis  
 
The French physician Rene´ Theophile Hyacinthe Laennec performed a series of 
autopsies on patients who had died of TB in the early 19th century and carefully 
described their pulmonary lesions including cavities [39] .  
 
“Whatever the form in which the tuberculous matter develops, it begins as a grey, 
semi-transparent matter that little by little becomes yellow, opaque, and dense. Then 
it softens, and slowly acquires a liquidity like pus, and, when it is expelled through 
the airways, it leaves cavities, commonly called ulcers of the lung, that we will 
designate as tuberculous excavations.” [39] 
 
Two centuries later, the exact mechanisms causing these cavities remain unclear, 
and are the subject of ongoing research and debate. One reason for this has been 
the lack of a suitable animal model of cavitatory pulmonary tuberculosis. Mice 
develop chronic fibrosis but do not develop caseous necrosis or cavitate. Guinea 
pigs and monkeys do develop caseous necrosis but this only variably leads to 
cavitation. Rabbits pre-sensitised with subcutaneous injections of heat killed M. bovis 
who then have M.bovis directly injected into the lungs reliably form cavities, but the 
same response is not seen with Mtb [40, 41].  
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It is clear that an immunopathological host response is at least partly responsible for 
cavitation. Patients with HIV have reduced numbers of T helper lymphocytes and a 
study showed that 32% of HIV positive patients had 1 or more zone with cavitation 
compared to 81% of HIV negative patients. The mean number of zones containing 
cavities was higher in HIV negative patients at 1.7 compared to 0.5 [42]. Reduced 
immune function is associated with aging and a  meta-analysis of 12 studies that 
compared pulmonary TB in older subjects and younger subjects showed that 
radiological cavitation and haemoptysis were more frequent in patients under 60 [43]. 
Studies in the 1960s showed that the M. bovis induced cavity formation in rabbits 
was attenuated by immunosuppressive agents such as azathioprine [44]. 
 
Because the caseating granuloma is a pathognomonic feature of Mtb infection 
theories have centred on this. The dogma suggests that immune cells, cytokines and 
lipids driving necrosis in TB, with cavities forming when caseating granuloma enlarge, 
undergo liquefaction and erode into bronchi [45]. However histopathological analysis 
of more than 100 cases of tissue sections from patients with untreated pulmonary TB 
from the pre-antibiotic era challenges this paradigm. Caseating granuloma were 
found in primary TB as the Ghon complex with calcified granulomas in the lung and 
hilar lymph nodes. However the histopathological features of post primary TB were 
very different. The upper lobes were predominantly involved. There was initially a 
lipoid pneumonia phase with accumulation of foamy alveolar macrophages which 
degenerated to leave lipoid debris. This then proceeded to a caseous pneumonia 
phase with necrosis and swelling of the tissue involving the alveolar septa, vessels 
and bronchi. These areas then softened and fragmented and were coughed up to 
leave cavities. No caseating granuloma were observed in the lungs of any of the 
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cases, nor was there any evidence that cavities form by erosion of caseating 
granuloma into bronchi [27]. 
 
1.7 Matrix Metalloproteinases  
 
When considering the histopathological findings in pulmonary TB, discussed in the 
previous section, the composition of lung tissue must be borne in mind. The lung has 
ECM components which support the alveoli, conducting airways and vascular tree. 
The most abundant macromolecules in the pulmonary ECM are Type I, II and III 
collagen and these are the primary structural fibrils of the lung. They have a fibrillar 
triple helical structure which provides the tensile strength of the lung. Second is 
elastin which is rubbery in nature and has a randomly oriented polymerised structure. 
It allows the lung to recoil after inspiration. Fibronectin and laminin are glycoproteins 
which are crucial in mediating the interactions between the alveolar epithelial cells, 
vascular endothelial cells, fibrillar collagens and elastin. They not only act as ligands 
for cell surface receptors, but also carry binding sites for the other ECM components. 
Laminin and the non-fibrillar type IV collagen are key components of the basement 
membrane. Proteoglycans are heavily glycosylated proteins which form large 
complexes binding together other extracellular matrix components [46].  
 
 
It is apparent that proteolysis of all of the pulmonary extracellular components 
described above would be a necessary pre-requisite for the destruction of lung tissue 
that occurs in cavitation. This implicates a group of enzymes known as matrix 
metalloproteinases (MMPs), which are collectively able to degrade all components of 
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the ECM including the basement membrane. An aetiological role for MMPs in tissue 
destruction and cavitation in TB can therefore be predicted. 
 
The MMPs are a family of zinc dependent proteolytic enzymes, which are either 
secreted or membrane bound. There are 23 MMPs in total in humans and they are 
classified based on domain organization and substrate preference, into collagenases, 
gelatinases, stromelysins, membrane-type (MT)-MMPs and others. They share 
common structural features. There is a signal peptide that targets them for secretion, 
a prodomain which interacts with the catalytic domain to maintain latency, and a 
carboxy terminal hemopexin domain which confers substrate specificity.  The 
membrane bound MMPs have an additional transmembrane domain and cytosolic 
tail. An interaction between a zinc ion in the catalytic domain and a thiol group of a 
cysteine residue in the prodomain maintains the enzyme in the inactive state. For 
secreted MMPs activation occurs extracellularly by proteolytic cleavage of the 
prodomain or modification of the cysteine thiol residue („cysteine switch‟). For 
membrane bound MMPs, activation occurs intracellularly by furin like pro-protein 
convertases.  They all have a furin recognition sequence RX[R/K]R at the C-terminus 
of the propeptide. They are therefore activated intracellularly and active enzymes are 
likely to be expressed on the cell surface [47, 48]. 
 
The MMPs and their many substrates are shown in Table 1. These include 
transmembrane proteins, latent cytokines, protease inhibitors and pro-MMPs in 
addition to ECM components [49-52]. The collagenases MMP-1, MMP-8, MMP-13 
cleave triple helical interstitial collagens I, II and III. The gelatinases  MMP-2 and 
MMP-9  cleave  gelatin and  digest the basement membrane type IV collagen, but 
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not the interstitial collagens I, II and III. The stromelysins MMP-3, MMP-10 and 
MMP-11 digest fibronectin, laminin, proteoglycans and the basement membrane 
type IV collagen, though not the interstitial collagens. MT-MMPs in humans  include 
four type I transmembrane proteins  MMP-14, -15, -16, and -24  and two 
glycosylphosphatidylinositol-anchored proteins  MMP-17 and -25.  All MT-MMPs, 
except MMP-17, cleave proMMP-2 to the active form. MMP-14 degrades interstitial 
collagens I, II, and III. Other MMPs fall into a miscellaneous group and include the 
matrilysin MMP-7 and macrophage metalloelastase, MMP-12 [47, 48].  
 
 
MMPs play a range of physiological roles. For example, in tissue repair they are 
important in ECM remodelling and cell migration.  In immunity, they are involved in 
cell migration, intercellular signalling and cleavage of chemokines and cytokines.  
However in excess they are pathological and are implicated in a range of disease 
involving uncontrolled ECM destruction and tissue remodelling, notably cancer and 
arthritis [47, 49]. 
Because of the potential for excessive activity to be pathological, MMPs are tightly 
regulated at many levels. Control primarily occurs at the level of gene expression, 
pro-enzyme activation and enzyme inactivation or compartmentalisation. Enzyme 
inactivation is mainly mediated by Tissue Inhibitor of Metalloproteinases (TIMPs). 
These bind MMPs in a one to one fashion and the ratio of MMPs to TIMPs plays a 
major role in the fine balance between physiological ECM turnover and the 
excessive degradation present in disease [49, 53]. There are four TIMPs -1, -2, -3 
and -4. They contain an N-terminal and a C-terminal subdomain. The TIMPs inhibit 
all the MMPs, though TIMP-1 is a poor inhibitor for MMP-14, MMP-16, MMP-19  and 
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MMP-24. The TIMP molecule is wedge shaped and slots into the active site of the 
MMPs. The catalytic zinc atom is chelated by an N-terminal amino group of four 
residues: Cys1-Thr- Cys-Val4 and the carbonyl group of Cys1 displaces a water 
molecule that is bound to the zinc atom, rendering the MMP inactive [48].  
 
 
A range of MMPs and TIMPs are expressed by cells of the monocyte/macrophage 
lineage, neutrophils, T-cells, pulmonary epithelial cells and pulmonary fibroblasts 
which are all cells present at the site of infection in pulmonary TB [53, 54]. Therefore, 
MMP expression may be both cell type and stimulus dependent. 
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Table 1: MMP subdivisions by substrate specificity 
Enzyme 
 
Other names Substrates Activates 
Collagenases 
 
   
MMP-1 Collagenase-1 
(Interstitial 
collagenase, 
fibroblast 
collagenase) 
Collagen I, II, III, VII, VIII, 
X, gelatin, proteoglycans, 
L-selectin 
 
α2-macroglobulin, latent 
TNF 
MMP-2 
MMP-8 Collagenase-2 
(Neutrophil 
collagenase) 
Collagen I, II, III, VII, VIII, 
X, gelatin, proteoglycans, 
fibronectin, laminin 
 
α2-macroglobulin 
ND 
MMP-13 Collagenase-3 
(Rat 
collagenase) 
Collagen I, II, III, IV, IX, X, 
XIV, gelatin, 
proteoglycans, fibronectin, 
laminin 
MMP-2, -9 
Gelatinases 
 
   
MMP-2 Gelatinase A 
(72-kDa 
gelatinase) 
Gelatin, collagen IV, V, 
VII, X, XI, XIV, 
proteoglycans, fibronectin, 
laminin, elastin 
 
 α2-macroglobulin, latent 
TNF  
MMP-9, -13 
MMP-9 Gelatinase B 
(92-kDa 
gelatinase) 
Gelatin, Collagen IV, V, 
VII, X, XIV, proteoglycans, 
fibronectin, elastin, fibrin 
 
α1-antitrypsin, α2-
macroglobulin, latent TNF, 
latent TGF-β1, latent 
VEGF 
ND 
Stromelysins    
MMP-3 Stromelysin-1 
 
Collagen IV, V, IX, X, 
gelatin, proteoglycans, 
fibronectin, laminin 
  
Latent TGF-β 
MMP-1, -8, -9, -13 
MMP-10 Stromelysin-2 Collagen III, IV, V, gelatin, 
proteoglycans, fibronectin, 
elastin 
MMP-1, -7, -8, -9 
MMP-11 
 
 
Stromelysin-3 fibronectin, laminin 
 
α1-proteinase inhibitor 
ND 
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Membrane type    
MMP-14 
 
 
 
MT1-MMP Collagen I, II, III, gelatin, 
preoteoglycans,  
fibronectin, laminin, fibrillin 
MMP-2 
MMP-15 MT2-MMP Proteoglycans, fibronectin, 
laminin, fibrin 
MMP-2 
MMP-16 MT3-MMP Gelatin, casein, fibrin 
 
Syndecan-1 
MMP-2 
MMP-17 MT4-MMP Gelatin 
 
Latent TNF 
ND 
MMP-24 MT5-MMP ND MMP-2 
MMP-25 MT6-MMP 
 
ND MMP-2 
Others    
MMP-7 Matrilysin Collagen IV, gelatin, 
stromelysins,  fibronectin, 
laminin, elastin 
 
Pro-α defensins 
FAS ligand, latent TNF, 
syndecan-1, E-cadherin, 
MMP-3 
MMP-12 Metalloelastase Collagen IV, gelatin, 
stromelysins,  fibronectin, 
laminin, fibrillin, elastin,  
 
Latent TNF, α1-antitrypsin 
ND 
 
ND – not delineated 
Modified from Parks et al[49], Kahari et al [50], Chandler et al [51] and Ashworth et al 
[52] 
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1.8 Matrix Metalloproteinases and Emphysema 
 
Before discussing the existing evidence relating to MMPs in TB it is appropriate to 
discuss the evidence for their role in another tissue destructive pulmonary disease, 
emphysema. These studies lend weight to the data suggesting a role for MMPs in 
pulmonary TB, and findings from both animal and human studies are presented. 
 
Emphysema is defined as the enlargement of peripheral air spaces of the lung, 
accompanied by destruction of the walls of these structures. The hypothesis that this 
process results from an imbalance of proteases and their inhibitors arose from the 
finding that severe alpha 1 antitrypsin (AAT) deficiency is associated with the 
development of emphysema in humans in the context of cigarette smoke exposure. 
AAT is the main inhibitor of neutrophil elastase and instillation of human 
 
n neutrophil elastase into ex vivo canine lungs produced anatomical emphysema, 
supporting the hypothesis. Subsequent immunohistochemical staining of the lungs 
demonstrated the presence of this elastase within the connective tissue in close 
proximity to elastase fibres [55].  
 
Subsequent animal and humans studies suggest a role for not only the elastolytic 
activity of MMP-9 and MMP-12, but also the collagenolytic activity of MMP-1, in the 
pathogenesis of emphysema.  
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1.8.1 Matrix metalloproteinase 1 
 
Transgenic mice expressing human MMP-1 in their lungs developed histological 
changes very similar to human emphysema but the control littermates did not [56]. 
Further mice studies used three types of transgenic mice with differing temporal 
MMP-1 expression. Early MMP-1 expression from 14 days post conception resulted 
in emphysematous changes at 5 days of age. Delayed expression to between birth 
and 2 weeks of age caused emphysema from 4 weeks of age. A very low expression 
delayed the emphysema to 1 year of age. The emphysema was associated with 
decreased immunohistochemical staining for type III collagen [57]. Smoke exposure 
in guinea pigs caused emphysematous changes. Immunohistochemical analysis 
revealed MMP-1 in the macrophages, alveolar walls and interstitium. The 
emphysematous lungs showed increased collagenolytic activity and reduced 
collagen content compared to controls not exposed to smoke [58].  
 
In human alveolar macrophages taken from patients with emphysema and 
maintained in vitro there was increased MMP-1 mRNA expression and increased 
collagenolytic activity in the supernatant compared to healthy controls [59]. 
Immunohistochemical analysis of human emphysematous lungs showed that MMP-1 
was present in the macrophages and epithelial cells of the patients but not healthy 
smokers [60]. MMP-1 mRNA, protein and collagenolytic activity was identified in the 
lung of emphysema patients who had stopped smoking but not healthy controls. The 
MMP-1 protein was expressed in alveolar epithelial cells of the patients but not 
healthy smokers [61].  
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1.8.2 Matrix metalloproteinase 9 
Transgenic mice expressing human MMP-9 in macrophages developed emphysema 
with a loss of alveolar elastin, but not control littermates [62].   
 
Stimulation of alveolar macrophages from patients with emphysema with cigarette 
smoke resulted in greater MMP-9 secretion than in healthy smokers [63]. In alveolar 
macrophages taken from patients with emphysema and maintained in vitro there was 
increased MMP-9 mRNA expression and increased secretion in the supernatant 
compared to healthy controls [59]. Immunohistochemical analysis showed that MMP-
9 was present in the neutrophils of human emphysematous lungs but not in healthy 
smokers [60].  In humans with AAT deficiency and emphysema, higher baseline 
plasma MMP-9 levels were associated with poorer lung function and exercise 
capacity. Baseline plasma MMP-9 levels also predicted the development of 
worsening emphysematous changes on computed tomography and air trapping on 
pulmonary function testing [64].  
1.8.3 Matrix metalloproteinase 12 
 
MMP-12 deficient mice did not develop emphysema in response to cigarette smoke 
exposure though wild type litter mates did [65].  
 
MMP-12 levels were higher in the induced sputum of patients with emphysema than 
in healthy current and ex smokers [66]. A high proportion of patients with severe 
emphysema are homozygous for the A/A allele of rs652438 in MMP-12. In cells 
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transfected with rs652438 A and G alleles, mean MMP-12 activity was higher for the 
A allele than the G allele. Increased emphysematous changes on CT were present 
for A/A homozygotes compared to G/G homozygotes [67]. 
 
 
1.9 Matrix Metalloproteinases and Tuberculosis 
 
Accumulating evidenced implicates MMPs in tissue destruction in TB, with this being 
the central theme of our group‟s work. Key data has come from studying both direct 
infection and the networking interactions between different cell types.   The Mtb 
induced intercellular network is mimicked by stimulating cells with Conditioned 
medium from Mtb infected monocytes (CoMTb). The number of mycobacteria in 
granulomas is low [68] and interactions between cells via cytokine, chemokine and 
growth factor secretion are important to cellular activation within the granuloma. 
CoMTb is rich in this cytokine, chemokine and growth factor milieu as well as Mtb 
antigens, but not live Mtb bacilli.  
1.9.1 Pulmonary tuberculosis 
 
 
The first study of MMPs in TB was relatively small. It showed that lipoarabinomannan 
(LAM, a lipoglycan cell wall component and major virulence factor in Mtb) 
upregulated MMP-9 mRNA and increased MMP-9 secretion from monocytic THP-1 
cells. LAM also upregulated MMP-1 mRNA in both THP-1 cells and peripheral blood 
monocytes.  Bronchoalveolar lavage (BAL) on 2 patients with active Mtb showed that 
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MMP-9 mRNA was upregulated [69]. Research in this field has steadily grown since, 
and the published data will be discussed in detail.  
Tissue destruction and cavitation are not a feature of pulmonary vaccine Bacillus 
Calmette-Guérin (BCG) infection, which causes a pulmonary pneumonitis with non 
caseating granulomas [70]. Mtb, but not BCG, significantly upregulated MMP-1 gene 
expression and secretion from human macrophages. Therefore only the pathogen 
which causes disease where collagen destruction is present drives expression of the 
collagenase MMP-1. TIMP-1 gene expression and secretion from macrophages was 
not upregulated by Mtb. Immunohistochemistry from lung biopsies of patients with 
active TB showed that macrophages express MMP-1 in areas adjacent to tissue 
destruction [71].  
 
Macrophages are not the only key cells producing MMPs in TB, and stromal cells 
may be equally important.  For example, CoMTb upregulated human pulmonary 
epithelial cell MMP-1 and MMP-9 gene expression and secretion. In lung biopsies of 
patients with active TB, MMP-9 was expressed in pulmonary epithelial cells adjacent 
to but not distant from granulomas [72, 73].  Fibroblasts are also important sources 
of MMPs, and CoMTb drives MMP-1 and MMP-3 gene expression and secretion 
from human pulmonary fibroblasts, and reduces TIMP-1 gene expression and 
secretion [74, 75].  
 
From the cellular data and immunohistochemical findings, it can be proposed that 
Mtb drives a matrix degrading phenotype of MMP activity unopposed by TIMPs in 
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human pulmonary TB. This is both by direct infection of macrophages and by an Mtb 
induced intercellular network stimulating epithelial cells and pulmonary fibroblasts.  
This proposal is further supported by more recent data from mouse and human 
studies. As discussed earlier animals do not provide good models for cavitatory TB, 
therefore studying patient samples is important. Mice do not express a pulmonary 
MMP-1 ortholog, therefore transgenic mice expressing human MMP-1 were studied. 
Mtb infected transgenic, but not Mtb infected wild type mice, showed alveolar wall 
destruction and collagen degradation in areas of macrophage infiltration [76]. MMP-1 
and MMP-3 in bronchoalveolar lavage and induced sputum of patients with 
pulmonary TB were elevated in comparison to controls while TIMP-1 and TIMP-2 
were suppressed. The MMP-1 in the sputum was proteolytically active on casein 
zymogram, and levels positively correlated with more extensive inflammation on 
chest radiograph. When Ro32-3555, a collagenase inhibitor of proven safety in man, 
was co-incubated with Mtb infected human macrophages, it abrogated MMP-1 
activity on casein zymography completely [76]. This provides good evidence for 
MMP-1 as a central effector in matrix degradation in pulmonary TB and raises the 
possibility of a therapeutic role for Ro32-355. 
 
To further elucidate the role of MMPs in driving tissue destruction in pulmonary TB in 
vivo, MMPs were measured in the induced sputum of a cohort of HIV negative and 
positive patients with pulmonary TB compared to controls. Comparing MMP levels in  
HIV negative and positive patients was considered an interesting line of investigation, 
as HIV positive patients with TB exhibit less tissue destruction and rarely develop 
cavities even in advance disease. MMP-1, -2, -3, -8 and -9 were elevated in TB 
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overall, but were lower in the HIV positive patients relative to HIV negative patients 
with TB. MMP-1 and MMP-2 correlated with the extent of tissue destruction on chest 
radiograph and were higher in patients with cavities.  These findings further 
implicate MMPs in tissue destruction in pulmonary TB [77].  
 
One interesting recent study suggests that a MMP-1 gene polymorphism is involved 
in the tissue destructive pulmonary TB phenotype. The -1607 MMP-1 allele 2G 
enhances expression of this gene in active TB. Hispanics expressing the 2 locus 
genotype MMP-1 2G/2G were more likely to have a tissue destructive pulmonary TB 
requiring surgical intervention, when compared to carriers of other genotype 
combinations that do not enhance MMP-1 gene expression to the same extent. They 
also had higher plasma levels of MMP-1 [78].  
 
Other data supporting a role for MMPs in pulmonary TB pathogenesis comes from 
microarray studies in humans and non-human primates, which though not 
specifically researching MMPs in their hypotheses provide valuable information. 
Monocytes from asymptomatic, cured patients with pulmonary TB and highly 
exposed individuals with latent TB were matured to macrophages and stimulated 
with Mtb H37Rv whole cell lysate. MMP-1 gene expression was upregulated 257 
times more in pulmonary TB relative to those with latent disease, suggesting that if 
an individual has a stronger macrophage MMP-1 gene expression response to Mtb 
this is associated with the outcome of active pulmonary disease [79]. Microarray 
analysis of  human pulmonary caseating granulomas and granulomatous lesions 
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from the lungs of Mtb infected non-human primates have showed increased 
expression of MMP-1, -2, -7, -9, -10 and –14 compared to normal lung tissue [80, 81].  
1.9.2 Central nervous system tuberculosis 
 
Tissue destruction is not only observed in pulmonary TB. Central nervous system 
(CNS) TB is particularly severe in its manifestations with marked inflammatory and 
tissue destructive changes present [82]. A body of evidence implicates MMPs in 
CNS TB also.  
 
CoMTb upregulated MMP-1 and MMP-3 gene expression and secretion in human 
microglia but did not alter TIMP-1 and downregulated TIMP-2 secretion. 
Immunohistochemical analysis of human brain biopsies showed MMP-1 and MMP-3 
staining at the centre of granulomas from patients with CNS TB, but no staining in 
controls. Dexamethasone reduces mortality in CNS TB [83], and steroids are 
protocol in CNS TB treatment [6]. Therefore it is particularly interesting that 
dexamethasone inhibited CoMTb driven microglial MMP-1 and MMP-3, but not 
TIMP-1 or TIMP- 2 secretion [84]. MMP-9 gene expression and secretion in human 
astrocytes was driven by CoMTb, but TIMP secretion was not. MMP-9 was 
expressed more abundantly in astrocytes in human brain biopsies from patients with 
CNS TB than in controls. Again dexamethasone inhibited astrocyte MMP-9, but not 
TIMP-1 or TIMP-2 secretion in response to CoMTb [85]. In vivo investigation 
revealed MMP-9 concentration in cerebrospinal fluid in tuberculous meningitis to be 
significantly higher than that in bacterial or viral meningitis. TIMP-1 was not elevated 
in the CSF in tuberculous meningitis [86].  
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From these findings in a cellular model and patient samples it can be proposed that 
an Mtb induced network of cytokines and chemokines stimulates microglial cells and 
astrocytes to drive a matrix degrading phenotype of MMP activity unopposed by 
TIMPs in human CNS TB.  
1.9.3 Granuloma formation 
 
Evidence from diverse lines of investigation are now implicating MMPs in non tissue 
destructive aspects of TB pathogenesis.  For example, in the zebrafish embryo 
model of granuloma formation, M marinum infected MMP-9 morpholinos formed 
fewer, smaller granulomas and had a lower bacterial burden. Morpholinos are 
synthetic antisense oligonucleotides which act to block initiation of translation or 
RNA splicing of the specific mRNA sequence [87]. This suggests that MMP-9 is 
important for macrophage recruitment in the wild type zebrafish. Region of difference 
1 (RD1) is a region present in the genome of Mtb and M.marinum which encodes 
virulence factors [88]. MMP-9 expression was reduced with M. marinum RD1 
deleted infection compared to wild type M. marinum, suggesting that such 
upregulation is RD1 virulence locus dependent [89].  
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1.10 Regulation of Matrix Metalloproteinase Expression  
 
An understanding of the control of MMP expression in TB is important to the future 
development of therapeutics. MMPs are regulated in multiple ways, but alteration of 
mRNA expression is the major mechanism controlling MMP activity. MMPs have 
differing promoter structures and can therefore vary in their response to cues, though 
shared elements can lead to co-expression. The MMP promoters contain consensus 
binding sites to numerous transcription factors, but NF-ĸB, AP-1, STAT, TCF/LEF, 
GC and Ets are prominent. A range of stimuli such as cytokines, chemokines, growth 
factors, microbial antigens, phagocytosis and mechanical stress act as stimuli. 
Through receptor binding, signal transduction pathways are activated and 
transcription factor promoter binding ensues, with resultant altered gene expression 
[47, 90].  
 
As MMP-1 was the first MMP discovered, the factors altering its gene expression 
have been studied in the most detail. The mitogen activated protein kinase (MAPK) 
signalling pathway involves p38 kinases, extracellular signal related kinases (ERK) 
and c-Jun-N-terminal kinases (JNK) as signal transducers and the transcription 
factors NF-ĸB, AP-1 and STAT, and has been highlighted as playing  roles in 
response to varying stimuli in different cell types [47].  
 
Cell/tissue specific activation would appear to relate to the presence of specific 
signalling proteins and transcription factors in some cells and not others. For 
example the RUNX-2 transcription factor binding site in the MMP-13 promoter is 
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essential for its expression. However RUNX-2 protein is primarily found in 
chondrocytes, therefore MMP-13 expression is normally limited to cartilage and bone 
[91].   
 
The existing data on the control of MMPs in TB will be discussed, focusing not only 
on both extracellular stimuli and intracellular signalling cascades. 
1.10.1 Cytokines and chemokines 
 
 
Data showing that Mtb induced intercellular networks drive MMP secretion has been 
discussed. Cytokines and chemokines are key extracellular stimuli which activate 
the downstream signalling pathways which ultimately increasing mRNA levels. In an 
attempt to identify a „master‟ regulatory cytokine or chemokine, neutralising 
antibodies, recombinant cytokines/chemokines and chemical inhibitors have been 
applied to the cellular models. 
 
With respect to pulmonary TB, neutralisation of TNFα, but not IL-1β, decreased 
CoMTb and Mtb induced MMP-9 secretion from monocytes. Recombinant TNFα 
directly stimulated MMP-9 secretion from monocytes [92]. Recombinant Oncostatin 
M synergized with TNFα to stimulate human pulmonary fibroblast MMP-1 and MMP-
3 secretion, while suppressing secretion of TIMP-1 and TIMP-2. Stimulating 
pulmonary fibroblasts with these recombinant cytokines individually had no effect 
[74]. TNFα neutralisation suppressed CoMTb driven human pulmonary epithelial cell 
MMP-1 secretion [72]. Similarly it was critical to upregulation of MMP-9 secretion 
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from pulmonary epithelial cells, but neutralisation of interleukin 1 beta (IL-1β) and 
interleukin 6 (IL-6) had no effect t [73].  
 
Moving on to CNS TB, TNFα and IL-1β neutralisation in CoMTb, decreased MMP-9 
secretion from astrocytes, but recombinant TNFα and IL-1β alone or in combination 
had no effect [85]. Neutralisation of TNFα and IL-1β in CoMTb decreased MMP-1 
and MMP-3 secretion from human microglial cells [84]. Supplementing CoMTb with 
the critical T cell cytokine IFNϒ resulted in an increased secretion of MMP-9 and 
reduced TIMP-1 and -2 from astrocytes.  
 
Chemokine signalling and MMP expression has only been investigated for 
pulmonary TB. Pertussis toxin (PT) is secreted by the organism Bordetella pertussis 
and inhibits signalling through Gi protein coupled pathways [93]. Downstream effects 
include inhibition of immune cell chemotaxis in response to chemokines [94], as well 
as reduced expression of the chemokines themselves [95]. However a range of other 
ligands signal through G protein coupled receptors, so the effects of PT are not 
specific to chemokines [93]. PT inhibited CoMTb driven MMP-9 secretion in THP-1 
cells and enhanced the inhibitory effect of an anti-TNFα antibody. However 
investigation of the potential chemokines present in CoMTb causing this effect did 
not identify a specific mediator [92].PT significantly suppressed CoMTb driven MMP-
1 secretion from human pulmonary epithelial cells. Cholera toxin (stimulator of G 
protein coupled receptor signalling) in combination with TNFα significantly 
upregulated MMP-1 secretion compared to TNFα alone. However, as previously, 
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investigation of the potential chemokines present in CoMTb causing this effect did 
not identify a specific mediator [72]. 
 
These findings can be explained by studies in mice deficient for individual 
chemokines. These have indicated a high degree of overlap in this system and the  
absence of individual chemokines does not result in adverse outcomes in murine 
Mtb infection. This is a consequence chemokines receptors binding multiple ligands 
[96].  
Therefore it is apparent that the regulation of MMPs driven by Mtb induced 
intercellular networks is relatively complex and not mediated by a single cytokine or 
chemokine, but that they act in combination and synergistically. 
1.10.2 Pathogen related factors  
 
The manner in which Mtb drives lung pathology to  spread to new hosts is not a 
central theme of research within the field, with comparison between strains focusing 
more on cytokine responses and genetic differences[97].  The finding that Mtb but 
not BCG drives MMP-1 secretion from human macrophages is of particular interest 
as it indicates that a specific factor present in Mtb but not BCG drives MMP-1 
secretion. M bovis causes pulmonary infection rarely in comparison to Mtb but does 
cause cavitation [98], and as mentioned previously BCG may cause a pneumonitis 
but not cavitation [70]. It is possible that the pathogen specific factor is encoded in 
the RD1 region of the Mtb genome, which is absent in the BCG  genome [99]. As 
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mentioned previously RD1 encodes virulence factors, specifically 6kDa early 
secretory antigenic target (ESAT-6)  and 10kDa culture filtrate protein (CFP-10) [88].  
1.10.3 Mitogen-activated protein kinase signalling 
 
MAPKs are serine/threonine-specific protein kinases involved in cellular responses 
to a diverse extracellular stimuli regulating among many other responses gene 
expression. MAPKs are catalytically inactive until they undergo multiple 
phosphorylation events in their activation loops, conducted by specialised enzymes. 
In vitro and in vivo evidence indicates that activation of the MAPK pathway proteins 
by phosphorylation is a key cellular response to Mtb infection [100, 101]. This will 
lead to increased MMP expression by downstream transcription factor activation [47]. 
The MAPK pathways are schematically represented in Fig. 1.  
 
In pulmonary TB, CoMTb drives p38 MAPK phosphorylation in human pulmonary 
epithelial cells. Chemical inhibition of p38 MAPK signalling results in decreased 
CoMTb driven MMP-1 secretion from the epithelial cells [72].  CoMTb stimulated 
human pulmonary fibroblasts show p38 and JNK MAPK phosphorylation, which is 
also induced by recombinant TNFα, IL-1β and Oncostatin M (cytokines present in 
CoMTb). Chemical inhibition of p38 MAPK signalling, leads to decreased CoMTb 
driven MMP-1 secretion from the fibroblasts [75]. Mtb infection drives p38 and ERK 
MAPK phosphorylation in human macrophages. In patients with pulmonary TB, 
immunohistochemical analysis shows  p38 MAPK phosphorylation in macrophages 
surrounding granulomas. Chemical inhibition of p38 MAPK and ERK MAPK results 
in reduced MMP-1 secretion from Mtb infected macrophages [100].  
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With regard to CNS TB p38, ERK and JNK MAPK phosphorylation is stimulated in  
human astrocytes by CoMTb and reduced when IL-1β in the CoMTb is neutralised 
[102]. 
1.10.4 NF-ĸB, AP-1 and STAT-3 transcription factors 
 
The transcription factors Nuclear factor kappa B (NF-ĸB), Activator protein 1 (AP-1) 
and Signal transducer and activator of transcription 3 (STAT3) are implicated as 
those which control MMP expression in TB by the research to date. AP-1 is a 
heterodimeric protein composed of subunits c-Fos, c-Jun, ATF and JDP families. 
STAT-3 is a monomeric protein. AP-1 and STAT-3 enter the nucleus and bind to 
promoters upon phosphorylation. NF-ĸB is a family of dimeric transcription factors 
made from monomers including RelA, RelB, c-Rel, p50 and p52. It binds the  
inhibitor of kappa B family (IĸB). Translocation of NF-ĸB into the nucleus is 
controlled by phosphorylation and subsequent degradation of IĸB by IĸB kinase (IKK) 
[47, 103]. The NF-ĸB pathway is schematically represented in Fig. 2. The MAPK 
pathways have a clearly defined role in activating AP-1, but the mechanism of 
interaction with STAT and NF-ĸB signalling is less well defined [47].  
 
With regard to pulmonary TB, CoMTb drives STAT-3 phosphorylation in human 
pulmonary fibroblasts. STAT-3 phosphorylation is observed in fibroblasts of lung 
granulomas from patients with TB. Chemical inhibition of STAT- 3 phosphorylation 
downregulates CoMTb driven MMP-1 secretion [75].  
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In CNS TB, CoMTb drives increased NF-ĸB and AP-1 DNA binding in human 
microglia. Chemical inhibition of NF-ĸB reduced CoMTb driven MMP-1 secretion. 
Immunohistochemical analysis of brain granulomas from patients with TB shows 
nuclear p65 NF-ĸB in the granuloma centre but not in control brain tissue. Deletion of 
the NF-ĸB and AP-1 binding site resulted in reduced CoMTb driven MMP-1 promoter 
activation [84]. 
 
Dissecting the transcriptional regulation of MMPs in TB therefore represents an area 
where much further work needs to be undertaken. 
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Figure 1: MAPK signalling pathway  
Extracellular stimuli bind cell surface receptors and this triggers intracellular phosphorylation 
cascades. Separate cascades are responsible for the phosphorylation required for the activation of 
the p38, ERK and JNK MAPKs. In the final step the activated MAPKs phosphorylate substrates such 
as transcription factors (TF) in the cytoplasm. The phosphorylated transcription factor then enters the 
nucleus and initiates mRNA transcription.  
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Figure 2:  NF-ĸB signalling pathway 
NF-ĸB is a family of dimeric transcription factors made from monomers including RelA, RelB, c-Rel, 
p50 and p52. Extracellular stimuli bind cell surface receptors and this triggers intracellular 
phosphorylation of IKK which phosphorylates IĸB, causing it to dissociate from the NF-ĸB dimer. The 
NF-ĸB dimer can then enter the nucleus and initiate mRNA transcription.   
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1.11 Matrix Metalloproteinase 14 
The studies outlined above have focussed on secreted MMPs.  However, the 
membrane bound MMPs may also be of critical importance in TB and have possibly 
been overlooked due to the comparative difficulty in studying them.  MMP-14, a 
membrane bound collagenase, is already implicated in TB.  MMP-14 gene 
expression was upregulated in monocytes by direct Mtb infection [76] and in human 
lung TB granulomas [80].  Notably, MMP-14 has been shown to be critical to cell 
migration and invasion in the context of other disease processes [104-106]. 
 
1.11.1 Cell migration in granuloma formation and mycobacterial dissemination  
 
The granuloma has traditionally been considered a feature of adaptive immunity. 
However a granuloma is at its simplest an organised aggregate of macrophages.  
Recent studies have indicated that these can not only form in the context of innate 
immunity but are highly dynamic structures which may play a role in bacterial 
expansion and dissemination, rather than being purely protective for the host. 
Monocyte/macrophage migration is a key feature of this phenomenon [16].  
 
The optically transparent zebrafish embryo is a natural host for M. marinum infection, 
which is a close genomic relative of Mtb. The embryo lacks lymphocytes and an 
adaptive immune system but has macrophages. Using state of the art imaging, it is 
possible to visualise and monitor host-pathogen interactions in vivo [107]. 
Macrophages phagocytose M marinum immediately after injection and extravasate 
into tissues within 1 day, forming tight aggregates within 3 days. Infected and 
uninfected cells are present within the granuloma and have tightly opposed 
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membranes and indistinct cell boundaries indicating the formation of epithelioid and 
multinucleate giant cells [107].  
 
An in vitro 2D granuloma model confirms that macrophages alone form early 
granulomas in humans. Septarose beads covalently coated with Mtb purified protein 
derivative were inoculated with healthy human peripheral blood mononuclear cells. 
Microscopy showed that monocytes were recruited from day 1 aggregating at the 
bead surface, then lymphocytes from day 4 [108]. 
 
Further work in the zebrafish embryo model demonstrated that macrophages are 
necessary for the initial control of mycobacterial infection but subsequently promote 
bacterial expansion and dissemination into deeper tissues. Wild type and pu 1 
morphant embryos, which lack macrophages, were infected with M marinum into the 
hindbrain ventricle. Mycobacteria achieved higher burdens in pu.1 morphant 
embryos confirming the importance of macrophages in containing mycobacterial 
infection. However, while bacteria disseminated out of the hindbrain ventricle in 
more than half of the control morphants, none of the pu.1 morphants displayed any 
extraventricular bacteria. All extraventricular bacteria in the control morphants 
resided within macrophages. A significantly higher number of control embryos had 
extravascular bacteria compared to pu.1 morphants. All bacteria in the control 
embryos appeared to reside within phagocytes [109]. M. marinum infected 
macrophages in granulomas recruited uninfected macrophages. The newly arriving 
macrophages phagocytosed dying macrophages, allowing further bacterial growth. 
Some infected macrophages left the primary granuloma and seeded distal 
secondary granulomas [110].   
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Taken together, these experiments suggest that macrophage recruitment is a 
double-edged sword, necessary for initial control of infection, but also aiding 
proliferation and dissemination.  However, the key regulators of cell migration into 
granulomas have not been fully defined. 
 
1.11.2 Matrix metalloproteinase 14 and cell migration  
 
MMP – 14 (or Membrane Type 1 Matrix Metalloproteinase) was the first membrane 
type MMP (MT-MMP) characterised. It was described as an activator of MMP-2, 
which was present on the surface of invasive lung carcinoma cells, and enhanced 
invasion of a reconstituted basement membrane in vitro [111]. Its main activity is as 
a collagenase degrading types I, II and III collagen, but it also degrades other 
components of the ECM including proteoglycans, fibronectin and laminin [112]. As 
with all MMPs, careful regulation of its activity is required. In addition to control at the 
level of gene expression and pro-enzyme activation, mechanisms of post 
translational modification involve inhibition by TIMP-2 in particular (but not TIMP-1), 
autodegradation [113], and internalisation via caveolae and clathrin coated vesicles  
with cycling back to the cell surface [114].  
 
The ECM is a barrier to cell migration and must be degraded focally at the front of a 
cell if they are to migrate and propel forwards. The secreted MMPs exhibit a 
generalized  rather than focal matrix resorptive activity. MMP-14 is unique because it 
is a membrane bound type I collagenase. By localising at the leading cell edge it can 
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breakdown ECM  focally in the immediate pericellular environment thus promoting 
cell migration and invasion in a focussed manner [115]. Bearing this in mind, MMP-
14 has been implicated not only in physiological processes such as wound healing 
but also diseases such as rheumatoid arthritis and malignancy. The evidence comes 
from both in vitro models and clinical samples. 
 
In a seminal study, Madin-Darby Canine Kidney epithelial cells were cultured on a 
collagen matrix and were transfected to overexpress diverse MMPs. Only 
overexpression of MMP-14 caused significant acceleration of invasion of the cells 
into the matrix, with complete degradation of the collagen substratum, via a TIMP-2 
sensitive process [116].  
 
 
In another study, murine skin fibroblasts from specific MMP null mice were seeded 
on type 1 collagen. Subjacent collagenolysis was lost for only the MMP-14 null 
fibroblasts.  Plasminogen restored subjacent collagenolysis to the MMP-14 null 
fibroblasts, by mobilizing secreted MMPs. However the MMP-14 null fibroblasts 
would not invade into a type 1 collagen gel even in the presence of plasminogen. 
This shows that MMP-14, rather than the secreted collagenases, serves a dual role 
of breaking down and promoting cell migration through collagen [117].  
 
In a wound healing model of endothelial cell migration, which is required for 
angiogenesis, MMP-14 expression was present on the surface of migrating 
endothelial cells with localisation at motility associated structures. Neutralisation of 
MMP-14 activity inhibited endothelial cell invasion of collagen [118].  
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Local invasion of the joint cartilage by synovial pannus is a key finding in rheumatoid 
arthritis, and involves collagen degradation. Primary synovial cells were isolated 
from rheumatoid arthritis joints and specimens. Using western blotting and 
immunohistochemistry, it was shown that MMP-14 was highly expressed in primary 
synovial cells and the pannus cartilage junction. Synovial cell invasion into collagen 
matrix and cartilage was inhibited by TIMP-2 and adenoviral expression of a non-
functional MMP-14 [104].  
 
 
MMP-14 expression in a breast cancer cell line was knocked down by a retroviral 
ribozyme transgene causing reduced invasiveness  in vitro compared to wild type 
cells [105]. Gastric carcinoma and fibrosarcoma cell lines were transfected with 
siRNA to knock down MMP-14 expression. Migration of these cells through matrigel 
was reduced compared to controls [106].  In those  who died of breast cancer, 
significantly  higher levels of MMP-14 mRNA were present in the tumour in 
comparison to patients who were disease-free 10 years after the initial operation 
[105].  In another study of breast cancer the highest MMP-14 mRNA expression  
was in specimens where  lymph node metastasis and/or lymph vessel invasion was 
present [119]. 
 
Taken together, these studies all suggest a key role for MMP-14 in facilitating cell 
migration and invasion by matrix destruction at the leading edge of the cell. 
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Evidence from a zebrafish embryo model was presented earlier, which indicates that 
monocyte/macrophage migration may be key to bacterial expansion and 
dissemination in mycobacterial infection. For monocytes to migrate to the primary 
site of infection in pulmonary TB, they would have to transmigrate the endothelium, 
then traverse the basement membrane and pulmonary ECM by focal degradation of 
components along their migratory path. Pulmonary ECM degradation would similarly 
be necessary for monocytes/ macrophages to egress the primary granuloma. As 
type I collagen is the primary structural fibril of the lung focal, collagen degradation at 
the leading migratory edge of the monocyte would be required. A role for MMP-14 in 
this process can therefore be predicted. 
 
Monocytes were first shown to express fully active MMP-14 on their surface in 
response to lipopolysaccharide stimulation [120]. Immunofluorescence microscopy 
showed that MMP-14 neutralisation with an antibody inhibited  monocyte 
transmigration through endothelium  and MMP 14 clustering was observed at motility 
associated protrusions of the monocytes [121]. Immature dendritic cells from wild 
type and MMP-14 null mice were cultured on cross linked gelatin. Using conventional 
and fluorescent light and electron microscopy it was shown that the dendritic cells 
formed protrusions into and degraded the gelatin matrix and that the gelatin 
degradation was MMP-14 dependent [122].  MMP-14 neutralisation with an antibody 
inhibited the migration human immature monocyte derived dendritic cells through 
Matrigel [123]. Therefore MMP-14 activity has already been implicated in the 
migration and invasion of cells of the monocyte/macrophage lineage.  
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This evidence raises the interesting possibility that MMP-14 may be involved two of 
the fundamental immunopathological processes in Mtb infection that are  discussed 
above, namely cell migration and collagen destruction. The focal collagenolytic 
activity of MMP-14 expressed at the leading edge of migrating monocytes may be 
promoting migration of the cells, and therefore enhancing cellular recruitment, 
bacterial expansion and dissemination. But for cells that remain at a site of infection, 
MMP-14 expression throughout the monocyte/macrophage surface may be driving 
pericellular collagen breakdown and thus local tissue destruction. Therefore 
investigation of MMP-14 in TB is a potentially interesting new line of enquiry.  
 
1.12 Matrix metalloproteinase 10 
 
In a similar manner to MMP-14 being overlooked in TB due to relative difficulty of 
investigation, MMP-10 (stromelysin-2) may have not have been investigated due to 
lack of readily available reagents.  It is a secreted MMP and a stromelysin with 
enzymatic activity for cleaving fibronectin, laminin and proteoglycans, but not triple 
helical collagens I, II and III. It shares 85% amino acid sequence homology with the 
much more extensively studied MMP-3 (stromelysin-1) through its catalytic domain 
and they are very similar in structure and substrate specificity [124]. However the 
MMP-3 and MMP-10 gene promoters differ in the binding sites present, resulting in 
differential transcriptional regulation and tissue expression [90, 125, 126]. 
Furthermore while MMP-3 has a higher proteolytic efficiency, MMP-10 binds TIMP-1 
and TIMP-2 with much lower affinity [124]. Therefore the role of MMP-10 in 
physiological and pathological processes will differ from MMP-3 and it warrants 
investigation in its own right.  
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A feature of particular interest is that MMP-10 is able to cleave the pro-forms of 
MMP-1 and MMP-8 to the active forms [127-129]. MMP-3 also has this action and 
generates a form of MMP-1 with tenfold greater collagenolytic activity than serine 
proteases alone [130].   
 
This action has been confirmed as being of potential importance in disease by in 
vitro models. Angiogenesis occurs within tumours and promotion of vascular 
regression is a potential therapy. In a model of capillary tube regression using 
endothelial cells (ECs) in three dimensional collagen matrices, the ECs were 
transfected to overexpress MMP-10. This increased activation of MMP-1 in a 
manner which temporally correlated with capillary tube regression and gel 
contraction. MMP-1 knockdown using small interfering RNA (siRNA) blocked the 
ability of MMP-10 overexpression to drive capillary tube regression and gel 
contraction [131], confirming the mechanism of MMP-10 activity being pro-enzyme 
activation of MMP-1. Malignant transformation of keratinocytes results in acquisition 
of a collagenolytic phenotype coincident with altered responsiveness to transforming 
growth factor (TGF) beta and epidermal growth factor (EGF). Neutralisation of active 
MMP-10 in supernatants of TGF-beta 1 and EGF stimulate keratinocytes lead to 
decreased conversion of pro MMP-1 to active MMP-1 and reduced keratinocyte 
invasion of a collagen gel [132].  
 
The potential for MMP-10 to be playing a role in tissue destructive diseases in vivo 
has primarily been suggested by analysis of malignant biopsies. Using an ex vivo 
fluorescent assay, MMP-10 activity was detected in 80% of lung cancer specimens 
and only 20%  of normal lung tissue samples [133]. High expression of MMP-10 was 
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frequently observed on immunohistochemical analysis of head and neck squamous 
cell carcinomas [134].  
 
Strong evidence supporting a role for MMP-1 in a matrix degrading phenotype in TB 
has been presented, and an important role for MMP-8 is emerging (unpublished 
data). It can be proposed that MMP-10 is involved in driving matrix degradation in 
pulmonary TB, not only through its direct action on the pulmonary ECM, but by 
cleaving and activating proMMP-1 and proMMP-8. Therefore, assessment of MMP-
10 in TB is a worthwhile and significant line of investigation.  
 
1.13 Matrix metalloproteinase 8 
 
An overview of MMP-8 is presented here because it emerges as potential mediator 
of tissue destruction in TB in one of the clinical studies undertaken for this thesis. 
Though there is a range evidence supporting a role for MMP-1 (collagenase-1) in 
tissue destruction in TB, MMP-8 (collagenase-2) has not been extensively studied. 
MMP-8 is primarily expressed in neutrophils and cleaves the triple helical collagens I, 
II and III as well as serine protease inhibitors and chemokines. It is also expressed in 
epithelial cells, macrophages, fibroblasts and T-cells [135].  
 
In contrast to MMP-14 and -10 the role of MMP-8 in cancer progression is 
controversial.  Some studies suggest that MMP-8 drives tumour progression, while 
others indicate that it is antimetastatic.  Serum MMP-8 was elevated in squamous 
cell carcinomas of the head and neck and significantly correlated with tumour stage 
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[136]. In another clinical study MMP-8 protein was detected by 
immunohistochemistry in a malignant invading tumour cell islands, fibroblasts, 
neutrophils and plasma cells of squamous cell carcinomas of the head and neck 
[137]. However a mouse study showed that in breast cancer cell lines MMP-8 
overexpression reduced metastasis, whereas knock-down increased metastasis 
[138].  
. 
Highly glycosylated forms of MMP-8 are stored in granules within neutrophils. 
Neutrophils are the first innate immune cells to influx at a site of inflammation. They 
degranulate after stimulation which results in extracellular release of MMP-8. 
Degradation of collagen driven by MMP-8 at the site of inflammation can influence 
disease outcome [135].  Bronchiectasis is characterized by chronic inflammation as 
a consequence of recurrent infection and permanent dilation of the bronchi ensues.   
 
 
The bronchoalveolar lavage fluid from patients with bronchiectasis of varying severity 
was incubated with Type I collagen and densitometric analysis of collagen 
breakdown products performed. The collagenolytic activity was greater the more 
severe the bronchiectasis - using the differential inhibitory capacity of doxycycline it 
was confirmed that neutrophil derived MMP-8 was the predominant collagenase 
present [139].  
 
Neutrophils are considered increasingly important in TB immunopathology and 
unpublished cellular and clinical data suggest a role for MMP-8 in collagen 
 60 
 
destruction in TB. Therefore it is important to continue to study MMP-8 in clinical 
samples from TB patients. 
 
1.13 Hypothesis 
 
 
MMPs drive tissue destruction in human tuberculosis and diverse MMPs have 
unique roles in immunopathology, including regulating  monocyte migration and 
augmenting tissue destruction.  
 
 
1.14 Objectives and aims 
 
1. To investigate the regulation of MMP-10 in a cellular model of human TB.  
 
2. To assess the role of MMP-14 in monocyte migration and monocyte associated 
collagen destruction in a cellular model of human TB. 
 
3. To measure MMP expression in clinical samples from patients with pulmonary 
TB including plasma, sputum and lung biopsies. 
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2. METHODS 
2.1 Mtb and BCG culture 
 
M.tuberculosis H37Rv (Mtb) and Pasteur vaccine Bacillus Calmette-Guérin (BCG) 
were cultured in Middlebrook 7H9 medium (BD Diagnostics, Oxford, UK) 
supplemented with 10% ADC enrichment medium (BD Diagnostics), 0.2% glycerol 
(Sigma, Poole, UK), 0.02% Tween 80 (Sigma) with agitation at 10rpm.  Culture 
growth was monitored with a Biowave cell density meter (WPA, Cambridge, UK) and 
both were subcultured when the optical density was 1.00.  The Mtb endotoxin level 
was measured by the amebocyte lysate assay (Associates of Cape Cod) and was 
<0.3 ng/ml LPS. 
 
2.2 Cell culture 
2.2.1 Monocyte purification  
 
Monocytes were isolated from single donor leucocyte-enriched cones (NHS Blood 
and Transfusion, London, UK) or fresh peripheral blood from healthy human donors, 
by density gradient centrifugation and adhesion purification.  
 
The blood was mixed with Hanks Balanced Salt Solution (HBSS, Gibco®, Life 
Technologies, Paisley, UK), and layered onto Ficoll (GE Healthcare Life Sciences, 
Little Chalfont, UK) before centrifugation at 1500rpm for 20-30mins. The leukocyte 
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cell layer was collected and washed repeatedly in HBSS by spinning at 1200 rpm for 
5 minutes and resuspending the cell pellet. The total monocyte number was 
calculated by counting the adherent cells in a haemocytometer, after a 5 minute 
incubation at 37oC. Monocytes were plated in RPMI 1640 (Gibco®), supplemented 
with 2mM glutamine (Invitrogen, Life Technologies, Paisley, UK) and 10μg/ml 
ampicillin (Sigma-Aldrich), at a density of 2.5 x105 cells per cm2. The monocytes 
were incubated at 37◦C for one hour to adhere and then washed three times in HBSS 
to remove non adherent lymphocytes.  
 
Experiments were set up in RPMI 1640 supplemented with, 2mM glutamine 
(Invitrogen) and 10μg/ml ampicillin (Sigma-Aldrich), 10% heat inactivated  fetal calf 
serum (FCS, Biowest, Nuaillé, France) . The monocytes were placed in a humidified 
incubator supplemented with 5% CO2 at 37
◦C for the duration of the experiment.  
 
2.2.2 Maturation of monocytes to macrophages 
 
Monocytes were isolated as above and matured to monocyte derived macrophages 
(MDMs) over  5 days in RPMI 1640, 2mM glutamine, 10μg/ml ampicillin and 10% 
heat inactivated FCS, supplemented with 10ng/ml of macrophage colony stimulating 
factor (R&D, Abingdon, UK)). Experiments were set up in Macrophage Serum Free 
Medium (Invitrogen). The MDMs were placed in a humidified incubator 
supplemented with 5% CO2 at 37
◦C for the duration of the experiment. 
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2.2. 3 Normal human bronchial epithelial cell culture 
 
Normal human bronchial epithelial (NHBE) cells (Clonetics®, Lonza, Slough) were 
cultured in Bronchial Epithelial Cell Growth Medium (BEGM®, Clonetics®). The cells 
were subcultured at 80-90% confluence using trypsin-EDTA for 2min and neutralized 
with trypsin neutralizing solution (Clonetics®). For experiments, cells were seeded at 
a density of 40,000 per cm2, rested overnight and experiments commenced at 80% 
confluence in BEGM. 
. 
2.2.4 Cell infection protocol 
 
Monocytes were infected immediately after the completion of adhesion purification 
and macrophages after 5 days of maturation.  Mtb or BCG at mid log growth at an 
optical density of 0.60 was used, which corresponds to 1 x 108 – 2 x 108 colony 
forming units (CFU) per ml and a multiplicity of infection (MOI) of 1.  
 
2.2.5 Preparation of conditioned medium from Mtb infected monocytes  
 
Monocytes were plated onto 60mm dishes in RPMI 1640 supplemented with 2mM 
glutamine and 10μg/ml ampicillin at a density of 2.5 x105 cells per cm2. These were 
immediately infected with Mtb at an MOI of 1 (CoMTb) or 7H9 medium (CoMCont). 
The dishes were placed in a humidified incubator supplemented with 5% CO2 at 
37◦C for 24 hours. The cell culture medium was aspirated and filtered through a 
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0.2μM Anopore membrane (Whatman, GE Healthcare Life Sciences, Little Chalfont, 
UK) [140]). The resulting cell culture supernatant is termed Conditioned Medium 
from Control Monocytes (CoMCont) or CoMTb as indicated.  
 
CoMTb is rich in an Mtb induced intercellular network of cytokines, chemokines and 
Mtb antigens. CoMCont or CoMTb were used at a 1:5 dilution to stimulate 
monocytes or NHBE cells. 
 
2.2.6 Chemical inhibitors  
 
MDMs were pre-incubated with inhibitors for 2 hours prior to infection, monocytes for 
1 hour prior to stimulation.  The chemical inhibitors used are shown in Table  2.  
 
2.2.7 ESAT-6 peptides  
 
6kDa early secreted antigenic target (ESAT-6), a protein encoded by the RD1 
virulence locus of Mtb, has the following amino acid sequence.  
MTEQQWNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQGVQ
QKWDATATELNNALQNLARTISEAGQAMASTEGNVTGMFA 
Peptides of 15 amino acid length with 10 overlapping amino acids (Pepceuticals, 
Enderby, UK) covering the entire sequence were used to stimulate MDMs. The 
sequences of these 17 peptides are shown in Table 3. Initially a pool of all ESAT-6 
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peptides was used a stimulus. Next overlapping pools containing 3-4 peptides as 
defined by the peptide matrix shown in Table 4 were used. Using the peptide matrix 
it was possible to deduce if there was a single 15 amino acid peptide sequence 
driving MMP-10 secretion from MDMs. The peptides were of >90% purity and time of 
flight mass spectrometry laser desorption for each showed a single peak only. 
 
All the reagents used in cell culture were endotoxin free.  
 
2.2.8 Harvesting of cell culture supernatants 
 
Cell culture supernatants were harvested at 72 hours from MDMs, NHBEs and MRC-
5 cells and 24 hours from monocytes. Where cells had been infected with live Mtb 
H37Rv the supernatants were filtered through a 0.2μm Durapore membrane 
(Millipore, Feltham, UK) [140]. 
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Table 2: Chemical inhibitors used in tissue culture 
 
 
 
 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Target IC50 Supplier 
SB203580 (SB): 
p38 MAPK 
 
 0.3-0.5  μM Enzo Life Sciences, , 
Exeter, UK 
PD98059 (PD): 
ERK MAPK inhibitor 
MEK 1  4 μM Calbiochem® 
SP600125 (SP): 
JNK MAPK inhibitor 
c-Jun 5-10  μM Calbiochem® 
SC-514: 
NF-ĸB inhibitor 
IKK-2  
 
3-12   μM GE Healthcare Life 
Sciences, 
Helenalin: 
NF-ĸB inhibitor 
p65 N/A Enzo Life Sciences 
Pertussis Toxin 
(PT): 
G-protein coupled 
receptor inhibitor 
G protein αi subunits N/A Calbiochem® 
 67 
 
Table 3: ESAT-6 peptide amino acid sequences 
 
  
Peptide no.  Amino acid sequence 
1. MTEQQWNFAGIEAAA 
2. WNFAGIEAAASAIQG 
3. IEAAASAIQGNVTSI 
4. SAIQGNVTSIHSLLD 
5. NVTSIHSLLDEGKQS 
6. HSLLDEGKQSLTKLA 
7. EGKQSLTKLAAAWGG 
8. LTKLAAAWGGSGSEA 
9. AAWGGSGSEAYQGVQ 
10. SGSEAYQGVQQKWDA 
11. YQGVQQKWDATATEL 
12. QKWDATATELNNALQ 
13. TATELNNALQNLART 
14. NNALQNLARTISEAG 
15. NLARTISEAGQAMAS 
16. ISEAGQAMASTEGNV 
17. QAMASTEGNVTGMFA 
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          Table 4: ESAT-6 peptide pools matrix 
 
 
2.3 Enzyme-linked Immunosorbent Assay  
 
Enzyme-linked Immunosorbent Assay (ELISA) Duosets (R&D) were used to 
measure the levels of MMP-10 and TNF alpha in cell culture supernatants.  
 
ELISA plates (Costar®) were coated with capture antibody (1µg/ml) overnight and 
blocked with 1% bovine serum albumin (BSA) for one hour. Next, standards and 
samples were incubated for 2 hours, followed by the detection antibody (100ng/ml) 
also for 2 hours. Streptavidin-Horse Radish Peroxidase (HRP) was added for 20 
minutes. Washes in 0.05% Tween-20 (Sigma-Aldrich) in phosphate buffered saline 
(PBS, Sigma-Aldrich) were performed between each of these steps. Finally, the 
substrate Tetramethylbenzide (Sigma-Aldrich) was added, the colour change was 
monitored and after 2-3 minutes stopped using 2M sulphuric acid. The plate was 
read at 450nm with a reference wavelength of 540nm on a µQuant plate reader 
(Biotek Instruments Inc).   
 
Peptide pool 
number 
5 6 7 8 9 
1 P1 P2 P3 P4 P5 
2 P6 P7 P8 P9 P10 
3 P11 P12 P13 P14 P15 
4 P16 P17    
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2.4 Luminex Bead Array 
 
Luminex corp has developed a microparticle based multiplex immunoassay for the 
accurate quantification of a range of analytes in very small volumes in various 
sample types (serum, plasma and cell culture supernatants). This was used to 
quantify cytokine/ chemokines and growth factors (Invitrogen) in CoMCont and 
CoMTb and MMPs (R&D) in sputum, bronchoalveolar lavage and plasma.  
 
Specific antibodies are pre-coated onto colour-coded microparticles or beads. 
Microparticles, standards, and samples were pipetted into a Luminex plate and 
agitated at 500rpm for 2 hours allowing immobilized antibodies to capture the analyte 
of interest. Biotinylated antibodies specific to the analyte were added and agitated for 
1 hour. Next, streptavidin phycoerythrin (PE) is added with agitation for 30 minutes to 
generate a signal. Washes are performed between each step. Finally, the beads are 
resuspended and read using the Luminex® dual laser analyser (Bio-Rad Bio-Plex 
200 System). One laser classifies the bead and determines the analyte which is 
being detected, the second laser determines the magnitude of the PE derived signal, 
which is in direct proportion to the analyte bound.  
 
 
MMP beads (R&D systems. Abingdon UK) were used for MMP-1, -2, -3, -7, -8, -9, -
10, -12 and -13.  The lower level of detection of the assay was 1.1, 12.6, 7.3, 6.6, 
16.6, 13.7, 3.2, 0.7 and 63.5 pg/ml respectively. Cytokine human 30-plex  beads 
(Invitrogen) were used for  CCL2 (MCP-1),  CCL-3(MIP-1α), CCL-4 (MIP-1β), CCL-5 
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(RANTES), CXCL-8 (IL-8), CXCL-9 (MIG), CXCL-10 (IP-10), CCL-11 
(Eotaxin),  IFNα, IFNϒ, IL-1β, IL-1 receptor antagonist, IL-2, IL-2 receptor,IL-4,  IL-5, 
IL-6, IL-7, IL-10, IL-12, IL- 13, IL-15, IL-17, TNFα, EGF,  FGF, G-CSF, GM-CSF, 
HGF, VEGF. 
2.5 Confocal Microscopy 
Confocal microscopy was used to detect cell surface expression of MMP-14 by 
fluorescent immunostaining. Monocytes were stimulated on chamber slides (Nunc* 
Lab-Tek* II Chamber Slide* System, Thermo Scientific, Hemel Hempstead, UK). At 
24 hours the cells were blocked with 5% human serum (Sigma-Aldrich)/1% BSA 
(Sigma-Aldrich) for 30 minutes and stained with either a mouse anti-human MMP-14 
monoclonal primary antibody (MAB3328, Millipore) or  a mouse isotype control 
antibody (ab18447, Abcam, Cambridge, UK) for 30 minutes. The cells were fixed in 2% 
paraformaldehyde (Sigma-Aldrich) for 1 hour, and stained with an Alexa647 
conjugated secondary antibody (A-21235 goat antimouse IgG Alexa647, Invitrogen) 
for 30 minutes. Washes in PBS were performed between each step. The nucleus 
was stained with DAPI (Invitrogen) and a borosilicate glass cover slip (Fisher 
Scientific, Loughborough, UK) mounted.  
Confocal microscopy was performed on a Leica TCS SP5 Confocal with the   Leica 
Application Suite 2.6.2 software. Images were analysed using  Image J software 
version 1.44p (NIH, USA). 
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2.6 Flow Cytometry 
 
Flow cytometry was used to detect monocyte surface expression of MMP-14 by 
fluorescent immunostaining. It differs from confocal microscopy in that it is a 
quantitative method.  
 
Monocytes were stimulated in 12 well plates. At 24 hours the cells were harvested 
using Cell Dissociation Buffer Enzyme Free (Invitrogen) at 37◦C for 15 minutes and a 
cell scraper. Harvested cells were counted using a haemocytometer and equal cell 
numbers per condition transferred to FACS tubes. They were centrifuged at 1200 
rpm for 5 minutes to pellet the cells and blocked with 10% heat inactivated human 
serum/1% BSA for 30 minutes on ice. The cells were pelleted and stained with either 
a  PE-conjugated mouse anti-human MMP-14 primary antibody or an PE-conjugated 
mouse IgG2B isotype control (IC0041P,  R&D ) for 1 hour on ice, in the dark A final 
wash in 1% BSA was performed.  If cells had been infected with Mtb they were also  
fixed in 2% paraformaldehyde for 1 hour.  
 
Flow cytometry was performed immediately after staining on a FACSCalibur (BD 
Biosciences, Oxford, UK) machine which was calibrated regularly using FACS 
CaliBRITE (BD Biosciences) beads. The baseline Forward Scatter, Side Scatter and 
FL2H settings were adjusted using an unstained, unstimulated sample of cells. Cell 
viability was assessed using propidium iodide (PI, Sigma-Aldrich) staining.  Flow Jo 
software (Version 7.6.2) was used for data analysis.  
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2.7 Western Blotting 
 
Western blotting was used for chemiluminescent detection of total MMP-14 and -10, 
and phosphorylated and total p38/ERK /JNK  as detailed below. 
 
Proteins were separated on the basis of weight by gel electrophoresis. The samples 
were defrosted and heat inactivated at 70◦C and an appropriate volume loaded into 
the wells of a NuPAGE® 4-12% Bis-Tris Gel (Invitrogen) in an XCell SureLock Mini-
Cell (Invitrogen), filled with the appropriate running buffer (MES buffer for proteins 
<60kDa, MOPS buffer for proteins >60kDa, Invitrogen). A full range rainbow protein 
molecular weight marker (GE Healthcare Life Sciences) was also loaded. The 
samples were separated on the gel by electrophoresis at 200V for 50 minutes. The 
gel was removed and placed with a nitrocellulose membrane (Amersham Hyobond – 
ECL, GE Healthcare Life Sciences) in an X-Cell II Blot Module (Invitrogen) soaked in 
Transfer Buffer (Invitrogen) with 20% methanol (Sigma-Aldrich)/0.6% SDS (Sigma-
Aldrich). Proteins were electro-transferred to the membrane at 30V for 90 minutes.  
The membrane was blocked with 0.1% Tween-20, 5% non-fat milk in Tris- buffered 
saline (Sigma-Aldrich) prior to staining with primary antibodies overnight. The 
membranes were then stained with HRP conjugated secondary antibodies for 1 hour. 
Washes with 0.1% Tween-20 in Tris- buffered saline were performed between each 
step. The membranes were then placed in chemiluminescent substrate (Amersham 
ECL Plus /Prime Western Blotting Detection System, GE Healthcare Life Sciences) 
for 1 to 2 minutes. They were exposed to chemiluminescence film (Amersham 
 73 
 
Hyperfilm ECL, GE Healthcare Life Sciences) and this was developed, showing the 
protein of interest as a dark band. 
2.7.1 Total MMP-14  
 
Monocytes were stimulated in 6 well plates and at 24 hours were scraped into SDS 
lysis buffer (62.5mM Tris, 2% SDS, 10% glycerol, 50mM DDT, 0.01% Bromphenol 
blue, Sigma-Aldrich). Beta- actin (β-actin) was used as the loading control. The 
primary antibodies were rabbit anti-human polyclonal anti-MMP-14 antibody 
(AB6004, Millipore) and mouse anti-human monoclonal anti-β-actin (A1978, Sigma-
Aldrich). The secondary antibodies were HRP -conjugated goat anti-rabbit IgG (7074, 
Cell Signalling Technology, Boston, USA) and HRP-conjugated goat anti-mouse IgG 
(115-035-062, Jackson ImmunoResearch Europe Ltd, Newmarket, UK).  
2.7.2 Phosphorylated and total p38/ERK /JNK  
 
Monocytes were stimulated in 60mm dishes and at 30 minutes were scraped into 
SDS lysis buffer. The primary antibodies were rabbit polyclonal phospho-p38/ total 
p38 (9211/9212), phospho-ERK/ total ERK (9101/9102) and phospho- JNK/ total 
JNK (9251/9252), (Cell Signalling Technology). The secondary antibody was HRP-
conjugated goat anti-rabbit IgG (7074, Cell Signalling Technology). The membrane 
was stripped with Restore Plus western blot stripping buffer (ThermoScientific) for 
consecutive probing of phosphorylated and total forms on the same membrane.  
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2.7.3 Total MMP-10 
 
Cell culture supernatants harvested from macrophages at 72 hours were loaded with 
2x loading buffer. The primary antibody was Rabbit polyclonal to MMP-10 (ab38930, 
Abcam) and secondary HRP-conjugated goat anti-rabbit IgG (7074, Cell Signalling 
Technology). 
 
The densitometry of bands was measured using  Image J software version 1.44p 
(NIH, USA). 
 
2.8 Real Time Polymerase Chain Reaction  
 
Real time polymerase chain reaction (RT-PCR) was used to measure MMP-10 
mRNA levels in macrophages and MMP-14 mRNA levels in monocytes.  
2.8.1 RNA extraction 
 
Total RNA was extracted from cells using phenol chloroform extraction and the 
Purelink RNA Mini Kit (Invitrogen) which is a column based nucleic acid purification 
kit.  
Monocytes or macrophages were stimulated in 6 well plates and after 6 or 24 hours 
scraped into 1ml TRIzol (Sigma-Aldrich). Samples were stored at -80 ºC for a 
maximum of 1 month. They were defrosted, chloroform (Sigma-Aldrich) added then 
centrifuged at 12 000 g for 5 minutes. The colourless upper phase (containing RNA) 
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was added to an equal volume of 70% ethanol. The RNA was then extracted onto 
the silica membrane of a spin column by a series of washes with buffers from the kit.  
The extracted RNA was finally eluted into 30µl RNAse free water and stored at -80 
ºC. The samples were defrosted and RNA concentration and quality determined on 
the NanoDrop ND-1000 spectrophotometer prior to cDNA synthesis.  
2.8.2 cDNA synthesis  
 
cDNA was synthesized using the Quantitect Reverse Transcription Kit 
(Qiagen,Manchester, UK).  The final reaction volume was 20 µl. For each sample a 
volume of RNA equivalent to 50ng, 200ng, 500ng or 1µg was diluted up to 12µl with 
RNase-free water. 2µl of genomic DNA wipeout buffer was added and heated at 42 
ºC for 2 minutes. A 6 µl mastermix containing random primers, reverse transcriptase 
and dNTPs was added and heated at 42ºC for 15 minutes, with primer annealing 
and strand extension occurring within the same reaction. The reaction was 
terminated by heating at 95 ºC for 3 minutes. The synthesized cDNA was stored at -
20˚C.  
2.8.3 Polymerase chain reaction 
 
The final PCR reaction volume was 25µl in nuclease fee water (Gibco®). It contained 
diluted cDNA or standard, 1x Brilliant II Taq polymerase (Agilent Technologies, 
Wokingham, UK), 1x primers/probe for the gene of interest (MMP-14 or MMP-10, 
Applied Biosystems, Manchester, UK) and a reference gene (β-actin). Applied 
Biosystems do not provide the end user with the primer/ probe sequences.  
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RT-PCR was performed in a Framestar 96 well PCR plate (4titude, Wotton, UK) on a 
Stratagene Mx3000Pro machine with an initial 10 minute denaturation step at 95˚C 
(Taq polymerase activation) followed by 40 cycles at 95˚C for 30 seconds (cDNA 
denaturation) then 60˚C for 1 minute (annealing of primers and probes/extension). 
Gene expression was normalised to 18S or β-actin. This reference genes was 
chosen for the stability of its expression across different experimental conditions. 
 
For MMP-14 and β-actin a plasmid standard was kindly synthesized by Dr Catherine 
Ong. Serial dilutions were used to generate a standard curve with a known number 
of gene copies. A plasmid standard was not available for MMP-10 therefore a 
standard curve was generated using the serial dilutions of the sample with the 
highest expected expression of the gene of interest and  „quantities‟ were assigned.  
 
The cycle threshold for the gene of interest and reference gene was extrapolated 
from the standard curve to give an amount.  The gene of interest was then 
normalized to the reference gene. The unstimulated sample was chosen as the 
„calibrator‟ sample and all others expressed as a fold change compared to this.  
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2.9 Fluorescent Collagen Degradation Assay 
 
A fluorescent collagen degradation assay was used to investigate monocyte driven 
collagen destruction in Mtb and the role of MMP-14 in the process.  
 
Chamber slides (PAA Laboratories Ltd,, Yeovil, UK) were coated briefly with 0.005% 
poly-L-lysine (Sigma-Aldrich) to create a substratum to improve cell adherence, then 
0.5% glutaraldehyde (BDH) to non-covalently couple the substratum to the 
fluorescent collagen. Fluorescein isothiocyanate (FITC) conjugated type I collagen, 
from bovine skin (Sigma-Aldrich) was diluted to 100µg/ml in 0.1M acetic acid, 
vortexed and a volume equating to 15µg/cm2 added to each chamber. The collagen 
solution was left to adhere to slides for 2 hours at room temperature with gentle 
agitation. Washes with sterile PBS (HyClone, Thermo Scientific) to remove all 
residual reagents were performed between each step, and all solutions were made 
using sterile PBS or Cell Culture Grade Water (HyClone, Thermo Scientific) to 
ensure the slides were suitable for tissue culture. The slides were stored at 4˚C 
overnight.  
 
Monocytes were adhered to commence an experiment as previously described. After 
24 hours incubation the chamber was removed. The slide was washed gently in PBS, 
stained and fixed as per the MMP-14 fluorescent immunostaining protocol above. 
Collagen degradation was indicated by absence of the green FITC signal on 
fluorescent microscopy.  
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Confocal microscopy was performed on a Leica TCS SP5 Confocal with the  Leica 
Application Suite 2.6.2 software. Images were processed and quantified using  
Image J software version 1.44p (NIH, USA). 
 
2.10 Agarose Spot Assay for Chemotaxis 
 
This assay was used to investigate monocyte migration towards CoMTb employed 
as a chemotactic agent rather than a direct stimulus. It is a modification of a 
previously described assay [141].  
 
A 0.5% agarose, low gelling temperature (Sigma-Aldrich) solution in sterile PBS was 
boiled and then allowed to cool to 40˚C on a hot block. RPMI 1640 or CoMTb was 
added to the agarose solution at a 1:10 dilution. Using cut tips 10µl of the solution 
was pipetted onto cover glass bottom chamber slides (PAA-Laboratories) pre-coated 
with type I collagen as above. This created a „spot‟ on the surface of the slide with 
the agarose acting as a media through which chemoattractants in the CoMTb can 
diffuse. Two spots per condition were pipetted. The slide was then left at 4˚C for 5 
minutes for the agarose to set.  
 
Monocytes were adhered immediately to commence an experiment. After 24 hours 
incubation the slide (with the chamber in situ) was washed gently in PBS and stained 
and fixed as per the MMP-14 fluorescent immunostaining protocol above except 
DAPI staining and cover slip placement were excluded. Images were taken using an 
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Olympus E-620 camera attached to the Olympus CK2 light microscope. Images 
were processed and quantified using Image J software version 1.44p (NIH, USA). 
 
 
2.11 Clinical Samples: Collection and Processing  
2.11.1 Plasma 
 
These samples had been collected previously by Dr Gurjinder Sandhu [142]. The 
study was ethically approved by Universidad Peruana Cayetano Heredia (Lima, 
Peru) and Imperial College London (London, United Kingdom). Written informed 
consent was obtained in all cases.  
 
Participants were recruited over a 2 year period from 16 community TB clinics 
serving the shantytown of Ventanilla in Lima, Peru. All patients provided four 
consecutive sputum samples for microscopy and culture.  Patients with active TB 
were recruited on the basis of positive sputum microscopy with subsequent 
confirmation by culture. Symptomatic controls were those who had symptoms 
suspicious of TB (persistent cough and 2 or more from fever, weight loss, decreased 
appetite or haemoptysis) but in whom active TB was subsequently excluded by 
sputum microscopy and culture. Healthy controls were recruited from randomly 
selected households in the community where patients with active TB were not 
resident.  
 
A 4 ml blood sample was obtained from each participant in an EDTA tube and 
transferred to the laboratory on ice. The plasma was separated (3500 rpm, 10 
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minutes) aliquotted and frozen at -70°C for subsequent analysis [142] . Prior to 
Luminex bead array analysis the samples were defrosted at 4°C and multiple 50μl 
aliquots were placed in 96 well plates before refreezing at -70°C. This minimized 
freeze thaw cycles of the samples prior to measurement of MMPs.  
 
2.11.2 Induced sputum – supernatant and RNA extraction 
 
The induced sputum samples from which the supernatant was analysed had been 
collected previously by Dr Naomi Walker [77]. The induced sputum samples from 
which the RNA was extracted and analysed were collected prospectively by Dr Tara 
Sathyamoorthy. The studies were ethically approved by the University of Cape Town 
(UCT) Research Ethics Committee. Written informed consent was obtained in all 
cases.  
 
Adult participants were recruited from Ubuntu clinic in the township of Khayelitsha, 
Cape Town, South Africa.  
 
TB patients met at least one inclusion criteria from: 
 
- Sputum smear positive for AFB on microscopy or sputum Gene Xpert positive or  
- Sputum culture positive for Mtb or  
- Clinical features highly suggestive of TB with diagnostic features on chest 
radiograph and started on TB treatment by a clinician 
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Control patients were asymptomatic individuals who presented voluntarily. Only 
patients within 72 hours of commencing treatment and HIV negative cases were 
included.. A brief clinical history and examination were performed, followed by a 
chest radiograph. Chest radiograph infiltration was scored using a previously 
developed modified system on a scale of 0 – 10  according to the number of 
segments involved (Fig. 3)  [143].  
 
Sputum induction was performed in designated, well ventilated, isolated areas using 
nebulised 5% saline. 1ml of RNA later (Qiagen) was added on site to the samples 
which would be processed for RNA extraction.  Two samples were sent for 
microbiological investigation (smear microscopy and culture) and one sample was 
transported to UCT BSL3 laboratory on ice.   
 
Mucolysis was performed by adding an equal volume of 0.1% Dithiothreitol (Sigma-
Aldrich) and agitating gently at room temperature for 20 minutes. In the case of 
samples processed for supernatant collection they were then centrifuged at 1600rpm 
for 5 minutes and the supernatant was aspirated and sterile filtered through a 0.2μM 
Durapore membrane (Millipore) [140] to remove Mtb. The filtrates were aliquotted 
and frozen at -20°C for subsequent analysis [77]. In the case of samples to be 
processed for RNA extraction the mucoid layer was filtered off by passing through 
100µM pore size strainer (BD) then the sample was centrifuged at 500g for 10 mins. 
The cell pellet was aspirated and 1.5ml of cold TRI reagent added before vortexing. 
The TRI reagent kills the Mtb. The samples were stored at minus 80 oC until RNA 
extraction. 
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Figure 3: Chest Radiograph Scoring 
Chest radiograph infiltration was scored using a previously developed modified system on a scale of 0 
– 10 according to the number of segments involved. The white lines shown on the chest radiograph 
here delineate the ten segments. 
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2.11.3 Bronchoalveolar lavage  
 
These samples had been previously collected by Dr Shivani Singh [144]. The study 
was ethically approved by the Nalanda University Hospitals Research Ethics 
Committee. Written informed consent was obtained in all cases. Participants were 
recruited over a 1 year period at Nalanda University Hospitals, Patna, India.  
 
BAL was performed on patients being investigated for respiratory symptoms. 
Patients with active TB were those with positive bronchoalveolar lavage microscopy 
with subsequent confirmation by culture. Control patients were those respiratory 
symptomatics in whom active TB was excluded by sputum microscopy and culture. 
Flexible bronchoscopes were used and the procedure was performed between two 
bronchoscopists.  
 
The samples were centrifuged at 1600rpm for 5 minutes. The supernatant was 
aspirated and sterile filtered through a 0.2μM Durapore membrane (Millipore) [140]. 
The filtrates were aliquotted and frozen at -20°C for subsequent analysis. 
2.11.4 Lung Immunohistochemistry 
  
This project was approved by the Hammersmith and Queen Charlotte‟s Research 
Ethics Committee.  Lung biopsy blocks taken from patients investigated for lung 
cancer but with a final diagnosis of tuberculosis were studied, along with control 
patients whose biopsies showed normal lung tissue. The blocks were deparrafinized  
and then rehydrated prior to antigen retrieval. The anti MMP-14 primary antibody 
(ab77965, Abcam) was applied, followed by a post primary HRP conjugated polymer. 
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Finally the diaminobenzedine substrate was added. The block was then 
haemotoxylin costained. Washes were performed between each step. The slides 
were reviewed with a histopathologist and images were taken using a Zeiss 
Askiospop 2 with Askioscan camera.  
 
2.12 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism 5 by Student‟s t-test, Mann 
Whitney U test or One Way Analysis of Variance (ANOVA) with Tukey‟s post hoc 
analysis. ROC curves were generated using R version 2.15.2 using the package 
pROC [145]. We have used Youden‟s index to calculate and optimal cut off threshold 
in each case [146]. Principal component analysis was conducted using Qlucore 
Omics Explorer 2.2 (Qlucore).  Clinical data and plasma MMPs were analyzed firstly 
for correlation by principal component analysis, and then the divergence between 
patient groups was studied. 
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3. ANALYSIS OF CIRCULATING MMPS INDICATES A DOMINANT 
ROLE FOR COLLAGENASES 
 
3.1 Introduction 
 
There has been a growing interest in analysis of biomarkers in TB, both as a 
diagnostic marker and also to monitor the efficacy of treatment.  However, analysis 
of plasma and serum inflammatory mediators, such as cytokines and chemokines, to 
better understand disease pathogenesis has generally not shown major differences 
between patients with TB and control groups [147].  Studies in small  patient cohorts  
have shown higher levels of  plasma MMP-8 and MMP-9 in patients with TB 
compared to controls [148-150].  However, a comprehensive analysis of circulating 
MMPs in a well-powered clinical cohort has not been previously performed. 
Therefore in this study we investigated the hypothesis that MMPs are key drivers of 
TB immunopathology by analysing the plasma levels of MMP-1, -2, -3, -7, -8, -9 and 
-10 in a set of prospectively collected samples from 380 patients with active 
tuberculosis, symptomatic controls (symptoms suspicious of TB but active disease 
excluded) and healthy controls.  These samples had been collected as part of a 
proteomic study [142] and I was able to study them with a hypothesis-driven 
approach.  
 
 
 
 
 86 
 
3.2 Results 
3.2.1 Baseline patient characteristics 
 
120 healthy controls, 109 symptomatic controls and 151 patients with active 
pulmonary TB were recruited (Table 5).  The healthy and symptomatic groups were 
well matched for age, but the TB group was significantly younger than the 
symptomatic group (median TB 28.5 years vs. symptomatic 32 years, p<0.05). There 
were a higher proportion of females in the healthy and symptomatic controls group 
(66% for both) and a higher proportion of males in the active TB group (56%). This 
may reflect a difference between the sexes in health seeking behaviour, as females 
tend to attend clinics more regularly than males [151]. All the patients with active TB 
were either smear or culture positive with 92% both smear and culture positive. All 
symptomatic controls were smear and culture negative. There was a lower 
proportion of patients with past TB in the healthy controls (3%) but similar proportion 
in the symptomatic controls (17%) and active TB (23%). Patients with active TB had 
a lower body mass index (BMI) at enrolment compared with symptomatic controls 
and healthy controls (TB 21.66 vs. symptomatic  24.15 and healthy 25.86 
respectively, p<0.001 for both), consistent with the diagnosis of pulmonary TB [152]. 
Symptomatic controls and patients with active TB had overlapping clinical symptoms 
though the duration was longer in the TB group (median TB 7 days vs. symptomatic 
2 days, p<0.001). 
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Table 5: Plasma matrix metalloproteinase analysis - Characteristics of patient cohort   
Patient characteristics 
 
    
 
  n % n % n %  
Total number of patients 120 31 109 29 151 40  
Median age (IQR) years 31 (23-40) 32 (24.5 - 47.5) 28.5 (22-38) 
p<0.05 Symptomatic vs. TB 
Sex ratio Male: Female 41:79 34:66 37:72 34:66 85:66 56:44 
 
Smear: 
      
 
          Positive n/a 
 
0 0 139 92 
 
          Negative n/a 
 
109 100 7 
 
 
Culture: 
      
 
          Positive n/a 
 
0 0 139 92 
 
          Negative n/a 
 
109 100 8 
 
 
Past TB 4 3 19 17 34 23 
 
Mean BMI (SD) 25.86 (4.33) 24.15 (4.67) 21.66 (2.97) 
 
 
p<0.001 Healthy or Symptomatic vs. TB 
 
Symptoms: 
      
 
          Cough 42 35 109 100 151 100  
          Haemoptysis 2 2 28 26 71 47  
          Fever 17 14 52 48 93 62  
          Weight loss 40 33 72 66 123 81  
          Appetite loss 
 23 19 57 52 109 72 
 
Median symptom duration 
(IQR) days   0   2 (1-10) 7 (1-30) 
p<0.001 Symptomatic vs. TB 
Healthy 
 
Symptomatic TB 
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3.2.2 Plasma MMP-1 and MMP-8 are elevated in active pulmonary TB and MMP-
8 is relatively TB-specific  
 
MMP-1, -2, -3, -7, -8, -9 and -10 were profiled in the plasma of all patients by 
Luminex multiplex array.  Samples from the archived cohort were defrosted in the 
cold room and aliquotted onto 96 well plates.  In preliminary studies, MMP-12 and 
MMP-13 were not detected in plasma and so were not included in this analysis of 
circulating MMPs. MMP-2 was detected but was excluded from statistical analysis as 
many values fell out of range above the standard curve.   
  
MMP - 1 was increased in both active pulmonary TB and symptomatics compared to 
healthy controls (p<0.001 and 0.01 respectively), but there was no difference 
between active TB and symptomatics (Fig. 4A).  The concentration of MMP-8 was 
specifically increased in the plasma of patients with active TB compared to both 
symptomatics as well as healthy controls (Fig. 4D both p <0.001). There was no 
difference between symptomatics and healthy controls.  MMP - 7 was increased in 
both active pulmonary TB and symptomatics compared healthy controls (p 0.01 for 
both), but there was no difference between active TB and symptomatics (Fig. 4C). 
However the median MMP-7 value in respiratory symptomatics was higher at 66pg/ 
ml compared to 20.1 pg/ml in both active pulmonary TB and healthy controls, 
suggesting that plasma MMP-7 is elevated in a small proportion of patients with TB 
only.  MMP-9 was increased in active TB only compared to healthy controls (Fig. 4E, 
p<0.05). There was no statistically significant difference in MMP-9 between active TB 
and symptomatic controls or symptomatic controls and healthy controls. MMP-3 and 
MMP-10 showed no difference between any of the groups (Fig. 4B and 4F).  
Therefore the MMPs that were elevated in TB were MMP-1, -7, -8 and -9, but MMP-8 
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was the most TB specific as it was elevated compared to respiratory symptomatics. 
Median values and interquartile ranges for all MMPs are provided in Table 6. 
 
 
 
 
      
 
      Table 6: Plasma MMP levels by patient group 
 
  Healthy Symptomatic TB 
MMP-1 1.55 (1.55-90.9) 223.9 (52.36 - 71.1) 229.2 (71.1 - 593.6) 
    MMP-3 6059 (3949 - 10656) 5956 (4097 - 9708) 7296 (4469 - 11386) 
    MMP-7 21 (21 - 21) 66 (21 - 222) 21 (21 – 147) 
    MMP-8 3236 (2244 - 6379) 3547 (2099 - 6259) 8359 (4471 - 16069) 
    MMP-9 58234 (39489 - 88224) 59853 (37009 - 97915) 73181 (47367 - 114444) 
    MMP-10  512 (363 – 711) 584 (372 – 894) 539 (384 – 759) 
      
        Median levels and interquartile ranges (in brackets) in pg/ml 
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Figure 4:  Neutrophil collagenase MMP- 8 is specifically upregulated in the 
plasma in active pulmonary TB 
Plasma samples were collected prospectively from patients in Lima, Peru. A, MMP-1 was increased in 
both active TB and symptomatic controls compared to healthy controls. B, MMP-3 showed no 
difference between the groups. C, MMP-7 was increased in both active TB and symptomatic controls 
compared to healthy controls. D, MMP-8 was specifically increased in active TB only compared to 
symptomatic controls and healthy control. E, MMP-9 was increased in active TB only compared to 
healthy controls. F, MMP-10 showed no difference between the groups.  MMP concentrations were 
measured by Luminex bead array. Statistical analysis was performed using a one way ANOVA with 
Tukey‟s post hoc test (***p<0.001, **p<0.01, *p<0.05). Each box represents the 25
th
 to 75
th
 centiles, 
the central line the median, and the whiskers the minimum and maximum values.  
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3.2.3 Plasma collagenases are higher in males than females and elevated 
levels are present in active TB in males and females analysed separately 
 
It has previously been shown that MMP-3, -8 and -9 are higher in males than in 
females [153]. In the cohort analysed above, MMP-1, -3, -8 and -9 were similarly 
higher in males (Fig. 5A to D and Table 7, MMP-1 p<0.05, MMP-8 p<0.001, MMP-3 
and MMP-9 p<0.0001).  
 
The active TB group had a higher percentage of males and the symptomatic control 
group more females. Therefore MMP-1, -3, -8 and -9 levels were analysed 
separately for each sex to ensure that the elevated levels observed were not 
artefactual. With sex-dependent analysis, MMP-1 remained increased in both active 
TB and symptomatics compared to healthy controls in males (Fig 6A, p<0.01 and 
0.05 respectively). However in females, it was only increased in active TB compared 
to healthy controls (Fig 6B, p<0.01). MMP-8 remained increased in active TB 
compared to symptomatics and healthy controls in both males (Fig. 6C p< 0.05 and 
0.01 respectively) and females (Fig 6D, p < 0.01 and 0.05 respectively). MMP-3 and 
MMP-10 shows no significant differences between the three clinical groups for the 
sexes when analysed separately.  The median values and interquartile ranges for 
MMP-1, -3, -8 and -9 for the sexes separately and across the three clinical groups
 are provided in Table 7.
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                    Table 7: Plasma MMP levels for males and females separately by patient groups 
 
    All Healthy Symptomatic TB 
MMP-1 Male 204 (9- 540) 7 (4-84) 344 (81-635) 287 (83-598) 
 
Female 83 (9-317) 10 (6-94) 202 (36-467) 178 (29-594) 
      
      MMP-3 Male 10134 (7302-14111) 10603 (7063 - 14968) 10725 (7836 - 14327) 9640 (7181 - 13789) 
  Female 4848 (3352 - 6774) 5177 (3344 - 7517) 4978 (3440 - 6774) 4702 (3273 - 6508) 
      MMP-7  Male 34 (20 – 116) N/A N/A N/A 
 
Female 3 (19 – 108)  
   
      MMP-8 Male 6277 (3201 - 12381) 3413 (2409 - 6368) 4069 (2363 - 6889) 10622 (5381 - 17359) 
  Female 4094 (2214 - 7725) 3125 (2040 - 6427) 3374 (2021 - 5722) 7043 (3909 - 13404) 
      MMP-9 Male 75150 (50272- 111266) 64786 (48935 - 107322) 77247 (46492 - 109487) 80411 (53645 - 117600) 
 
Female 55631 (38356 - 92406) 52659 (34556 - 82052) 53285 (35007 - 88313) 63861 (42572 - 108639) 
      MMP-10  Male 543 (376 – 788) N/A N/A N/A 
 
Female 526 (364 – 764) 
   
       
                    Median levels and interquartile ranges (in brackets) in pg/ml 
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Figure 5:  Plasma MMP -1, -3, -8 and -9 are higher in males than females  
All the plasma MMPs measured were analysed separately by gender across the entire cohort. A, 
MMP-1 B, MMP-3 C, MMP-8 and D, MMP-9 were all higher in males than females. MMP 
concentrations were measured by Luminex bead array. Statistical analysis was performed using a 
one Mann-Whitney U Test (****p<0.0001, ***p<0.001, *p<0.05). Each box represents the 25
th
 to 75
th
 
centiles, the central line the median, and the whiskers the minimum and maximum values. 
 
 
 
 94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:  Plasma MMP-1 and MMP-8 remain elevated in TB when analysed by 
gender 
Across the entire cohort MMP-1 and MMP-8 were higher in men than women. As there was a higher 
proportion of women in the healthy control and symptomatic control groups MMP-1 and MMP-8 in the 
clinical subgroups were analysed individually for males and females. A, In males MMP-1 was 
increased in TB and symptomatics compared to healthy controls. B, In females MMP-1 was only 
increased in TB compared to healthy controls. C, In males MMP-8 was specifically increased in TB 
only compared to symptomatic controls and healthy controls.   D, Similarly in females MMP-8 was 
specifically increased in TB only compared to symptomatic controls and healthy controls (p<0.01 and 
0.05 respectively). MMP concentrations were measured by Luminex bead array. Statistical analysis 
was performed using a one way ANOVA with Tukey‟s post hoc test (**p<0.01, * p<0.05). Each box 
represents the 25
th
 to 75
th
 centiles, the central line the median, and the whiskers the minimum and 
maximum values. 
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3.2.4 Principal component analysis demonstrates a distinction between TB and 
control patients but not between TB and respiratory symptomatics 
 
Next, the association between selected clinical features and plasma MMPs was 
investigated, using Principal Component Analysis (PCA).  PCA is a mathematical 
algorithm, which is used to identify patterns in large data sets and reduces the 
dimensionality of the data while expressing it in a manner that highlights similarities 
and differences.  The dimensionality of the data is reduced by looking for directions 
along which the variation is maximal, known as principal components [154]. 
Individual points on the plot generated represent a single analyte or patient. The 
distance between points reflect their Pearson correlation coefficient, whereby a short 
distance demonstrates close correlation.   
 
Utilising the Qlucore multivariate analysis software, I  analysed the relationship 
between circulating MMPs and clinical characteristics such as cough, body mass 
index (BMI), past TB, sex, sputum smear result, tuberculin skin test (TST) and IFNϒ 
release assay (IGRA)  (Fig. 7A). MMP-1, -7, -8 and -9 were included in the analysis 
as they were elevated in TB. The variables that associated most closely were TST 
and IGRA, consistent with both depending on the host immune response to Mtb, and 
MMP-8 and MMP-9, suggesting that both have a common source, consistent with 
them being co-secreted by neutrophils.   Further analysis using all the variables 
demonstrated a relatively good separation between healthy controls and TB patients 
(Fig. 7B).  However, when the same analysis was performed for TB against 
respiratory symptomatics, there was relatively greater overlap between the groups 
(Fig. 7C), suggesting that the utilisation of these 11 variables to differentiate TB from 
respiratory symptomatics may be of limited applicability. 
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Figure 7:  PCA demonstrates good 
discrimination between controls and 
TB, but not TB and respiratory 
symptomatics 
A, Three dimensional network principal 
component analysis plot demonstrating the 
association between different analytes.  
Individual points represent a single analyte, and 
the distance between points reflect their Pearson 
correlation coefficient, whereby a short distance 
demonstrates close correlation.  B, C, Three 
dimensional network PCA plot generated using 
key parameters that differed between patients 
with TB and controls: cough, BMI, past TB, sex, 
sputum smear result, TST and IGRA, MMP-1, -7, 
-8 and -9. Each point represents one patient.  
Control patients are purple, TB patients are blue 
and respiratory symptomatics are yellow.   
Divergence is demonstrated between controls 
patients and TB patients (B) but there is greater 
overlap between respiratory symptomatics and 
TB patients (C). 
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3.2.5   Plasma MMP-8 may help differentiate patients with active pulmonary TB 
from symptomatic controls  
 
Next, receiver operating characteristic (ROC) analysis was performed utilising MMP-
8 as a single variable to determine if it helped differentiate active TB from 
symptomatics (symptoms suspicious of TB but active disease excluded), because 
this was the most highly discriminatory analyte of all MMPs measured. The area 
under the curve (AUC) was 0.765 (Fig. 8A) with a Youden's criteria for optimal cut-off 
of MMP-8 = 6600 pg/ml with a specificity of 77.3% and sensitivity of 64.3%.  
 
When ROC curves were plotted separately for males and females they showed that 
plasma MMP-8 has a greater predictive ability for active TB in men compared to 
women (Fig. 8B and 8C). For men the AUC was 0.798 with a Youden‟s criteria of 
6967 pg/ml and a higher specificity (80.8%) and sensitivity (68.2 %.)  For women the 
AUC was 0.721 with a Youden‟s criteria of 3780 pg/ml and a lower specificity (57%) 
though a higher sensitivity (79.7%) than the ROC curve for the sexes combined or 
men alone. 
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Figure 8: Plasma MMP-8 discriminates 
TB from symptomatic controls with 
moderate accuracy 
ROC curves were plotted to investigate the ability 
of MMP-8 to discriminate TB from symptomatic 
controls (symptoms suspicious of TB but active 
disease excluded). A, For the entire cohort the 
AUC was 0.77 indicating moderate accuracy as a 
discriminator, optimal cut off MMP-8= 6600 
pg/ml, specificity 77.3%, sensitivity 64.3%. B, For 
males separately the AUC) was 0.80 indicating 
good accuracy as a discriminator, optimal cut off 
MMP-8= 6967 pg/ml, specificity 80.0%, sensitivity 
68.2%. C, For females separately the AUC was 
0.72 indicating moderate accuracy as a 
discriminator, optimal cut off MMP-8= 3780 
pg/ml, specificity 57%, sensitivity 79.7%. 
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3.2.6 Plasma MMP-8 negatively correlates with BMI in TB 
 
Finally, as it was noted that patients with active TB had a lower BMI at enrolment, 
the relationship between BMI and plasma MMP-8 levels was assessed for this 
subgroup. Low BMI is a marker of poor nutritional status and is a risk factor for 
developing TB [152], relapse after treatment [155] and death [156]. A negative 
correlation between plasma MMP-8 and the BMI of TB patients was identified (Fig. 9 
r= - 0.460; **** p<0.0001).  Though I was unable to find published data indicating a 
negative correlation between BMI and extent of cavitation, underweight patients with 
cavities have been identified as particularly high risk for relapse [155]. Therefore the 
negative correlation between BMI and MMP-8 supports a role for this collagenase in 
driving tissue destruction in TB patients  
 
 
 
 
 
 
 
 
 
Figure 9: Plasma MMP-8 negatively correlates with BMI in TB 
Plasma MMP-8 negatively correlated with the BMI of patients with TB by Spearman correlation 
coefficient (r= - 0.460; **** p<0.0001).   
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3.3 Discussion 
 
A cohort of 380 patients with active pulmonary TB, respiratory symptomatics 
(symptoms suspicious of TB but active disease excluded) and healthy controls was 
prospectively recruited and carefully characterised. The first comprehensive analysis 
of circulating MMPs comparing healthy controls, patients with pulmonary TB and 
respiratory symptomatics was performed.  Two collagenases, MMP-1 and MMP-8, 
were elevated in active TB, but MMP-8 was specifically upregulated in TB compared 
to both symptomatics and healthy controls. MMP-1, -3, -8 and -9 were higher overall 
in males than females. Analysis of the sexes separately confirmed that MMP-8 was 
increased in active TB compared to symptomatic and controls, and MMP-1 was 
increased in both active TB and symptomatic controls. Consequently, the results 
were not being falsely skewed by the higher number of female symptomatics and 
healthy controls.  The ROC curve for MMP-8 showed that it may help discriminate 
active pulmonary TB from symptomatics.  
 
Previous studies have assessed MMPs at the primary site of disease rather than in 
the circulation, by analysis of sputum and lung biopsies.  An early study showed that 
in two patients with active TB compared to a single control, MMP-9 mRNA measured 
by northern blot was elevated [69]. Immunohistochemical analysis showed MMP-1 
expression both in the macrophages of TB granulomas and adjacent epithelial cells 
[71, 72]. MMPs -1, -2, -3 and -8 were increased in the induced sputum of patients 
with pulmonary TB [77]. MMP-1 and MMP-2 correlated with the extent of infiltration 
on chest radiograph and were higher in those patients with cavitation [76, 77]. The 
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MMP-1 in the sputum was shown to be proteolytically active by casein zymography 
[76]. A longitudinal study of induced sputum MMP concentrations at diagnosis and 
then at the second week, eighth week and end of TB treatment showed that MMP-1,-
2,-3,-8 and -9 were increased in pulmonary TB compared to healthy controls at 
diagnosis. MMP-1 and -3 were associated with higher TB severity scores. Treatment 
resulted in a rapid reduction of MMP-1, -3 and -8 levels [157].  
 
Therefore, in this study of circulating MMPs, where the collagenases MMP-1 and 
MMP-8 were elevated, there is some consistency with the induced sputum studies 
but there are also differences in sampling the two compartments.  MMP-1 seems 
predominant in the sputum, whereas MMP-8 is the best marker in the plasma, 
suggesting that analysis of plasma does not completely reflect events in the lung 
interstitium.  It is interesting to note that two collagenases were elevated in plasma, 
as collagen is the primary structural fibril of the pulmonary ECM and our findings 
support the hypothesis that excessive collagenolytic activity is of particular 
importance to the tissue destruction seen in pulmonary TB.  
 
Plasma MMPs in tuberculosis have previously been investigated in TB. The first 
study compared plasma MMP-2 and MMP-9 levels in 20 patients with active 
tuberculosis and 20 healthy controls in Poland, using quantitative zymography. 
Elevated MMP-9 but not MMP-2 levels were identified in TB. The MMP-9 levels 
correlated with radiological disease severity as measured by  computed tomography 
[149]. More recently plasma MMP-1, MMP-7, MMP-8 and MMP-9 levels were 
measured in 28 patients with tuberculous pleural effusions and 16 patients with non-
tuberculous effusions in India, who were all HIV seronegative, using ELISA. Plasma 
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MMP-8 only was significantly elevated in TB compared to non-TB. Plasma MMP-1 
and MMP -9 but not MMP-7 showed a trend towards being higher in TB, though 
statistical significance was not achieved [148].  
 
Two studies that investigated plasma MMPs in TB were published in 2013, indicating 
growing interest in the area. One study measured plasma MMP-8 levels in  patients 
with active pulmonary TB and  healthy controls in South Africa, of mixed HIV 
seroprevelance, using Luminex bead array. Plasma MMP-8 was elevated in TB 
compared to healthy controls. In this study, Procollagen III N-terminal peptide 
(PIIINP) was also measured, which is released during the synthesis and breakdown 
of Type III Collagen.  Plasma levels of PIIINP were also elevated in the TB group. 
ROC analysis combining plasma PIIINP and MMP-8 differentiated pulmonary TB 
from healthy controls with an AUC of 0.832, a sensitivity of 89.5% and specificity of 
65% [150]. The second study used an unbiased approach of DNA aptamers for 
proteomic profiling of paired serum of TB patients at enrolment and after 8 weeks of 
quadruple antituberculous chemotherapy. MMP-1 fell after the treatment period in all 
39 patients and MMP-9 fell in 36 patients, where as MMP-2 was increased in 38 
patients [158]. 
 
The results of these studies are supportive of our findings and show that plasma 
MMP-8 is elevated in TB patients in different geographical locations with varying HIV 
seroprevalence. The study we have performed differs in two main ways. Firstly it 
includes a much larger number of participants and secondly and more importantly 
has a respiratory symptomatic control group. This allows conclusions about plasma 
MMPs in TB specifically compared to other respiratory infections to be drawn.  
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Of the MMPs studied, MMP-8 emerges as being specifically upregulated in the 
plasma in active TB only compared to other respiratory infections, while MMP-1 is 
non-specifically upregulated in respiratory infection.  It could initially be considered 
surprising that MMP-1 is elevated almost equally in the plasma of active TB and 
symptomatic controls, given the previous published data on MMP-1 in induced 
sputum in TB. However the symptomatic controls had symptoms consistent with 
pulmonary infection, though TB was not the final diagnosis. MMPs have a range of 
non tissue destructive roles which are important in the innate immune response. 
Their ability to cleave host defence proteins such as toll like receptors, cytokines and 
chemokines, has effects such as promoting leukocyte recruitment to the site  of 
infection, activating inflammatory cells, initiating inflammatory signalling cascades 
and augmenting microbicidal activity [49, 159].  
 
The elevated plasma MMP-1 in the context of symptomatics, who do not have a 
tissue destructive pulmonary pathology, may reflect a role in innate immunity rather 
than matrix degradation. For example, incubation of LPS stimulated monocytes with 
the broad spectrum MMP inhibitor BB-94 resulted in decreased secretion of the 
active form of TNFα as analysed by Western blot, and this was not due to reduced 
mRNA levels. Incubation of recombinant proTNFα with individual recombinant MMPs 
alone and in the presence of BB-94, with the mixtures subsequently analysed by 
Western blot showed that MMP-1 was able to convert proTNFα to the active form 
[160]. Therefore, the effect of MMP-1 may be more diverse than matrix destruction 
alone. 
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Elevated MMP-8 in active TB implies the presence of excessive neutrophil activity in 
these patients. Neutrophils are the main cellular source of MMP-8, though it may be 
expressed by other cell types [135]. MMP-8 and MMP-9 are stored in granules within 
neutrophils with their release occurring on cellular activation and degranulation [161].  
In our study the close association of MMP-8 with MMP-9 by Principal Component 
Analysis, suggests that neutrophils are the primary source of MMP-8 in the plasma 
of TB patients. This is consistent with an emerging concept of dysregulated 
neutrophil activity driving pathology in pulmonary TB [162].  
 
For example, a higher percentage of neutrophils compared to macrophages were 
found in the sputum and bronchoalveolar lavage fluid of patients with active 
pulmonary TB. The neutrophils contained more intracellular bacteria than the 
macrophages [163]. A mouse strain that are highly genetically  susceptible to TB 
showed a large influx of neutrophils to lung tissue within 1 week of infection, which 
persisted to 3-4 weeks, and was associated with a higher number of mycobacteria 
phagocytosed by neutrophils  and higher bacterial burden overall compared to a less 
susceptible mouse strain [164]. Both studies suggest in their concluding remarks that 
neutrophils may represent a permissive site for mycobacterial growth, and that the 
neutrophil activation and degranulation which ensues would cause damage to lung 
tissues. MMP-8 would be among the products released into lung tissue on neutrophil 
degranulation.  
 
Whole blood genome profiling in a large training and validation set, which specifically 
compared patients with active pulmonary TB to other inflammatory diseases and 
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bacterial infections, identified an interferon inducible neutrophil driven 86 gene 
transcription signature specific to TB. The module with the largest number of 
transcripts changing within it related to type I interferon alpha-beta inducible 
signalling. Separation of white blood cells show that these transcripts were mostly 
overexpressed in neutrophils, and to a lesser extent monocytes though not T-cells 
[162].  
 
Previous investigation of plasma MMPs in other respiratory infections has focussed 
on the measurement of MMP-9 in isolation in community acquired pneumonia (CAP). 
Three studies have shown that plasma MMP-9 levels measured by ELISA and/ or 
activity measured by gelatin zymography were elevated compared to healthy 
controls and that levels returned to normal  after antibiotic treatment [165-167].  
However, a comprehensive analysis of MMPs in diverse infectious conditions has 
not been performed. 
 
 While it is interesting to note that plasma MMPs are elevated in respiratory 
infections other than TB, CAP is largely a non tissue destructive respiratory infection, 
with cavitation rarely occurring except in severe cases. Therefore the immunological 
importance of MMP-9 in CAP may relate to roles such as activating chemokines and 
cytokines, promoting leukocyte migration to the site of infection and promoting 
bacterial killing that have been mentioned previously.  However the causative micro-
organisms in hospital acquired pneumonia (HAP) differ from CAP and pulmonary 
tissue destruction is a more common feature.  One study measured MMP-8 and 
MMP-9 by ELISA and showed that they were elevated in both the bronchoalveolar 
lavage fluid and plasma of patients with HAP compared to healthy controls [168]. 
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The finding of elevated plasma MMPs in a non tuberculous respiratory infection 
associated with tissue destruction is complementary to our data. 
 
We observed gender differences in circulating MMPs within our cohorts.  It is 
recognised that men mount a greater and often more damaging inflammatory 
response to infection compared to women. A proposed mechanism is that male sex 
hormones are damaging and female sex hormones are protective [169].   For 
example in sepsis the mortality rate of  men can be as high as 70% compared to 
26% in women, and men have higher levels of pro-inflammatory TNFα, but lower 
levels of the immunosuppressive IL-10 [170]. Female neutrophils have been found to 
express decreased MMP-9 and TNFα during the period of the menstrual cycle when 
oestrogen levels are higher [171]. With specific reference to mycobacteria, M 
marinum infected male mice showed numerous granulomatous inflammatory lesions 
and a high bacterial burden in their lungs at 3 weeks post infection, where as female 
mice had few small lesions with comparatively health lung parenchyma and a lower 
bacterial burden. The findings in male and female mice were more similar if the 
males were castrated and reverted to the original pattern if the castrated males were 
administered  testosterone [172].  
 
Men have a higher reported incidence, retreatment rate and mortality in TB as well 
as greater infiltration on chest radiograph and more frequent haemoptysis [173]. 
Elevated  plasma MMPs in men compared to women has been previously identified 
[153] and was confirmed in this study for MMP-1, MMP-3, MMP-8 and MMP-9. The 
higher plasma MMP-8 levels we identified in men with TB are consistent with the 
studies discussed above which describe a greater pro-inflammatory response to 
 107 
 
infection in males. This may in part be responsible for the more severe tissue 
destruction and poorer outcome exhibited in men. 
 
In summary, I demonstrated that plasma MMP-1 and MMP-8 are elevated in active 
pulmonary TB and implicate excessive collagenase activity in tissue destruction in 
TB. The increased plasma MMP-8 is specific to TB patients and is not elevated in 
respiratory symptomatic controls with other respiratory infections. As MMP-8 is 
largely derived from neutrophils, this finding is consistent with neutrophils having an 
important role in driving TB immunopathology. 
 
My plasma analysis suggests critical importance of collagenolytic MMPs in tissue 
destruction in TB.  These MMPs are secreted as zymogens, requiring proteolytic 
cleavage, and so I was interested in the possibility that the other MMPs that were not 
elevated in the plasma in active TB were still playing an important role at the site of 
disease. My attention was specifically drawn to MMP-10 because it can 
proteolytically activate MMP-1 and MMP-8 [129] and is upregulated in Mtb infected 
macrophages [71], but has been little investigated in any disease process. MMP-10 
(Stromelysin-2) is a stromelysin which cleaves proteoglycans, laminin and type IV 
collagen, but unlike MMP-1 and MMP-8 does not directly cleave the triple helical 
collagens. Therefore MMP-10 may indirectly promote breakdown of triple helical 
collagens, the primary structural fibrils of the lung, by activating the collagenases. I 
therefore proceeded to investigate MMP-10 expression and regulation in a 
macrophage based cellular model of human TB and in patients with pulmonary TB. 
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4. MMP-10 IS UPREGULATED BY THE Mtb VIRULENCE FACTOR 
ESAT-6 
4.1 Introduction  
 
MMP-10 (Stromelysin-2) has been less studied in TB compared to other MMPs for 
which reagents are widely available.  MMP-10 directly cleaves proteoglycans, 
laminin and type IV collagen within ECM, but does not cleave the triple helical 
collagens [47]. However, MMP-10 is able to cleave the pro-form of the collagenases 
MMP-1 and MMP-8 to the active form [129] . Therefore MMP-10 may be involved in 
promoting tissue destruction in pulmonary TB, not only through its direct action on 
proteoglycans, laminin and type IV collagen  within the pulmonary ECM, but by 
indirectly augmenting degradation of triple helical collagen, the primary structural 
fibrils of the lung. MMP-10 driven activation of MMP-1 has been found to be of 
importance in disease in models of angiogenesis [131] and malignant keratinocyte 
invasion [132].  
 
To date there are no studies investigating MMP-10 in TB or in any other human 
infection in detail. However, preliminary data do suggest that MMP-10 may be 
implicated in TB pathogenesis.  Unbiased gene profiling studies analyzing all MMPs 
found that Mtb drove MMP-10 gene expression in human macrophages and 
monocytes [71, 76]. MMP-10 gene expression was 14 fold higher in human TB 
granulomas compared to normal lung tissue on microarray analysis of tissue excised 
at time of surgery for TB [80]. Furthermore, the active metabolite of vitamin D 
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reduced Mtb induced MMP-10 mRNA expression in peripheral blood mononuclear 
cells and monocytes [174]. 
 
Therefore, these diverse data implicating MMP-10 in TB led me to investigate the 
hypothesis that MMP-10 is a driver of tissue destruction in TB.  My approach was to 
investigate MMP-10 expression and regulation in a macrophage based cellular 
model of human TB and in patients with pulmonary TB.  
 
4.2 Results 
4.2.1 Mtb infection drives MMP-10 secretion from human MDMs  
 
 
First, MMP-10 secretion from MDMs directly infected with Mtb was investigated. Mtb 
at an MOI of 0.1, 0.5 and 1 caused a dose dependent upregulation of MMP-10 of 1.3, 
20.2  and 29 fold with mean levels of 481±108, 7462±2074  and  10719±1713 pg/ml 
respectively compared to 370±331pg/ml from uninfected MDMs at 72 hours 
incubation (Fig. 10A, MOI 0.1 not significant, p<0.001 for MOI 0.5 and 1). Kinetics 
studies showed  Mtb infection had no effect at 24 hours compared to uninfected 
MDMs, but a 5.1-fold upregulation of MMP-10 secretion occurred at 48 hours rising 
to 31.5-fold at 72 hours (Fig. 10B, p<0.01 and p<0.001 respectively). Western 
blotting confirmed the ELISA findings, showing MMP-10 as a dark band at 54kDa in 
the supernatant from Mtb infected but not uninfected MDMs (Fig. 10C). The growth 
medium used to culture Mtb, 7H9 alone, had no greater effect on MMP-10 secretion 
than no stimulus. 
 110 
 
Mtb upregulated MMP-10 mRNA gene expression (normalized to β-actin),182-fold 
compared to uninfected MDMs at 24 hours (Fig.10D, p< 0.0001). This shows that the 
increased MMP-10 secretion seen in Mtb infected MDMs is secondary to increased 
mRNA accumulation.  
 
4.2.2 Mtb upregulates MMP-10 secretion from pulmonary epithelial cells via 
monocyte-dependent networks 
 
Next, we investigated the effects of local monocyte dependent networks in driving 
MMP-10 secretion from pulmonary epithelial cells. CoMTb increased MMP-10 
secretion 4.5-fold from epithelial cells with levels of 2525±209pg/ml from 
unstimulated cells compared to 11250±286 pg/ml from stimulated cells at 72 hours 
(Fig. 11A, p<0.0001).  In a separate experiment CoMTb increased MMP-10 secretion 
16.6-fold from epithelial cells compared to CoMCont, with levels of 5649±226 pg/ml 
compared  to  340±56 pg/ml respectively at 72 hours (Fig. 11B, p<0.0001).   
 
CoMTb was prepared by filtering the supernatants of infected monocytes through a 
Whatman Anopore filter, which binds MMPs [140] and consequently CoMTb itself at 
the dilutions used to stimulate cells contained MMP-10 levels in the range of 380 to 
2220 pg/ml, significantly lower than  that detected after 72 hours of cellular 
stimulation. 
  
 111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Direct Mtb infection drives MMP-10 expression in MDMs 
A, MMP-10 secretion from MDMs infected with increasing MOI of Mtb. Increased MMP-10 was 
secreted as the MOI for Mtb increased from 0.1 to 1. B, Kinetics of MMP-10 secretion from Mtb 
infected MDMs. Mtb (MOI 1) caused a gradual increase in MMP-10 secretion from 24 hours through 
to 72 hours. MMP-10 concentration in MDM supernatants was measured by ELISA and is expressed 
as pg/ml. C, Western blot analysis of MMP-10 secretion from Mtb infected MDMs. Increased MMP-10 
secretion from Mtb infected (MOI 1) MDMs at 72 hours was confirmed by Western blot analysis using 
an MMP-10 specific antibody. MMP-10 was detected in MDM supernatants as a dark band at 54kDa. 
D, MMP-10 gene expression in Mtb infected MDMs. Mtb (MOI 1) upregulated MMP-10 gene 
expression (normalised to β-actin) at 24 hours. MMP-10 and β-actin gene expression were measured 
by RT-PCR. Statistical analysis was performed using a one-way ANOVA with Tukey‟s post hoc test or 
a Student‟s unpaired t-test (** p <0.01, *** p <0.001, **** p <0.0001). 
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Figure 11: Mtb induced intercellular networks drive MMP-10 secretion from 
human pulmonary epithelial cells  
MMP-10 secretion from CoMTb stimulated pulmonary epithelial cells. CoMTb (1:5 dilution) increased 
MMP-10 secretion from pulmonary epithelial cells at 72 hours in comparison to both  A, unstimulated 
cells and B, CoMCont stimulated cells. MMP-10 concentration in cell culture supernatants was 
measured by ELISA and is expressed as pg/ml. Mean +/- SD for an experiment performed in triplicate 
are shown and are representative of two independent experiments. Statistical analysis was performed 
using Student‟s unpaired t-test (**** p <0.0001) 
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4.2.3 MMP-10 is increased in the respiratory secretions of patients with 
pulmonary TB  
 
To investigate the relevance of the cellular findings on increased MMP-10 secretion 
to clinical disease, we measured MMP-10 levels in the respiratory secretions of two 
separate patient cohorts. The first was in the induced sputum of patients with TB 
(n=21) and a mixture of healthy and respiratory symptomatic controls (n=21) from 
Khayelitsha Township, South Africa. The second was in the BALF of TB patients 
(n=17)   and control patients with non-tuberculous respiratory disease (n=14) from 
Calcutta, India. The final diagnoses in these control patients were asthma, 
pneumonia, carcinoma, sarcoidosis, foreign body aspiration and pulmonary vasculitis 
[144]. The characteristics of the patient cohorts are detailed in the references 
indicated [77, 144].  
 
MMP-10 was increased in patients with TB compared to controls groups for both the 
induced sputum and BALF cohorts (Fig. 12  and 13, p<0.05). In the induced sputum 
study in South African patients, median MMP-10 concentrations were 5067 pg/ml 
(interquartile range 1440 – 19077) in TB patients compared to  2648 pg/ml (797 – 
5914) in controls. For the BALF study in Indian patients, MMP-10 concentrations 
were median 6531 pg/ml (interquartile range 637 -11929) in TB patients compared to 
783 pg/ml (76-5473) in controls. These data show that MMP-10 concentrations are 
higher present at the site of disease in pulmonary TB.  
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Figure 12: MMP-10 is elevated in the induced sputum of South African patients 
with active pulmonary tuberculosis (TB)  
Induced sputum samples were collected prospectively from patients with active pulmonary TB and a 
mixture of healthy and respiratory symptomatic controls in Cape Town, South Africa. MMP-10 was 
increased in induced sputum in active pulmonary TB (n=21) compared to controls (n=21). MMP-10 
concentrations were measured by Luminex bead array and are expressed as pg/ml.  Each circle 
represents one patient and the horizontal line the median value. Statistical analysis was performed 
using a Mann Whitney U test (* p <0.05).  
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Figure 13: MMP-10 is elevated in the BALF of Indian patients with active 
pulmonary TB  
BALF samples were collected prospectively from patients with active pulmonary TB and control 
patients with other pulmonary diseases in Patna, India. MMP-10 was increased in BALF in active 
pulmonary TB (n=17) compared to controls (n=14) with other pulmonary diseases. MMP-10 
concentrations were measured by Luminex bead array and are expressed as pg/ml.  Each circle 
represents one patient and the horizontal line the median value. Statistical analysis was performed 
using a Mann Whitney U test (* p <0.05). 
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4.2.4 MMP-10 secretion from Mtb infected MDMs is MAPK dependent but NF-
B independent   
 
Next, we investigated the role of key signalling pathways in the control of Mtb driven 
MMP-10 secretion using specific chemical inhibitors.  The signalling pathways that 
regulate MMP-10 are poorly defined, but it has previously been demonstrated that 
the MAPK pathways regulate MMPs in other inflammatory conditions[47]. The MAPK 
and NF-B pathways are briefly illustrated in Fig. 1 and 2.  Mtb infection drives 
phosphorylation of the signalling molecules p38 and ERK MAPK in MDMs [100].  
 
To assess the role of p38 MAPK signalling, chemical inhibition was undertaken using 
SB203580 (SB). SB inhibits the activation of MAPKAP kinase 2 by p38 MAPK by 
binding to the ATP-binding pocket, and thus inhibiting phosphorylation of 
downstream proteins [175]. SB caused a dose dependent decrease in Mtb driven 
MMP-10 secretion from MDMs at 72 hours of 75% at  1μM and 92% at 10μM (Fig. 
14A, p<0.01 and 0.001 respectively). ERK MAPK inhibition using PD98059 (PD), 
which binds to inactive forms of ERK thus preventing their activation [176], 
decreased MMP-10 secretion by 15% at 1μM (not significant) and 33% at 10μM (Fig. 
14B, p<0.01).  Blockade of the  p38 and ERK MAPK pathways using 10μM  of each 
inhibitor downregulated  Mtb driven MMP-10 gene expression (normalized to β-actin) 
by 82% and 91% respectively  (Fig. 14C, p<0.01 for both). This shows that Mtb 
driven MMP-10 secretion in MDMs is regulated by the p38 and ERK MAPK signalling 
pathways acting at the level of gene expression. The JNK MAPK inhibitor SP600125 
caused excessive cell death and therefore this pathway was not assessed further.  
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Figure 14: MMP-10 expression is p38 
and ERK MAPK dependent in Mtb 
infected MDMs 
MMP-10 gene expression and secretion from Mtb 
infected MDMs with chemical inhibition of p38 
and ERK MAPK signalling. MDMs were pre-
incubated with the p38 MAPK inhibitor SB203580 
(SB) or the ERK MAPK inhibitor PD98059 (PD) at 
1µM or 10µM for 2 hours prior to Mtb infection 
(MOI 1).  A, SB and B, PD caused a dose 
dependent reduction in Mtb driven MMP-10 
secretion from MDMs at 72 hours. MMP-10 
concentration in MDM supernatants was 
measured by ELISA and is expressed as pg/ml. 
C, SB and PD caused a reduction in Mtb driven 
MMP-10 gene expression normalised to β-actin 
at 24 hours. MMP-10 and β-actin gene 
expression were measured by RT-PCR. Mean +/- 
SD for an experiment performed in triplicate are 
shown and are representative of two independent 
experiments. Statistical analysis was performed 
using a one-way ANOVA with Tukey‟s post hoc 
test (* p<0.05, ** p <0.01, *** p <0.001). 
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NF-ĸB is considered a critical transcriptional regulator in innate immunity [103], but  
MMP-10 does not have a consensus NF-ĸB binding site in its promoter [90], 
However using chromatin  immunoprecipitation in human fibroblasts, non-canonical 
binding was shown in the  promoter of the related stromelysin MMP-3, with 
modulation of  MMP-3 gene expression as a result [177]. The promoter regions of 
MMP-3 and MMP-10 share many similarities.  Therefore we proceeded to investigate 
if this critical transcription factor was regulating MMP-10 expression in Mtb infection.  
 
Chemical inhibition of NF-ĸB signalling using SC-514 and Helenalin was performed. 
SC-514 binds to the ATP-binding pocket of IKKβ, thus inhibiting its activity. IKKβ 
normally activates NF-ĸB by phosphorylating its inhibitor IĸB which then dissociates 
[178].  NF-ĸB  is composed of a p50 and p65 subunit, and Helenalin has been shown 
to alkylate and inhibit the p65 subunit as well as reduce its expression[179].  Neither 
SC-514 or Helenalin altered Mtb driven MMP-10 secretion from MDMs (Fig. 15A and 
B, not significant). The MMP-1 promoter carries a consensus NF-ĸB binding site [90]. 
Therefore to assess if these chemical inhibitors regulated expression of a gene with 
the clear potential to be under the control of NF-ĸB, we measured MMP-1 in the 
same supernatants. We found that SC-514 reduced Mtb driven MMP-1 secretion by 
6% at 1μM (not significant) and 51% at 10μM (Fig 15C, P<0.001). Helenalin reduced 
MMP-1 secretion by 45% at 0.25μM (not significant)    and 63% at 0.5μM (Fig. 15D, 
P<0.05).  These data show that MMP-10 secretion from MDMs in Mtb infection is not 
transcriptionally regulated by NF-ĸB, but that the chemical inhibitors were functioning 
as predicted as they suppressed MMP-1 secretion. 
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No cell death was observed with the concentrations of inhibitors used. Dimethyl 
Sulfoxide (DMSO), the carrier for the inhibitors, had no effect on Mtb driven MMP-10 
secretion when used at equivalent concentrations alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15:NF-ĸB does not regulate the transcription of MMP-10 in Mtb infected 
MDMs 
MMP-10 and MMP-1 secretion from Mtb infected human MDMs with chemical inhibition of NF-ĸB 
mediated signalling using SC-514 and Helenalin. MDMs were pre-incubated with SC-514 at 1µM or 
10µM and Helenalin at 0.25µM or 0.5µM for 2 hours prior to Mtb infection (MOI 1).  A, SC-514 and B, 
Helenalin had no effect on Mtb driven MMP-10 secretion from MDMs at 72 hours. C, SC-514 and D, 
Helenalin caused a dose dependent downregulation of MMP-1 secretion from MDMs at 72 hours. 
MMP-10 and MMP-1 concentrations in MDM supernatants was measured by ELISA and is expressed 
as pg/ml. Mean +/- SD for an experiment performed in triplicate are shown and are representative of 
two independent experiments. Statistical analysis was performed using a one-way ANOVA with 
Tukey‟s post hoc test (* p<0.05, *** p <0.001). 
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4.2.5 MMP-10 expression in MDMs is driven by Mtb but not by mycobacterial 
LAM or vaccine BCG  
 
LAM is a mycobacterial cell wall component that has been implicated in driving TB 
pathogenesis and  principally a Toll-like receptor 2 (TLR-2) agonist known to be 
important in inflammatory responses to Mtb [101].  Stimulation of MDMs with LAM 
resulted in MMP-10 secretion which was 5% of that observed with direct Mtb 
infection (Fig. 16A, p<0.001). MMP-1 secretion and TNF secretion were measured 
in the same supernatants.  LAM upregulated proportionately higher MMP-1 secretion 
at 30% of that driven by direct Mtb infection (Fig. 16B), while TNF secretion was 
equal (Fig. 16C). This shows that LAM is not a critical Mtb derived factor in driving 
MMP-10 secretion from MDMs, even when cellular activation (as measured by TNF 
secretion) is equal. 
 
To further investigate the relationship between MMP-10 and TB pathogenic factors, 
we compared upregulation by Mtb and the vaccine strain M. bovis BCG.  Tissue 
destruction is not a feature of pulmonary infection with the vaccine strain M. bovis 
BCG [70], and the primary attenuation is the loss of a secretion system entitled RD1 
(region of difference 1). 
 
 MMP-10 secretion after  BCG infection of MDMs was 586 ± 97 pg/ml compared to  
2048 ± 347 pg/ml from Mtb infected MDMs at 72 hours (Fig. 17A, p<0.001). Mtb 
infection drove MMP-10 gene expression (normalized to β-actin)   that was 4 fold 
higher than that cause by BCG infection (Fig. 17B, p< 0.001) of MDMs at 24 hours. 
This indicates that the divergent effects of BCG and Mtb, with respect to MMP-10 
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secretion, are transcriptionally regulated. Measurement of TNF in the same 
supernatants showed that Mtb and BCG stimulated similar levels of TNFα secretion 
(Fig. 17C, no significant differences between the conditions). The Mtb and BCG 
cultures used for infection were plated on agar, and colony counting performed after 
2 weeks incubation. This confirmed that an equal number of CFUs of Mtb and BCG 
were used to infect the MDMs in these experiments (Fig. 17D). These data show that 
a factor present in Mtb but not BCG is responsible for driving MMP-10 secretion from 
MDMs. 
  
Figure 16: Mycobacterial LAM is a 
poor stimulus for MMP-10 secretion 
from MDMs in comparison to Mtb 
MMP-10, MMP-1 and TNFα secretion from 
MDMs in response to Mtb infection (MOI 1) and 
stimulation with mycobacterial LAM (10 µg/ml). A, 
Mtb drove twenty times greater MMP-10 
secretion than LAM from MDMs at 72 hours. B, 
Mtb drove three times greater MMP-1 secretion 
than LAM from MDMs at 72 hours. C, Mtb and 
LAM produced equal TNFα secretion from MDMs 
at 72 hours. MMP-10 and TNFα  concentrations 
in MDM supernatants were measured by ELISA 
and are expressed as pg/ml. Statistical analysis 
was performed using a one-way ANOVA with 
Tukey‟s post hoc test (*** p <0.001). 
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Figure 17: MMP-10 gene expression and secretion from MDMs is driven by Mtb 
but not vaccine BCG 
MMP-10 gene expression and secretion and TNFα secretion from Mtb infected (MOI 1) MDMs 
compared to BCG infected (MOI 1) MDMs. A, Mtb drove greater MMP-10 secretion from MDMs than 
BCG at 72 hours.  B, Mtb drove greater MMP-10 gene expression (normalised to β-actin) in MDMs 
than BCG) at 24 hours. C, Mtb infection and BCG infection produced equal levels of TNFα secretion 
at 72 hours. D, CFUs produced by Mtb and BCG cultures. Equal volumes of Mtb and BCG cultures of 
an optical density of 0.6 produced equal numbers of colony forming units when plated and grown on 
agar for 2 weeks. MMP-10 and TNFα concentrations in MDM supernatants were measured by ELISA 
and are expressed as pg/ml. MMP-10 and β-actin gene expression were measured by RT-PCR. 
Statistical analysis was performed using a one-way ANOVA with Tukey‟s post hoc test (*** p <0.001).  
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4.2.6 Mtb driven MMP-10 Secretion is dependent on a specific 15 Amino Acid 
Peptide Sequence in ESAT-6  
 
Since BCG did not drive MMP-10 secretion and lacks the RD1 region in its genome 
[99], we investigated ESAT- 6, a protein encoded by the RD1 region. It is implicated 
in Mtb virulence [180, 181] and modulation of the host immune response [182, 183].  
Furthermore, ESAT-6 has been implicated in driving MMP-9 secretion from epithelial 
cells [89]. 
 
 MDMs were stimulated with a series of short linear peptide sequences from ESAT-6 
set up as a series of peptide pools (Table 3). Stimulation of MDMs with the total pool 
of all ESAT-6 peptides at a concentration of 10 μg/ml caused a 3.7 fold increase in 
MMP-10 secretion of 137.2 ± 56.5pg/ml compared to 36.3 ± 25.9 pg/ml with 
stimulation by the ESAT-6 peptides at 1 μg/ml at 72 hours.  (Fig. 18,p<0.001).  
Unstimulated MDMs secreted for this donor secreted 7.8 ± 7.9 pg/ml.   
 
Next overlapping pools containing 3-4 peptides at a total concentration of 10 μg/ml, 
as defined by the matrix shown in Table 4, were used to stimulate MDMs. This is a 
method to identify key immunostimulatory peptides with the minimal number of 
experimental variables. Pools 1 and 8 were the only pools that caused significantly 
higher MMP-10 secretion at 72 hours than that from unstimulated MDMs, with a 5.2 
fold and 3.9 fold upregulation respectively (Fig. 19A, p<0.001 and p<0.01 
respectively).  It can be deduced from the matrix in Table 4 that the single peptide 
common to both these pools is ESAT-6 peptide 4 which has the amino acid 
sequence SAIQGNVTSIHSLLD (Table 3). Stimulation of MDMs with ESAT-6 peptide 
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4 (10 μg/ml) alone drove 3.8 fold higher MMP-10 secretion of 66.7  ± 11.7 pg/ml) 
compared to 23.3 ± 4.9 pg/ml with ESAT-6 peptide 13 at 72 hours (Fig. 19B 
p<0.001).   ESAT-6 peptide 13 was chosen as the negative control peptide because 
it was present in the non-stimulatory peptide matrix pools 3 and 7. Unstimulated 
MDMs for this donor secreted 17.3 ± 0.6 pg/ml. These data suggest that the amino 
acid sequence SAIQGNVTSIHSLLD within ESAT-6 is a specific Mtb derived factor 
which drives MMP-10 secretion.  
 
 
 
 
 
 
 
 
 
 
 
Figure 18: A peptide pool of the entire ESAT-6 sequence drives MMP-10 
secretion from MDMs 
 MMP-10 secretion from MDMs stimulated with a pool of 17 overlapping ESAT-6 peptides spanning 
the entire protein sequence at concentrations of 1 µg/ml and 10 µg/ml (see METHODS Table 2). The 
ESAT-6 peptide pool drove MMP-10 secretion from MDMs in a dose dependent manner. MMP-10 
concentrations in MDM supernatants were measured by ELISA and are expressed as pg/ml. Mean +/- 
SD for two experiments performed in triplicate are shown. Statistical analysis was performed using a 
one-way ANOVA with Tukey‟s post hoc test (*** p <0.001). 
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Figure 19: A single 15 amino acid peptide sequence from ESAT-6 drives MMP-
10 secretion from MDMs 
To identify if an individual peptide from the 17 peptides in the ESAT-6 pool was stimulating the MMP-
10 secretion from MDMs, a peptide matrix was used (see METHODS Table 3). A, MMP-10 secretion 
from MDMs stimulated with the smaller ESAT-6 peptide pools (10µg/ml) from the peptide matrix table. 
Pools 1 and 8 drove greater MMP-10 expression than the other pools, indicating that ESAT-6 peptide 
4 was stimulating the MMP-10 secretion. B, MMP-10 secretion from MDMs stimulated with ESAT-6 
peptide 4 and ESAT-6 peptide 13 (10µg/ml) individually. ESAT-6 peptide 4 alone stimulated greater 
MMP-10 secretion that ESAT-6 peptide 13. ESAT-6 peptide 13 was used as a negative control 
peptide as it was present peptide matrix pools 3 and 7 which did not stimulate MMP-10 secretion from 
MDMs. MMP-10 concentrations in MDM supernatants were measured by ELISA and are expressed 
as pg/ml. Mean +/- SD for two experiments performed in triplicate are shown. Statistical analysis was 
performed using a one-way ANOVA with Tukey‟s post hoc test (** p<0.01, *** p <0.001). 
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4.3 Discussion 
 
Mtb upregulated MMP-10 secretion from MDMs in a time and dose dependent 
fashion. Mtb induced local monocyte networks drove MMP-10 secretion from human 
pulmonary epithelial cells and fibroblasts. Elevated levels of MMP-10 were identified, 
at the site of disease in the respiratory secretions of patients with pulmonary TB 
compared to controls in two separate cohorts from South Africa and India.  MMP-10 
secretion from Mtb infected macrophages was under the control of the p38 and ERK 
MAPK pathways but not dependent on NF-ĸB signalling. Mtb drove greater MMP-10 
secretion from macrophages than LAM and vaccine BCG. A specific 15 amino acid 
sequence peptide within the virulence factor ESAT-6, which is specifically secreted 
by Mtb but not BCG, stimulated MMP-10 secretion from macrophages. These data 
support our hypothesis that MMP-10 plays a role in driving tissue destruction in 
pulmonary TB and is upregulated by Mtb to facilitate tissue destruction and hence 
transmission.  
 
Macrophages are the main cell type involved in the immune response to Mtb, but 
pulmonary epithelial cells and fibroblasts are also present adjacent to the site of 
infection. Though these cells do not directly phagocytose Mtb, they participate in the 
immune response by way of paracrine signalling. Mtb infected macrophages in the 
lungs secrete cytokines, chemokines and growth factors which modulate the activity 
of these adjacent cells.    The finding that MMP-10 is secreted both in response to 
direct Mtb infection of MDMs and by epithelial cells and fibroblasts exposed to local 
Mtb induced networks is consistent with previous data for MMP-1. Direct Mtb 
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infection drove MMP-1 gene expression and secretion in MDMs and CoMTb 
upregulated pulmonary epithelial cell and fibroblast MMP-1 gene expression and 
secretion [71, 72, 75]. The data also suggest that MMP-10 present at the site of 
infection may come from diverse cellular sources and potentially achieve high 
concentrations.  
 
Our cell culture studies were supported by the finding of increased levels of MMP-10  
in the induced sputum and BALF of patients with TB compared to controls. This 
shows that this increased MMP-10 gene expression identified in human TB 
granulomas [80]  translates to the presence of a protein which is potentially 
functionally active and therefore important to  clinical disease. It should also be noted 
that both control groups contained patients with non tuberculous respiratory disease, 
therefore the result indicates some specificity of increased MMP-10 expression to 
pulmonary TB, a disease which is particularly tissue destructive in its nature.  
 
 
Increased MMP-10 in respiratory secretions was present across two racially and 
geographically distinct patient cohorts, that are likely to have been infected with 
genetically different Mtb strains. For example  a study of the London immigrant 
population suggested that the CAS strain predominates in the Indian subcontinent 
and the LAM strain  in Southern Africa [184] This shows that MMP-10 secretion is a 
preserved feature of the immune response in Mtb infection. 
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There are multiple intracellular signalling pathways involved in the innate immune 
response to Mtb infection and the MAPK signalling pathways are considered 
particularly important [101]. These pathways have been shown to regulate MMP 
expression in Mtb infection. Analysis of multiple signalling molecules by 
phosphoarray has shown that Mtb infection results in much greater phosphorylation  
of the signalling molecules p38 and ERK MAPK in MDMs than other molecules such 
as JNK, MSK and AKT [100].  Chemical inhibition of the p38 MAPK and ERK MAPK 
signalling pathways reduced  MMP-1 secretion, from Mtb infected MDMs, as a 
consequence of reduced gene expression [100].  
 
To our knowledge, the role of p38 and ERK MAPK signalling in controlling MMP-10 
expression in Mtb infection has never been investigated. Considering the paucity of 
data in this area and the existing knowledge in relation to their role in control of 
MMP-1 expression, it seemed interesting to investigate their role in controlling MMP-
10 expression. We showed that MMP-10 secretion is also controlled by the p38 and 
ERK MAPK pathways in Mtb infected MDMs and that the regulation occurs 
predominantly at the level of gene expression.  The secretion data would suggest 
that the p38 pathway is more critical in regulation than the ERK pathway, but the 
gene expression data showed equal suppression. This may be due to differing 
importance of each pathway in individual donors, or the p38 pathway having 
additional effect on the mRNA which prevents subsequent protein translation, such 
as mRNA stabilisation [185].   
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The stimulation of TLRs by mycobacterial components acting at  the surface of 
macrophages is considered a critical aspect of the innate immune response to Mtb. 
[101], The transcription factor NF-ĸB is considered an important downstream 
signalling component for the TLR2 signalling, which activates NF-ĸB via Myd88. This 
drives TNFα expression which in turn further activates NF-ĸB [186]. Chemical 
inhibition and promoter analysis showed that NF-ĸB regulated CoMTb driven MMP-1 
expression from CNS microglial cells [84]. Despite the absence of a consensus NF-
ĸB  binding site in the MMP-10 promoter, the critical importance of the TLR-2 and 
NF-ĸB  signalling in the innate immunes response to Mtb, and the finding of non-
canonical binding of NF-ĸB  to the promoter of close related MMP-3 prompted us to 
investigate this further. However we found that MMP-10 secretion in Mtb infected 
MDMs was not NF-ĸB dependent. It is likely that  the minimal MMP-10 secretion 
driven by mycobacterial LAM is a consequence of the absence of NF-ĸB  as a 
regulator, as the TNFα levels showed that the Mtb infected and LAM stimulated cells 
were equally activated. This theory is supported by the data showing that LAM was a 
more potent stimulator of MMP-1 secretion by MDMs, which was NF-ĸB dependent 
unlike MMP-10 secretion. It is possible that the independence of MMP-10 expression 
from the NF-ĸB /TLR2 signalling pathway may be part of a regulatory network to limit 
inflammation, as less MMP-10 at the site of disease may prevent excessive tissue 
destruction.  
 
 Potential candidates for the transcription factors activating MMP-10 gene expression 
are AP-1 and STAT, both of which have consensus binding sites in the MMP-10 
promoter [90] . In cardiomyocytes, siRNA knock down of AP-1 and STAT-3 
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expression reduced CRP driven MMP-10 secretion, measured by Western blotting. 
[187], and so future studies studying these transcription factors may be more fruitful 
 
Tissue destruction and cavitation are a feature of pulmonary TB. Intravesical BCG 
treatment for bladder transitional cell carcinoma can occasionally cause systemic 
infection in the context of immunocompromise. This presents as a pneumonitis with 
non caseating granuloma and cavitation is absent [70]. It is known that BCG does 
not drive MMP-1 secretion from MDMs as potently as Mtb, and this is an interesting 
finding considering that TB is a tissue destructive disease while BCG is not. We 
therefore decided to investigate MMP-10 secretion from MDMs in response to Mtb 
and BCG infection. We found that Mtb drove greater MMP-10 secretion, secondary 
to increased gene expression, from MDMs than the vaccine strain BCG. Both 
mycobacteria drove similar levels of TNFα secretion, therefore reassuring me that 
the difference was not purely a consequence of poorer pro-inflammatory stimulation 
of the cells by BCG or a lower infectious dose. This suggests that specific factors 
present in Mtb but not BCG are responsible for driving MMP-10 expression, and 
these are likely to be related to pathogenicity.  
 
Region of difference 1 (RD1) is a region absent in the genome of all BCG strains 
derived from the original cultures by Camlette and Guerin, but present in both 
virulent M.bovis, from which BCG is derived, and virulent Mtb [99]. The reintroduction 
of RD1 into BCG  creates a protein expression profile almost identical to virulent M. 
bovis and Mtb [188]. Animal studies suggest that the proteins encoded by this region 
are important to the difference in the disease pathologies seen. Lungs from mice 
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infected with a BCG:RD1 knock in showed an increased bacterial burden and 
greater inflammatory cell infiltration  with granuloma formation on histopathological 
analysis, that was absent with control BCG [189].   
 
RD1 encompasses nine genes which encode the proteins ESAT-6 and culture filtrate 
protein 10 (CFP-10) and the secretion apparatus to transport these proteins across 
the hydrophobic, impermeable Mtb cell wall [88]. In vitro and in vivo studies implicate 
ESAT-6 and CFP-10 in Mtb virulence, with a specific role in membrane cytolysis 
leading on to mycobacterial dissemination proposed. Using fluorescent microscopy, 
it was shown that macrophages infected with  an M. marinum CFP-10/ESAT-6 
knockout  exhibited less cytolysis and cytotoxicity compared to wild type, and this  
was restored by the insertion of CFP-10/ ESAT-6 from Mtb [190]  .Electron 
microscopy of human dendritic cells showed that Mtb but not vaccine BCG 
translocated from the phagolysosome to the cytosol, but that this was absent in Mtb 
ESAT-6 and CFP-10 deletion mutants [191]. 
 
ESAT-6 also modulates the host immune response as a consequence of its 
membrane lysing activity [182, 183]. One study showed that stimulation of THP-1 
cells with the full length ESAT-6 protein activated caspases and drove IL-1 beta 
secretion.  Using fluorescent microscopy it was shown that this effect was because 
ESAT- 6 facilitated translocation of the immunostimulatory agent AG85 into the cell 
cytosol [183].  
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However, the hypothesis that ESAT-6 may be in part driving pathology by 
upregulating metalloproteinase secretion from macrophages has not been 
investigated.  I therefore chose to investigate the role of the ESAT-6 amino acid 
sequence, independent of its membrane lysing activity, via interactions with cell 
surface receptors triggering downstream signalling cascades in stimulating MMP-10 
secretion. We did this by employing an approach where we used peptide pools 
spanning the entire ESAT-6 sequence to stimulate MDMs. We were able to identify a 
single linear sequence (SAIQGNVTSIHSLLD) which alone was sufficient to drive 
MMP-10 secretion from MDMs. This confirms for the first time that a virulence factor 
specific to Mtb drives MMP-10 expression from MDMs.  
 
The role of MMP-10 in activating MMP-1 has been alluded to as being potentially 
important in promoting pulmonary collagen destruction. It is therefore worth noting 
the similarities and differences identified in their regulation. If MMP-1 and MMP-10 
do indeed function synergistically, then it is logical that they are both driven by Mtb 
but not BCG, and that they are both regulated by p38 and ERK MAPK signalling. 
However, there is a divergence in their control at the level of TLR2/ NF-ĸB signalling 
axis, though as mentioned it is possible that this has evolved as host mechanism to 
limit excessive tissue destruction.  
 
In summary, MMP-10 is elevated in the respiratory secretions of patients with TB, 
suggesting a role in tissue destruction in vivo. In a cellular model of TB, MMP-10 
expression was driven by Mtb and was regulated by the p38 and ERK MAPK 
pathways, but not the TLR2/ NF-ĸB signalling axis. Mtb infection drove greater MMP-
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10 expression than BCG infection. A specific 15 amino acid sequence from ESAT-6, 
a Mtb virulence factor which is not present in BCG, drove MMP-10 secretion. These 
data implicate MMP-10 in the immunopathological tissue destruction seen in 
pulmonary TB. It is of particular interest that ESAT-6 may be driving this process, 
which in addition to the role it plays in Mtb virulence will contribute to the success of 
the organism by facilitating transmission and promoting drug resistance.  
 
MMP-10 is a secreted protease and through the Luminex profiling, we had 
investigated the majority of secreted MMPs in TB.   However, this approach will not 
identify the membrane-bound MMPs in TB. The membrane bound collagenase 
MMP-14 has a particularly important role in cell migration as well as collagen 
degradation because of its cell surface localisation [116]. We have previously shown 
increased MMP-14 gene expression in Mtb infected monocytes [76], but this initial 
observation of increased gene expression had not been studied further, I therefore 
proceeded to investigate MMP-14 regulation and its role in collagen degradation and 
leukocyte migration  in patients with pulmonary TB and a functional monocyte based 
cellular model of TB.  The findings will be presented and discussed in the next 
chapter. 
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5. CELL SURFACE MMP-14 DRIVES COLLAGEN DEGRADATION 
AND LEUKOCYTE MIGRATION  
5.1 Introduction 
 
MMP-14 is membrane bound and its chief substrates are type I, II and III collagen 
[112].  Because of its cell surface localisation it degrades collagen in the immediate 
pericellular environment. A key role for MMP-14 in driving cell migration, by clearing 
a path at the leading edge of cells for movement through extracellular matrix, has 
been identified [116, 118, 192]. Accumulating evidence from a zebrafish embryo 
model indicates that monocyte/macrophage migration may drive bacterial expansion 
and dissemination in mycobacterial infection [107, 109, 110]. MMP-14 has been 
implicated in promoting migration of cells of the monocyte lineage [121-123] 
 
Unbiased approaches implicate MMP-14 in TB pathogenesis. For example, a 
microarray study showed MMP-14 gene expression to be 28.6 fold greater in human 
lung TB granulomas than normal lung [80]. Similarly, whole blood gene expression 
profiling has shown MMP-14 expression to be higher in patients with active TB than 
healthy controls [193]. However, to our knowledge there has never been a detailed 
study of the role of MMP-14 in TB pathogenesis.  
 
Therefore we investigated the hypothesis that MMP-14 drives two 
immunopathological processes in TB; leukocyte migration to foci of Mtb infection 
 136 
 
and    localised collagen degradation at sites of disease, using functional monocyte 
based cell culture model and samples from TB patients.  
 
5.2 Results 
5.2.1 MMP-14 is increased in the sputum of TB patients and correlates with 
lung infiltration  
 
We investigated MMP-14 gene expression in the sputum of patients with TB (n=15) 
and controls (n=10) to identify if MMP-14 was expressed in cells in vivo from areas of 
inflammation and tissue destruction.  
 
The patient cohort is described in Table 8. The TB and control group were closely 
matched for age, but a higher proportion of females were present in the control 
group which may reflect a difference between the sexes in health seeking behaviour 
[151]. TB patients had significantly more symptoms (fever, cough, night sweats, 
weight loss and breathlessness), a lower BMI and higher number of abnormal 
respiratory examinations, consistent with the underlying diagnosis.  
 
All the controls were smear and culture negative for Mtb. Twelve of the TB cases 
were culture positive and of the 3 remaining cases, one was smear positive. These 3 
patients all had clinical and radiological features highly suggestive of TB and had 
been started on TB treatment by a clinician.  
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MMP-14 gene expression (normalised to β-actin), was higher in the sputum of 
patients with TB compared to controls (Fig. 20A p<0.05). The median value and 
interquartile ranges (in brackets) for MMP-14/ β-actin gene expression in arbitrary 
units was for patients with TB 97.7 (56.7 – 150) and for controls 19.1 (7-97.2). 
Despite the relatively small sample size, the level of MMP-14 gene expression 
positively correlated with the degree of lung infiltration on chest radiograph (Fig. 20B, 
r=0.483; p<0.05). These data confirm that MMP-14 is present at the site of disease. 
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Table 8: Induced sputum matrix metalloproteinase analysis - Characteristics of 
patient cohort 
 
Patient characteristics Control TB  
Total no. 10 
 
15  
Male: Female 4:6 
 
10:5  
Median age (range) years 31.5 (21-48) 
 
40  (24-73) ns 
Symptoms (duration in days)    
          Any 1 
 
15  
          Fever 1 
 
11  
          Cough 0 
 
14  
          Haemoptysis 0 
 
1  
          Night sweats 1 
 
12  
          Weight loss 0 
 
8  
          Breathlessness 0 
 
6  
          Pleuritic pain 1 
 
11  
          Anorexia 1 
 
3  
          Median duration  
         (range) 
 
0 (0-4) 
 
30 (7-98) p<0.0001 
Examination    
         Median BMI  
         (range) 
25.4  (17.5 - 55.7) 
 
21.6 (18.5 – 29.1) p<0.05 
    
         Temp>37.5 0 
 
1 ns 
          Abnormal respiratory system 4 
 
13  
Smear    
          Positive 0 
 
8  
          Negative 10 
 
7  
Culture    
         Positive 0 
 
12  
         Negative 10 
 
  3 *  
 
*One of these 3 patients was smear positive and all had clinical features highly suggestive of TB with 
diagnostic features on chest radiograph  
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Figure 20: MMP-14 gene expression is increased in the sputum of patients with 
pulmonary TB and correlates with lung infiltration on chest radiograph 
Induced sputum samples were collected prospectively from healthy controls (n=10) and TB patients 
(n=15) in Cape Town, South Africa. MMP-14 and β-actin gene expression were analysed in the 
sputum cell pellets by RT-PCR.  The degree of lung infiltration on chest radiograph was scored on a 
scale of 0-10. A, MMP-14 gene expression (normalised to β-actin) was increased in the sputum of TB 
patients compared to healthy controls. Each circle represents one patient and the horizontal line the 
median value. Statistical analysis was performed using the Mann Whitney U Test (*p<0.05).   B, 
MMP-14 gene expression in the sputum of TB patients positively correlated with the degree of lung 
infiltration on chest radiograph by Spearman correlation coefficient (r=0.483; *p<0.05).   
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5.2.2 Mtb infection of primary human monocytes drives MMP-14 expression  
 
Next, we studied the effect of direct Mtb infection on MMP-14 expression in a cellular 
model. MMP-14 driven degradation of pericellular collagen requires its presence at 
the cell surface.  Flow cytometric analysis showed that Mtb infection caused an 
increase in the MFI for MMP-14 on unpermeabilised monocytes compared to 
uninfected cells at 24 hours (Fig. 21A). Quantification showed a 31.7 fold increase in 
MMP-14 surface expression with Mtb infection (Fig. 21B, p<0.05).  
 
Next, we analysed the kinetics of MMP-14 gene expression in Mtb infected 
monocytes. Mtb infection caused a non significant 1.4 fold increase in MMP-14 gene 
expression (normalised to β-actin) at 3 hours rising to 10.6 fold at 6 hours and 73.4 
fold at 24 hours incubation relative to uninfected monocytes (Fig. 22A, p<0.001 for 6 
and 24 hours). This increased MMP-14 mRNA resulted in higher MMP-14 total 
protein expression in whole cell lysates of Mtb infected monocytes at 48 hours (Fig. 
22B). Quantification demonstrated a 14.8 fold increase in the MMP-14 total protein 
expression compared to uninfected monocytes (Fig. 22C, p<0.01).  
 
7H9 alone, which was the growth medium for the Mtb, had no greater effect on 
MMP-14 cell surface expression or gene expression than no stimulus. 
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Figure 21: Mycobacterium tuberculosis (Mtb) infection of primary human 
monocytes drives surface MMP-14 expression  
Human monocytes were infected with Mtb at a MOI of 1 and MMP-14 expression was analysed by 
flow cytometry. A, Surface MMP-14 expression was increased in Mtb infected monocytes compared 
to unstimulated monocytes at 24 hours. B, Analysis of MMP-14 median MFI for three separate 
donors, confirmed increased MMP-14 expression. The mean +/- SD is shown. Statistical analysis was 
performed using Student‟s t-test (*p<0.05). 
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Figure 22: MMP-14 gene expression and total protein expression in monocytes 
is upregulated by direct Mtb infection 
Human monocytes were infected with Mtb (MOI 1) and MMP-14 expression was analysed by RT-PCR 
and western blotting. A, Mtb infection caused increasing MMP-14 mRNA (normalised to β-actin) from 
3 hours through to 24 hours, while no change occurred in unstimulated monocytes. Mean +/- SD for 
an experiment performed in triplicate is shown and is representative of two independent experiments. 
B, Mtb infection increased MMP-14 protein at 48 hours compared to unstimulated monocytes. β-actin 
was probed as a loading control. C, Densitometric analysis of MMP-14 and β-actin bands, confirmed 
increased MMP-14 total protein expression. Mean +/- SD for an experiment performed in triplicate is 
shown and is representative of two independent experiments. Statistical analysis was performed 
using Student‟s t-test (**p<0.01, ***p<0.001). 
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5.2.3 MMP-14 causes pericellular collagen degradation in Mtb infected 
monocytes 
 
To determine whether MMP-14 was having a proteolytic effect, we performed  
fluorescent microscopy of cells plated on fluorescent collagen.   Mtb infection drove 
surface MMP-14 expression on unpermeabalised monocytes at 24 hours incubation 
(Fig. 23). Mtb infection caused collagen degradation, as indicated by the black zones 
where fluorescence is absent, which co-localised with areas of MMP-14 expression. 
Pericellular collagen degradation co-localising with MMP-14 expression was not 
seen with the unstimulated monocytes.   
 
To determine specificity, we neutralised MMP-14 activity with an inhibitory antibody.  
A neutralising concentration of 10µg/ml for the MAB3328 antibody is recommended 
in the data sheet and has been employed in other assays [121]. This downregulated 
the Mtb driven collagen degradation (Fig. 24). The zones of collagen clearance were 
present in close association with the Mtb infected monocytes (Fig. 24B), but were 
absent in those Mtb infected monocytes incubated with the MMP-14 inhibitory 
antibody (Fig. 24C). The surface area of degraded collagen was quantified, 
demonstrating that Mtb infection drove 42.8 times more collagen degradation by 
monocytes in comparison to no stimulus and that MMP-14 inhibition resulted in a 73% 
reduction in this collagen degradation (Fig. 24E p<0.001). A matched isotype control 
antibody had no effect on the collagen degradation driven by Mtb infected 
monocytes. This demonstrates that the Mtb driven pericellular collagen degradation 
is MMP-14 dependent  (Fig. 24D and E).  
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Figure 23: MMP-14 expression co-localises with collagen degradation driven 
by Mtb infected monocytes 
Human monocytes were seeded on FITC conjugated Type I Collagen and infected with Mtb (MOI 1). 
MMP-14 surface expression and collagen degradation were analysed by immunofluorescent staining 
and microscopy. Blue=DAPI nuclear stain, Magenta=MMP-14, Green= Type I Collagen.  Mtb infection 
increased surface MMP-14 expression and caused  black zones of pericellular collagen degradation 
that were not seen with  unstimulated monocytes at 24 hours incubation. MMP-14 surface expression 
co-localised with areas of Type I Collagen degradation. The images are representative of 3 
independent experiments.   
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Figure 24: Mtb driven collagen degradation is MMP-14 dependent 
Human monocytes were seeded on FITC conjugated Type I Collagen and infected with Mtb (MOI 1). 
Collagen degradation was analysed by immunofluorescent microscopy. Blue=DAPI nuclear stain, 
Green= Type I Collagen. MMP-14 activity was neutralised with an inhibitory anti MMP-14 antibody 
(Ab, MAB3328, Millipore) at 10µg/ml. A, Pericellular collagen was intact around unstimulated 
monocytes at 24 hours. B, Mtb infected monocytes degraded pericellular collagen C, Neutralisation of 
MMP-14 activity suppressed pericellular collagen degradation. D, A matched isotype control antibody  
did not suppress pericellular collagen degradation by Mtb infected monocytes. E, Degraded collagen 
area was quantified for five images per condition and is expressed as the area of degraded collagen 
per cell (µm
2
). Neutralisation of MMP-14 activity reduced pericellular collagen degradation. The 
results shown are from a single experiment and are representative of 3 independent experiments. The 
mean +/- SD is shown. Statistical analysis was performed using a one-way ANOVA with Tukey‟s post 
hoc test (***p<0.001).  
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5.2.4 MMP-14 is expressed in granulomas of patients with TB and is 
upregulated by Mtb induced intercellular networks 
 
To further investigate the significance of the cellular data to clinical tuberculosis, 
biopsies from patients with active TB (n=3) and normal lung tissue at the excision 
margins of samples from patients with lung cancer (n=3) were immunostained for 
MMP-14. MMP-14 immunoreactivity was identified diffusely in TB granulomas both in 
Langerhan‟s multinucleate giant cells and also in the surrounding epithelioid 
macrophages (Fig. 25A). In the normal lung tissue of the control patients MMP-14 
immunoreactivity was detected only in alveolar macrophages. We have previously 
shown increased MMP-14 gene expression at the site of disease and this finding 
confirms the presence of the  MMP-14 protein.   
 
MMP-14 was diffusely expressed in the granuloma, but mycobacteria are relatively 
sparse in granulomas [68]. This lead to investigation of Mtb induced intercellular 
networks and MMP-14 expression, in addition to direct infection. Fluorescent 
microscopy showed that cell surface MMP-14 expression was increased in CoMTb 
stimulated unpermeabalised monocytes at 24 hours incubation compared to 
unstimulated cells (Fig. 25B). Permeabalisation of cells prior to staining  
demonstrated that MMP-14 was increased intracellularly  at 24 hours, as well as on 
the cell surface. Paraformaldehyde fixation is necessary before permeabalisation of 
cells with Triton X. We found that it was not possible to detected MMP-14 on the 
surface of unpermeabalised cells that had been paraformaldehyde fixed prior to 
immunostaining. This was  likely a consequence of  antigen cross linking impairing 
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antibody binding [194]. Therefore the MMP-14 detected in the images of 
permeabalised monocytes was intracellularly located. 
 
Flow cytometric analysis demonstrated an increase in the MMP-14 MFI for CoMTb 
stimulated  unpermeabalised monocytes compared to unstimulated cells at 24 hours 
(Fig. 26A). Quantification showed a 17.5 fold increase in MMP-14 surface expression 
with CoMTb (Fig. 26B, p<0.05). These data show that Mtb induced intercellular 
networks, as well as direct infection, drive monocyte surface and intracellular MMP-
14 expression.  
 
CoMTb stimulation drove a 5.2 fold increase in MMP-14 gene expression 
(normalised to β-actin) at 3 hours rising to 22.6  fold at 6 hours and 45.4 fold at 24 
hours (Fig. 26C, p<0.001 for 6 and 24 hours), indicating that the increased surface 
expression of MMP-14 protein was secondary to increased gene expression. 
  
In a separate experiment to that shown in Fig. 26A the effect of CoMCont on MMP-
14 cell surface expression compared to no stimulus and CoMTb was measured by 
flow cytometry. The MFI (arbitrary units) for CoMTb stimulated unpermeabalised 
monocytes was 25.1 compared to CoMCont 12.8 and unstimulated 14.3 (Fig. 26D).  
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Figure 25: MMP-14 is expressed in 
granulomas of patients with TB and is 
upregulated by Mtb induced 
intercellular networks 
A, MMP-14 immunohistochemistry was 
performed on biopsies from patients with culture 
proven TB (n=3) and normal lung tissue at the 
excision margins of patients with lung cancer 
(n=3). MMP-14 immunoreactivity appears brown 
against the blue haemotoxylin counterstain. 
MMP-14 was expressed throughout the 
granuloma within both giant cells and epithelioid 
macrophages. In control biopsies MMP-14 was 
expressed only in alveolar macrophages. Boxed 
areas represent higher magnification image and 
white arrows indicate Langerhan‟s multinucleate 
giant cells which are surrounded by epithelioid 
macrophages. B, Monocytes were stimulated 
with CoMTb. MMP-14 expression was analyzed 
by immunofluorescent staining. Blue=DAPI 
nuclear stain, Magenta=MMP-14. CoMTb 
stimulation increased both cell surface and 
intracellular MMP-14 expression at 24 hours 
compared to unstimulated monocytes. The 
images are representative of 3 independent 
experiments. 
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Figure 26: Mtb induced intercellular 
networks drive monocyte MMP-14 
expression  
Human monocytes were stimulated with CoMTb 
and MMP-14 expression analysed by flow 
cytometry (A, B and D) and RT-PCR (C). A, 
Surface MMP-14 expression was increased in 
CoMTb stimulated monocytes compared to 
unstimulated monocytes at 24 hours. B, Analysis 
of MMP-14 MFI for three separate donors, 
confirmed increased MMP-14 expression. The 
mean +/- SD are shown. C, CoMTb caused a 
progressive increase in MMP-14 mRNA 
(normalised to β-actin) from 3 hours through to 
24 hours incubation, while no change was seen 
in unstimulated monocytes. Mean +/- SD for an 
experiment performed in triplicate is shown and is 
representative of two independent experiments. 
Statistical analysis was performed using 
Student‟s t-test (*p<0.05, ***p<0.001). D Surface 
MMP-14 expression was increased in CoMTb 
stimulated monocytes compared to unstimulated 
monocytes at 24 hours, but not in monocytes 
incubated with CoMCont. 
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5.2.5 MMP-14 expression driven by Mtb induced intercellular networks is 
regulated by p38 and JNK but not ERK MAPK signalling  
 
 MMP-14 expression in TB may be regulated by the MAPK pathways [100, 101] and  
therefore we investigated regulation of monocyte MMP-14 expression by these 
pathways. The MAPK pathways are briefly illustrated in Fig. 1. 
 
CoMTb driven phosphorylation of the p38, ERK and JNK MAPK signalling molecules 
in whole cell lysates was investigated. CoMTb stimulation of monocytes caused a 3 
fold increase in p38 phosphorylation (normalised to total p38) compared to 
unstimulated cells at 30 minutes incubation (Fig. 27A and B, p<0.05). A 2.7 fold 
increase in ERK phosphorylation (normalised to total ERK) was similarly observed 
(Fig. 27A and C, p<0.05). However for JNK, increased levels of not only the 
phosphorylated but also the total protein were identified (Fig. 27A), therefore 
densitometric quantification was not performed. The reasons for this unusual finding 
are unclear, but were consistent across two experiments performed in triplicate. The 
initial suspicion was that the total JNK antibody was cross reacting with the 
phosphorylated JNK that has not been fully removed from the membrane by the 
stripping process. However Cell Signalling Technology advise that the total JNK 
antibody (9252) does not cross react with phosphorylated JNK, and this antibody has 
been widely used since 2000, and cited in recent papers where this problem was not 
experienced [195] . 
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Specific chemical inhibitors and flow cytometric analysis of MMP-14 MFI on 
unpermeabalised monocytes were used to investigate the role of the MAPK 
signalling pathways in controlling MMP-14 expression. The mechanism of action of 
SB and PD has already been discussed. SP600125 (SP) is a reversible ATP 
competitive inhibitor of JNK phosphorylation [196].  Inhibition of the p38 MAPK 
signalling pathway by SB203580  resulted in a 26% reduction in CoMTb driven 
surface MMP-14 expression on unpermeabalised monocytes at 24 hours incubation 
(Fig. 28A and B, p<0.05). Inhibition of the JNK MAPK signalling pathway by SP 
produced a 28% reduction (Fig. 28E and F, p<0.05) In contrast, inhibition of the ERK 
MAPK pathway with PD98059 had no effect (Fig. 28C and D). These data showed 
that monocyte surface MMP-14 expression driven by intercellular networks was 
regulated by p38 and JNK but not ERK MAPK signalling  
 
PI staining showed that the chemical inhibitors cause no cell death at 24 hours 
incubation. DMSO, the carrier for the inhibitors, had no effect on MMP-14 surface 
expression when used at equivalent concentrations alone. 
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Figure 27: Mtb induced intercellular networks drive p38, ERK and JNK MAPK 
phosphorylation in monocytes 
A, p38, ERK and JNK MAPK phosphorylation was analyzed by western blotting. CoMTb stimulation 
increased phosphorylated p38 and ERK in monocytes compared to unstimulated monocytes at 30 
minutes, while total p38 and ERK were unchanged. However CoMTb stimulation increased both 
phosphorylated and total JNK. B and C, Densitometric analysis of phosphorylated and total p38 and 
ERK bands, confirmed increased phosphorylation of p38 and ERK. Mean +/- SD for an experiment 
performed in triplicate is shown and is representative of two independent experiments. Statistical 
analysis was performed using Student‟s t-test (*p<0.05). 
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Figure 28: Intercellular network driven 
monocyte MMP-14 expression is 
regulated by p38 and JNK but not 
ERK MAPK signalling  
Human monocytes were pre-incubated with the 
p38 inhibitor SB203580 (SB) 1µM, ERK inhibitor 
PD98059 (PD) 10µM or JNK inhibitor SP600125 
10µM for 1 hour prior to stimulation with CoMTb. 
MMP-14 surface expression was measured by 
flow cytometry.  A, C, E Chemical inhibition of the 
p38 and JNK but not the ERK MAPK pathway 
downregulated CoMTb driven surface MMP-14 
expression on  monocytes at 24 hours. B, D, F 
Analysis of MMP-14 median fluorescence 
intensity (MFI) for three separate donors, 
confirmed CoMTb driven surface MMP-14 
expression is regulated by the p38 and JNK but 
not the ERK pathway. The mean +/- SD are 
shown. Statistical analysis was performed using 
Student‟s t-test (*p<0.05). 
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5.2.6 The components of Mtb induced intercellular networks 
 
We analyzed cytokines, chemokine and growth factors present in CoMCont and 
CoMTb from 4 different monocyte donors. Table 9 presents the median values with 
interquartile ranges for all 4 donors combined.  The full list of the thirty cytokines, 
chemokines and growth factors analysed is detailed in METHODS.  
 
The cytokines IL-1β, IL-6, TNFα, interferon alpha (IFNα), IL-12, interleukin 1 (IL-1) 
receptor antagonist and interleukin 2 (IL-2) receptor were increased in CoMTb. CCL2 
(monocyte chemoattractant protein 1, MCP-1), CCL3 (macrophage inflammatory 
protein 1 alpha, MIP-1α), CCL4 (macrophage inflammatory protein 1 beta, MIP-1β), 
CXCL8 (interleukin 8, IL-8) and CXCL9 (monokine induced by gamma interferon, 
MIG) were the chemokines that were elevated in CoMTb. Finally the growth factors 
granulocyte macrophage colony stimulating factor (GM-CSF), vascular endothelial 
growth factor (VEGF), granulocyte colony stimulating factor (G-CSF) and fibroblast 
growth factor (FGF) were higher in CoMTb.   
 
It was protocol to filter sterilize CoMTb through a 0.2μM pore size Anopore 
membrane as discussed in METHODS. It has been shown that Anopore (aluminium 
oxide) filtration removes all MMP -1, -7 and 9 but that Millipore (polyvinylidene 
fluoride) filtration does not remove MMP -1 [140]. Therefore, I investigated the effect 
of Anopore vs. Millipore filtration on the levels of the above cytokines, chemokines 
and growth factors  in CoMTb.  
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The mean levels that were found in the four Anopore filtered CoMCont and CoMTb 
samples are shown in comparison to mean levels in four Millipore filtered CoMCont 
and CoMTb samples in Table 10. This shows that the Millipore filtration removed IL-
1β, IL-6, TNFα, IFNα, IL-2 receptor, CCL3, CCL4, CXCL9, GM-CSF, VEGF, G-CSF 
and FGF.  Anopore filtration removed CCL8, though a large concentration remained. 
It was therefore appropriate that Anopore filtration was the standard protocol. This 
resulted in the CoMTb containing a higher concentration of the cytokines, 
chemokines and growth factors that constitute the Mtb induced intercellular network.  
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     Table 9: Cytokines, chemokines and growth factors in  
      CoMCont and CoMTb 
 
 
 
 
 
 
                     
 
 
 
 
 
 
 
 
                         
 
         Median levels and interquartile ranges (in brackets) in pg/ml 
 
 
 
  
  CoMCont  CoMTb  
Cytokines 
  IL-1β 165 (39-192) 31813 (7994 - 39014) 
IL-6 1 (1-1) 50914 (11903 - 63160) 
TNFα 1 (1-1) 15369 (1607 - 63755) 
IFNα 6 (6-6) 340 (69 - 550) 
IL-12 2 (2-2) 752 (167 - 3853) 
IL-1 receptor 
antagonist 628 (144-744) 8893 (3774 - 11242) 
IL-2 receptor 2 (2-25) 994 (574 - 1326) 
   Chemokines 
  CCL2 ((MCP-1) 6 (6-10) 1184 (334 - 2780) 
CCL3 (MIP-1 α) 4 (4-4) 
215660 (19320 - 
361100) 
CCL4 (MIP-1 β) 2 (2-2) 19799 (5630 -238242) 
CXCL8 (IL-8) 34 (9-41) 96439 (7176 - 180980) 
CXCL9 (MIG) 47 (8-86) 175 (50 - 217) 
   Growth factors 
  GM-CSF 3 (3-3) 286 (70-1324) 
VEGF 35 (7-45) 168 (95 - 192) 
G-CSF 3 (3-3) 1394 (245 - 1896) 
FGF 256 (64 - 259) 343 (94 - 378) 
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            Table 10: Anopore vs. Millipore filtration of CoMCont and CoMTb 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 Median levels and interquartile ranges (in brackets) in pg/ml 
        
 
Filter CoMCont  CoMTb  
Cytokines 
   IL-1β Anopore 132 26274 
  Millipore 3 978 
IL-6 Anopore 1 41992 
  Millipore 3 978 
TNFα Anopore 1 26910 
  Millipore 4 2430 
IFNα Anopore 6 319 
  Millipore 6 30 
IL-12 Anopore 2 1590 
  Millipore 7 1399 
IL-1 receptor 
antagonist Anopore 506 7969 
  Millipore 345 5042 
IL-2 receptor Anopore 9 964 
  Millipore 2 104 
Chemokines 
   CXCL8 (IL-8) Anopore 28 94865 
  Millipore 32117 17977623 
CCL3 (MIP-1 α) Anopore 4 198693 
  Millipore 40 12651 
CCL4 (MIP-1 β) Anopore 2 87890 
  Millipore 103 4481 
CCL2 ((MCP-1) Anopore 7 1426 
  Millipore 251 1016 
CXCL9 (MIG) Anopore 47 147 
  Millipore 21 49 
Growth Factors    
GM-CSF Anopore 3 560 
  Millipore 3 191 
VEGF Anopore 29 151 
  Millipore 0 48 
G-CSF Anopore 3 1178 
  Millipore 3 31 
FGF Anopore 193 271 
  Millipore 1 28 
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5.2.7 Signalling through Gi protein coupled pathways regulates monocyte 
MMP-14 expression driven by Mtb induced intercellular networks 
 
CC chemokines are considered critical to monocyte chemotaxis and migration to 
sites of infection including Mtb [197]. We chemically inhibited  signalling through Gi 
protein coupled pathways using PT [93]. Chemokines signal through Gi proteins and  
downstream effects of PT  include inhibition of chemotaxis [94]. However a range of 
other ligands signal through G protein coupled receptors, so the effects of PT are not 
specific to chemokines [93]. PT caused a 35% reduction in CoMTb driven surface 
MMP-14 expression on unpermeabalised monocytes at 24 hours incubation (Fig  
29A  and B, p<0.05).  This shows that the component of the Mtb induced 
intercellular network  that signal through Gi protein coupled pathways were driving 
monocyte surface MMP-14 expression. This component includes but is not limited to 
chemokines.  
 
Investigation of the individual chemokine in CoMTb which was responsible for driving 
MMP-14 expression was attempted. The focus was placed on CCL2 given its 
established role in monocyte chemotaxis [197]. However recombinant CCL2 used at 
much higher levels than that identified in CoMTb of 100ng/ml did not increase MMP-
14 cell surface expression on flow cytometry. When combined as a stimulus with Tb 
supernatant there was only a very small augmentation of MMP-14 MFI on 
unpermeabalised monocytes compared to Tb supernatant alone. Therefore the next 
logical step was to attempt neutralisation of CCL2 in CoMTb using a specific 
antibody. However the neutralising antibody itself stimulated the cells, making the 
results uninterpretable.  
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Figure 29: Signalling through Gi protein coupled pathways regulates monocyte 
MMP-14 expression driven by Mtb induced intercellular networks 
Human monocytes were pre-incubated with PT 10ng/ml for 1 hour prior to stimulation with CoMTb. 
MMP-14 surface expression was measured by flow cytometry.  A, Chemical inhibition of G-protein 
coupled receptor signalling downregulated CoMTb driven surface MMP-14 expression on monocytes 
at 24 hours. B, Analysis of MMP-14 median MFI for three separate donors, confirmed that CoMTb 
driven surface MMP-14 expression is regulated by G-protein coupled receptor signalling. The mean 
+/- SD are shown. Statistical analysis was performed using Student‟s t-test (*p<0.05). 
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5.2.8 Monocyte migration is driven by Mtb induced intercellular networks and  
regulated by MMP-14 
 
We next investigated the role of MMP-14 in promoting monocyte migration using the 
agarose spot assay for chemotaxis. Monocytes migrated towards  CoMTb-
impregnated agarose spots, forming clusters around the edge at 24 hours incubation 
that were not observed in control spots (Fig. 30A and B), demonstrating that CoMTb 
was a chemotactic stimulus for monocyte migration. Monocytes migrating towards 
the CoMTb spot expressed higher levels of surface MMP-14 than the cells around 
the control spot (Fig. 30C and D), indicating that CoMTb drove MMP-14 expression 
in migrating cells.  
 
Therefore, we investigated if inhibition of MMP-14 activity on monocytes reduced 
their migration towards CoMTb. MMP-14 inhibition reduced the size of monocyte 
clusters around spots (Fig. 31C and E). Migration was quantified using the 2 spots 
per condition with the diameter of monocyte clusters measured at 4 radial points per 
sphere. The diameter of the monocyte clusters for CoMTb was twice that for the 
control spots, and inhibition of MMP-14 activity resulted in a 44% reduction in the 
diameter of the monocyte clusters (p<0.005). A matched isotype control antibody 
had no effect on monocyte migration toward CoMTb (Fig. 31D and E).. These data 
show that monocyte migration towards Mtb induced intercellular networks is MMP-14 
dependent.  
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Figure 30: Mtb induced intercellular networks induce monocyte migration and 
concurrent MMP-14 expression 
RPMI (Control) or CoMTb-impregnated agarose spots were set on slides coated with Type I collagen. 
Human monocytes were then added. White arrows indicate the agarose spot and migratory stimulus, 
while the dashed line indicates the spot edge. Surface MMP-14 expression was measured by 
immunofluorescent staining, Magenta=MMP-14.  A, B, Light microscopy images show that monocytes 
migrated towards the CoMTb spot forming a cluster at 24 hours, which did not occur for the control 
spot. C, D, Surface MMP-14 expression was greater on monocytes migrating towards the CoMTb 
spot than the control spot at 24 hours incubation. E, F, Merged images.   Images are representative of 
3 independent experiments.  
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Figure 31: MMP-14 regulates monocyte migration driven by Mtb induced 
intercellular networks 
RPMI (Control) or CoMTb-impregnated agarose spots were set on collagen-coated slides. Human 
monocytes were seeded on these slides. MMP-14 activity was neutralised with an inhibitory anti 
MMP-14 antibody (MAB3328, Millipore) at 10µg/ml. Light microscopy and image capture was 
undertaken at 24 hours. A, No clustering of monocytes occurred around the control spot. B, 
Monocytes migrated towards CoMTb agarose spots and formed clusters. C, Neutralisation of MMP-14 
activity reduced the cluster size around CoMTb spots. D, A matched isotype control antibody did not 
reduce the cluster size around CoMTb spots E, Monocyte migration was quantified using two spots 
per condition with images taken at 4 radial points per spot. Maximum diameter of the monocyte 
clusters was measured, confirming that MMP-14 neutralisation reduced monocyte migration. The 
results are mean +/- SD from a single experiment and are representative of 2 independent 
experiments. Statistical analysis was one-way ANOVA with Tukey‟s post hoc test (***p<0.001). 
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5.3 Discussion 
 
By investigation of patients with TB and functional cell culture models, we 
demonstrate that TB upregulates MMP-14 expression to cause both collagen 
destruction and cell migration.  MMP-14 gene expression was increased in the 
sputum of TB patients, positively correlating with the degree of lung infiltration on 
chest radiograph, and MMP-14 is expressed diffusely in TB granulomas. Mtb and 
monocyte dependent intercellular networks upregulate expression of MMP-14 
secondary to increased gene expression. MMP-14 expression causes type I collagen 
degradation. Monocyte migration was dependent on MMP-14 activity. The MMP-14 
expression driven by intercellular networks was mediated by p38 and JNK MAPK 
and chemokine signalling. These data support the hypothesis that MMP-14 is a 
central regulator of collagen degradation and leukocyte migration in human 
pulmonary tuberculosis.  
The existing data on MMP-14 in TB was discussed earlier, and the evidence for a 
role in other destructive lung disease is limited. An early study showed more intense 
immunoreactivity for MMP-14 in epithelial cells, fibroblasts and alveolar 
macrophages of emphysematous lung compared to healthy tissue, confirmed by 
western blotting. Analysis by gelatin zymography showed a higher ratio of the active 
to the proform of MMP-2 in emphysema, suggesting in situ activation by MMP-14 
[198].  Immunohistochemical staining for MMP-14 in lung biopsies from patients with 
combined idiopathic pulmonary fibrosis/ emphysema and emphysema and controls 
was performed. This showed higher MMP-14 expression in interstitial fibroblasts 
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adjacent to areas of parenchymal destruction in diseased compared to healthy lung 
[199].  
 
There is also some relevant published data on the role of MMP-14 in Toxoplasma 
infection. Toxoplasma gondii is an obligate intracellular parasite, which crosses basal 
membranes within macrophages and dendritic cells and invades ECM. Toxoplasma 
infection of THP-1 cells and macrophages upregulated MMP-14 expression 
measured by western blotting and flow cytometry [200, 201].  
 
 
We demonstrated that MMP-14 expression on the monocyte surface is driven both 
by direct Mtb infection and the paracrine signalling of Mtb induced intercellular 
networks. This is important because although all monocytes/macrophages have the 
capacity to phagocytose Mtb, the number of intracellular bacilli present at the site of 
disease is low [68], but because of intercellular signalling networks there is still the 
potential for high MMP-14 expression. This was confirmed by our in vivo findings of 
increased MMP-14 mRNA in induced sputum, and diffuse MMP-14 expression 
throughout the granuloma of biopsies form TB patients. Mtb induced intercellular 
network have also previously been shown to drive MMP-9 secretion from monocytes 
[92].  
.  
 
We found that p38 and ERK MAPK signalling regulated the surface MMP-14 
expression on monocyte stimulated by intercellular networks.  The role of MAPK 
signalling in controlling MMP-14 monocyte surface expression has not been 
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previously studied, so the findings are novel though neither p38 nor JNK are a 
master regulator, as only small changes were noted with inhibition of their activity. 
We did not demonstrate regulation by ERK MAPK in monocytes, but studies using 
malignant cells have identified a role for ERK in driving constitutive MMP-14 
expression [202, 203],  suggesting cell specific regulation.  
  
The Mtb driven MMP-14 surface expression was secondary to increased mRNA 
accumulation. The MMP-14 gene promoter has a NF-ĸB consensus binding site and 
we attempted chemical inhibition of NF-ĸB signalling. Unacceptably high cell death 
occurred in the presence of SC-514 and Helenalin even at low concentrations 
therefore it was not possible to pursue this line of enquiry.  However NF-ĸB remains 
the most likely candidate for the transcriptional regulator driving MMP-14, given its 
importance in innate immunity and inflammation [103]  and the role already identified 
in other models [204]. A future experimental strategy would be to use siRNA 
technology to knockdown expression of the NF-ĸB gene.  
 
 
We also demonstrated that MMP-14 upregulation was G-protein coupled receptor 
dependent, implicating chemokine activity.  Chemokines are considered critical to 
leukocyte migration to TB granulomas [96].CCL2 signalling through the CCR2 
receptor may be important to monocyte-macrophage migration from studies utilising 
knockout  mice [197]. In our cellular model, chemokine signalling drives expression 
of MMP-14 on the monocyte surface, which is the critical cell surface MMP for 
migration [116]. Using fluorescent microscopy MMP-14 clustering has been 
observed at motility associated protrusions of CCL2 stimulated monocytes 
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transmigrating through endothelium [121], and CCL2 and CXCL8 promote MMP-14 
surface expression, clustering and activity in endothelial cells [205]. 
 
Historically, attempts to identify individual chemokines within the Mtb induced 
intercellular network driving MMP expression, by using neutralising antibodies, have 
proved unsuccessful [72, 92]. This was thought to be a consequence of redundancy 
within chemokine receptor signalling [206]. I still felt it worthwhile exploring the role of 
CCL2 specifically in driving monocyte MMP-14 expression, as this chemokine has 
such a critical role in monocyte migration[197]. However efforts were thwarted by 
difficulties such as the stimulatory effect of the CCL2 neutralising antibody, as 
discussed in the results section.  As mentioned for investigation of NF-ĸB signalling a 
future approach would be to use siRNA technology to knockdown CCL2 gene 
expression when generating CoMTb.  
 
Unlike the secreted MMPs, MMP-14 is activated intracellularly then inserted at the 
cell surface [207]. We were able to show that neutralisation of cell surface MMP-14 
activity reduced Mtb driven pericellular Type I collagen degradation in our fluorescent 
collagen degradation assay. This is particularly critical to our hypothesis and gives 
strength to the proposal that the MMP-14 expressed at the site of disease will be 
driving collagen degradation. Evidence indicates that MMP-14 drives pericellular 
collagen degradation in other systems.  siRNA technology was used to abrogate 
human gingival fibroblast MMP-14 expression, in a similar assay utilising 
fluorescently labelled collagen,  with almost complete loss of type I collagen 
degradation [208]. Again it seems that applying siRNA technology to our model may 
provide data to support the findings with the MMP-14 neutralising antibody.  
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Although the granuloma has traditionally been viewed as a host strategy to control 
mycobacterial growth, accumulating evidence suggests that monocyte migration may 
have deleterious effects to the host. As previously discussed, in  the M. marinum 
infected  zebrafish model, macrophages migrating into granulomas become newly 
infected allowing bacterial expansion and then egress the granuloma, disseminating 
infection to new sites [107, 110]. In mice, intranasal administration of polyinosinic-
polycytidylic acid, a type I interferon inducer, caused a CCR2 dependent excessive 
accumulation of monocytes in the lungs of Mtb infected mice, with increased 
bacterial burden and decreased survival [209].  
 
However, the proteases responsible for driving this leukocyte migration are not 
considered. We demonstrated that Mtb induced intercellular network drove MMP-14 
expression in migrating cells, that the monocyte migration in TB was MMP-14 
dependent, and that MMP-14 surface expression was potentially upregulated by 
chemokine signalling.  
 
The background data presented earlier suggesting a critical role for MMP-14 in cell 
migration, largely pertained to cells invading 3D matrices. The agarose spot assay 
used in this work was a 2D assay where the cells can migrate on top of the  type I 
collagen layer.  This indicates that MMP-14 was promoting the monocyte migration 
independently of ECM degradation, and therefore three potential mechanisms will be 
discussed. 
 
There is a body of evidence suggesting that MMP-14 cleaves cell surface proteins to 
promote the organised cell adhesion-deadhesion required for migration. For example, 
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syndecan-1 is a transmembrane heparan sulphate proteoglycan which binds 
extracellular matrix components including collagen, and is cleaved by MMP-14. 
MMP-14 differs from the secreted MMPs in that its activity is inhibited by TIMP-2 but 
not TIMP-1. Migration of fibrosarcomatous cells in a wound healing assay was 
reduced in cells transfected to express a mutant uncleavable syndecan-1, but 
enhanced in cells transfected with normal syndecan-1 in a process inhibited by 
TIMP-2 but not TIMP-1 [210]. CD44 is a receptor for haemagglutinin, which is 
abundant in many tissues, and other ECM components such as Type I collagen. A 
breast cancer cell line was transfected with plasmids to express CD44 and MMP-14. 
Using western blotting and a phagokinetic track motility assay, it was shown that 
MMP-14 cleaves CD44 to produce a soluble fragment. Expression of MMP-14 or 
CD44 alone did not stimulate cell migration, but co-expression did. Co-expression of 
a CD44 deletion mutant, which cannot be cleaved by MMP-14, resulted in loss of cell 
migration [211]. MMP-14 dependent cleavage of other cell surface proteins which 
interact with ECM components such as integrins and transglutaminase are also 
considered important to migration of malignant cells [212, 213] 
 
Other evidence suggests internalisation of MMP-14 from the leading cell edge is 
important in driving migration. A Chinese hamster ovary cell line was transfected with  
wild-type MMP 14 and varying deletion mutants with different domains absent. 
Fluorescent microscopy, a matrigel invasion assay and phagokinetic track assay 
were used. The cytoplasmic tail was required for the internalisation of MMP-14 from 
the leading edge of the cell in clathrin coated pits, and that this process of 
internalisation was important to the migration and invasion driven by MMP-14 [214]. 
Initially it was postulated that this could be because degraded or TIMP-2 inhibited 
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MMP-14 was not being removed from leading edge and replaced with “fresh” MMP-
14. However in a separate study HeLa cells were transfected with wild type MMP-14, 
MMP-14 with Thr 567 glutamate substituted (permanently phosphorylated) or MMP-
14 with Thr 567 alanine substituted (not possible to phosphorylate). Phosphorylation 
of Thr 567 is required for internalisation of MMP-14. Using fluorescent microscopy, a 
transwell migration assay and matrigel invasion assay it was shown that the 
glutamate substitution reduced MMP-14 cell surface expression, but promoted 
migration and invasion. However the alanine substitution increased cell surface 
expression, while reducing migration and invasion [215]. This clearly indicates that 
the MMP-14 internalisation process itself drives cell migration, though the exact 
underlying mechanism is yet to be elucidated.   
 
It has also been postulated that MMP-14 promotes cell migration by driving ERK 
MAPK phosphorylation. MMP-14 siRNA technology was employed in a human 
fibrosarcoma cell line. Western blotting, a Type I collagen coated transwell migration 
assay, and chemical inhibition of ERK and MMP-14 were used to show  that TIMP-2 
binding to MMP-14 drove ERK signalling, which increased cell migration 
independently of the direct enzymatic activity of MMP-14 [216]. TIMP-2 interacts with 
MMP-14 through its catalytic domain [217].  
 
The antibody used to neutralise MMP-14 activity binds and inhibits the catalytic 
domain. Therefore it is possible that loss of MMP-14 driven alteration of the cell 
surface proteome and ERK activation were responsible for the reduced monocyte 
migration to CoMTb containing agarose spots. It is less clear how the MMP-14 
neutralising antibody would impact on internalisation of MMP-14.  
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Finally the role that matrikines may be playing in this process needs to be 
considered. Matrikines are protein domains derived from ECM, that  act as direct 
extracellular signals to cells.  These signals are frequently cryptic sites revealed  to 
the cells only after cleavage of ECM components. Matrikines may signal via integrins 
or growth factor receptors to alter cell adhesion to an intermediate promigratory state.  
ECM proteins that signal to produce this intermediate adhesion state include 
laminins, tenasicin C, thrombospondin and secreted protein-rich in cysteine [218].  
 
Laminin-332 (previously laminin-5) is an epithelial basement membrane substrate for 
cell adhesion and migration. Western blotting and a cell migration assay in cell lines 
for  colon and breast carcinomas, hepatomas and hepatocytes showed that 
migration on Ln-332 correlated with expression of membrane bound MMP-14. The 
migration was reduced by MMP-14 antisense oligonucleotides. MMP-14  colocalised 
with laminin-332 in colon and breast cancer tissue. It is the ϒ2 subunit of laminin-332 
that is cleaved and released by MMP-14 [219]. This ϒ2 subunit carries cryptic sites 
that are EGF like and stimulate cancer cell migration by signalling through EGF 
receptors [220]. While laminin-332 was not present in the agarose spot assay I used, 
it is possible that MMP-14 cleaves and releases matrikines from Type I Collagen, 
though there is currently no data from other models to support this.  
 
In summary, MMP-14 expression was demonstrated in the sputum and granulomas 
of TB patients. Mtb and intercellular networks upregulated monocytes MMP-14 
expression in a p38 / JNK MAPK and chemokine dependent manner.  MMP-14 
drove collagen degradation and monocyte migration in the functional cellular model 
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of TB. MMP-14 may be a central regulator of two immunopathological processes in 
TB, tissue destruction and excessive leukocyte migration.  
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6. DISCUSSION 
In summary, the collagenases MMP-1 and MMP-8 are elevated in active pulmonary 
TB in the plasma. The increased plasma MMP-8 is specific to TB patients, and is not 
elevated in controls with other respiratory infections. The stromelysin MMP-10 is 
elevated in the respiratory secretions of patients with TB and in vitro MMP-10 
expression is driven by ESAT-6, an Mtb specific virulence factor. The membrane 
bound collagenase MMP-14 is expressed in the induced sputum and granulomas of 
TB patients, and MMP-14 drives collagen degradation and leukocyte migration in a 
functional cellular model of TB. 
 
6.1 A model of synergistic MMP activity causing 
immunopathology in Mtb infection  
 
My data suggest involvement of a range of MMPs in TB immunopathology, and this 
contrasts with established thinking, which focuses on immune cells, cytokines and 
lipids driving necrosis in TB [45]. However this model does not take into account the 
constituents of lung ECM – the primary structural fibril collagen can only be 
degraded by MMPs at neutral pH [221]. By considering lung ECM structure in 
conjunction with the complex, diverse and overlapping functions of MMPs, a model 
comprising activity of at least MMP-1, -8, -10 and -14 involvement in TB 
immunopathology can be proposed.  To consider a single protease dominant in TB 
may oversimplify the situation in vivo. 
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Though only MMP-1, -8 and -14 can degrade types I, II and III collagen, MMP-10 
may be co-operating with these collagenases to degrade the primary structural fibrils 
of the lung.  Destruction of the extracellular matrix will involve a diverse array of 
proteases, and cannot be performed by a single protease.  At a site of pulmonary 
Mtb infection, stromelysin MMP-10 may cleave the proteoglycans crosslinking the 
collagen fibrils and thereby expose the fibrils, leaving them more vulnerable to the 
enzymatic activity of the collagenases, MMP-1, -8 and -14. For monocytes entering 
the pulmonary ECM from capillaries MMP-14 promotes migration not only by 
cleaving fibrillar collagen at the leading edge of the cell to clear a path, but by 
altering the cell surface proteome and modulating intracellular signalling. Once the 
monocytes have arrived at a focus of Mtb infection MMP-14 will work alongside 
MMP-1 and MMP-8, driving localised collagen destruction. The cellular sources and 
interplay of MMP-1,-8, -10 and  -14 are illustrated in Fig. 32.  
The role of these individual MMPs in driving TB immunopathology has been 
discussed in detail in their respective chapters, so now the implications of these 
findings for TB management must be considered.  
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Figure 32: The interaction of MMP-1, -8, -10 and -14 in cell migration and 
extracellular matrix destruction in pulmonary TB 
Mtb infection of macrophages and intercellular network stimulation of respiratory epithelial cells 
drives secretion of the stromelysin MMP-10. Active MMP-10 directly cleaves proteoglycans 
cross-linking triple helical collagen fibrils, thus exposing the fibrils to collagenases such as  
MMP-1 and MMP-8. These are secreted from Mtb infected macrophages and neutrophils 
respectively.  MMP-10 converts MMP-1 and MMP-8 from the pro to active forms with greater 
enzymatic activity against triple helical collagen. Meanwhile Mtb induced intercellular networks 
stimulate MMP-14 expression on monocytes migrating into the ECM from capillaries. MMP-14 
cleaves triple helical collagen at the leading edge of the cell to clear a path and also promotes 
migration by altering the cell surface proteome and modulating intracellular signalling. Once 
monocytes arrive at the site of Mtb infection more generalised cell surface MMP-14 drives local 
degradation of triple helical collagen, working alongside the secreted collagenases MMP-1 and -8 
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6.2 MMPs and point of care TB diagnostics  
 
The finding that plasma MMP-8 was specific elevated in TB patients but not controls 
with other respiratory infections is of particular relevance to TB diagnostics. The 
need for improved case detection is highlighted in the WHO STOP TB Strategy. A 
study published in 2011 showed a case detection rate for pulmonary TB of only 56% 
in HIV infected and 65% in HIV uninfected patients in a rural Western Kenyan 
community. A large proportion of the unidentified cases were a consequence of  
cases failing to present to health care services, but it was estimated that 16% could 
have been detected earlier if case detection facilities were improved [222].  
 
Patients in these settings are assessed in community clinics which have limited or no 
laboratory facilities, technicians or even electricity. Sputum smear microscopy is the 
main diagnostic technique in pulmonary TB, but requires some infrastructure to be in 
place, such as a microscope, centrifuge and perhaps most importantly well trained 
staff.  A centre providing this service may be a considerable distance from the 
patient‟s home and consequently logistics of specimen transfer and defaulting from 
healthcare becomes a major problem. The ideal TB test would be an inexpensive, 
rapid serological test, which would require minimal training and equipment for 
implementation, for example a blood or urine dipstick test.  This would allow 
diagnosis and  initiation of treatment at the community clinic within hours of 
presentation [20].  
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An appropriate point of care test for low and middle income countries has remained 
elusive. The Xpert MTB/RIF is accurate and easy to use [223] but expensive and 
requires  sophisticated machinery [224]. The existing commercially available 
serodiagnostic tests, which are used widely in low and middle income countries, 
have only very low quality data supporting their use, are imprecise and inconsistent 
and are not endorsed by WHO [225]. 
 
Plasma MMP-8 shows significant potential but as an isolated biomarker would lack 
sensitivity and specificity. However, it may be amenable to a blood dipstick test, 
combined with other markers as part of a „biosignature‟ could be a more accurate 
diagnostic tool. For example one study showed that a combined detection of 
antibodies to Mtb protein antigens TbF6, DPEP and malate synthase in the serum 
had 85% sensitivity and 97% specificity [226], and so host-targeted biomarker panels 
including MMP-8 warrant further investigation.  
 
 
6.3 Targeting TB immunopathology by MMP inhibition  
 
It is conceivable that in the future tissue destruction in TB could be targeted with 
specific MMP inhibitors, which function by binding within the catalytic domain. The 
MMP inhibitor trials in malignancy in the 1990s were thwarted by the inhibitors 
lacking specificity, and broad spectrum inhibition causing musculoskeletal  side 
effects [227]. Since that time, some effort has been invested in developing more 
specific inhibitors, with varying levels of success for different MMPs.  For example a 
peptidomimetic inhibitor regasepin1 was synthesized,  and showed considerable 
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specificity for MMP-8 compared to the other secreted collagenases MMP-1 and -13 
[228].  
Two newly developed MMP-14 inhibitors have been applied to animal models of 
malignancy. An MMP-14 inhibitory antibody, DX 2400, was identified by Fab library 
screening. Gelatin zymography showed that it blocked conversion of proMMP-2 to 
the active form by MMP-14 in fibrosarcoma cells.  The antibody impaired invasion 
and migration of endothelial cells through matrigel.  In vivo it slowed orthotopic 
breast cancer progression and reduced metastasis in mice [229]. A selective MMP-
14 inhibitor peptide G was developed and demonstrated to inhibit migration and 
invasion of fibrosarcoma cells through matrigel. It also inhibited tongue squamous 
carcinoma growth in mice and prolonged survival [230]. Therefore, specific MMP-14 
inhibition in the context of disease is a viable prospect, though the approaches 
above may be difficult to deliver in resource-poor settings. This approach of targeting 
MMP-14 in TB would require care. While reduction of collagen degradation would 
have clear benefits, excessive inhibition of leukocyte migration could be deleterious 
due to inadequate phagocytosis of Mtb and effectively cause immunocompromise by 
preventing cellular recruitment to the site of infection.  
 
 
6.4 Future work  
 
I have demonstrated that MMP-8 is a potential plasma biomarker of TB and that 
MMP-10 is another metalloproteinase that is likely to contribute to pathology in TB, 
working in conjunction with other MMPs to degrade lung matrix.  However, in my 
opinion, the experiments performed pertaining to MMP-14 yielded the most 
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interesting and intriguing data and it is this area that would be focussed on in the 
future.  MMP-14, being cell surface bound, is relatively difficult to study compared to 
the secreted MMPs, but by acting both as a collagenase, a sheddase and also 
regulating cellular behaviour, it potentially has a diverse range of actions. 
 
6.4.1 Clinical samples 
 
The finding of increased MMP-14 gene expression in the induced sputum of TB 
patients could be investigated further by looking at MMP-14 cell surface expression 
in respiratory secretions from TB patients. Historically fluorescent staining of BALF 
cytospin preparations was favoured for such work. However, it has become apparent 
that flow cytometric analysis is more accurate in identifying leukocyte subsets and by 
using dead cell markers non-viable cells can be excluded [231].  
 
One difficulty that arises here is that sputum induction is increasingly being 
performed on patient with suspected pulmonary TB for diagnostic purposes rather 
than BAL. This is because it is cheaper and less invasive and in large studies of 
pulmonary TB patients of mixed HIV seroprevalence has been shown to have an 
equivalent diagnostic yield to BAL [232].  
 
Sputum was always considered a difficult sample for flow cytometric analysis due to 
the large amount of mucus in addition to squamous epithelial cell and dead cell 
debris contamination, which causes autofluorescence and non-specific staining. 
However, recent studies have shown with good induction technique, quick 
processing and selection of sputum plugs from the surrounding fluid, it is possible to 
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reduce salivary epithelial cell and dead cell contamination to a minimum [233]. With 
appropriate antibody panels and careful gating strategies major leukocyte 
populations can be identified [234].  Therefore, flow cytometric analysis of MMP-14 
expression in patients with TB would confirm the initial observation of increased 
gene expression. 
 
One area in which cytospin could prove useful is to demonstrate functional activity of 
MMP-14 on the surface of monocytes/ macrophages in induced sputum or BAL. The 
cells would be spun down on to a slide precoated with fluorescent collagen, and 
incubated prior to using fluorescent microscopy to look for zones of collagen 
clearance in the absence and presence of the MMP-14 neutralising antibody.  Taken 
with the flow cytometric data, this would prove a functional collagenolytic effect of 
MMP-14 expression in TB. 
 
6.4.2 Cellular model 
 
When considering future work in the functional cellular model of TB the most critical 
area to explore is the role MMP-14 plays in chemoinvasion of monocytes through a 
3D collagen matrix. Transwell chamber inserts of varying pore size are commercially 
available for this type of assay, and can be coated with a layer of collagen. The 
chemotactic stimulus, in this case CoMTb, would be placed in the lower chamber 
and the cells seeded on top of the collagen in the upper chamber. The number of cell 
migrating through the collagen into the lower chamber in the absence and presence 
of the MMP-14 neutralising antibody would be quantified using flow cytometry or a 
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haemocytometer, to prove that MMP-14 activity was necessary for cellular migration 
through the matrix. 
To elucidate the role of MMP-14 in driving monocyte migration in vivo, the M. 
marinum infected zebrafish embryo model of granuloma formation discussed 
previously could be utilised. An MMP-14 zebrafish embryo morpholino has already 
been created [235], meaning this is a feasible line of enquiry.  My hypothesis would 
be that cellular recruitment to mycobacterial granulomas would be suppressed in the 
MMP-14 morpholino, and since monocytes seem to be a site for mycobacterial 
proliferation and dissemination, the size and number of granulomas would be lower 
in the morpholino.  The ability to perform real-time imaging as the embryo is 
translucent would also permit me to study cellular migration in the presence or 
absence of MMP-14 expression. 
 
Until relatively recently, siRNA transfection  of primary cells especially monocytes, 
macrophages and neutrophils was considered virtually impossible due to high levels 
of cytotoxicity [236]. However, as technology has advanced and new methods of 
delivering siRNA to cells have emerged, this picture is changing. For example, a 
peptide delivery system was recently successfully used to transfect human synovial 
fluid  monocytes and macrophages [237].  In the context of the cellular TB model, 
there were concerns that Mtb infection would cause excessive cell death in the 
context of siRNA transfection. However our group has recently successfully siRNA 
transfected Mtb infected human MDMs using a lipid delivery system without 
unacceptable levels of cell death (unpublished data).  Therefore, siRNA technology 
would be a useful method to establish the role of MMP-14 in monocyte migration and 
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collagen degradation in the cellular TB model. I have also alluded to using it for 
investigating signalling pathways in previous chapters.   
 
In conclusion, my data support a role for MMP-1, -8, -10 and -14 in driving collagen 
degradation and leukocyte migration in TB.  A model of multiple MMPs contributing 
to immunopathology is emerging, with the collagenases being the final effectors of 
matrix destruction, while the stromelysins may not only cleave cross-linking fibrils to 
expose cleavage sites but also proteolytically activate the collagenases, and 
membrane bound MMP-14 regulates cellular recruitment to the granuloma.   Further 
studies in man and in appropriate model systems will be required to establish the 
true diagnostic and therapeutic potential of these MMPs. In particular those which 
are true targets need to be identified, as opposed to those which are physiologically 
required and may lead to poorer outcomes if inhibited inappropriately. 
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9.  ABBREVIATIONS 
AAT: alpha 1 antitrypsin  
AFB:  Acid-fast bacilli  
ANOVA: Analysis of variance 
AP-1:  Activator protein 1  
AUC: Area under the curve  
β-actin: Beta- actin  
BAL: Bronchoalveolar lavage  
BALF: Bronchoalveolar lavage fluid  
BCG: Bacillus Calmette-Guérin  
BEGM®: Bronchial Epithelial Cell Growth Medium  
BMI: Body Mass Index 
BSA: Bovine serum albumin  
CAP: Community acquired pneumonia  
CFP-10: Culture filtrate protein 10  
CFU: Colony forming unit 
CNS: Central nervous system  
CoMCont: Conditioned Medium from Control Monocytes  
CoMTb: Conditioned Media from Mtb infected monocytes  
DMSO: Dimethyl Sulfoxide  
ECM: Extracellular matrix 
EGF: Epidermal growth factor  
ELISA: Enzyme-linked Immunosorbent Assay  
EMEM: Eagle‟s Minimal Essential Medium   
ERK: Extracellular signal related kinases  
ESAT-6: Early secreted antigenic target 6  
FCS: Fetal calf serum  
FGF: Fibroblast growth factor  
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FITC: Fluorescein isothiocyanate 
G-CSF: Granulocyte colony stimulating factor  
GM-CSF: Granulocyte macrophage colony stimulating factor  
HBSS: Hanks Balanced Salt Solution  
HIV: Human Immunodeficiency Virus  
HRP: Horse Radish Peroxidase  
IFNα: Interferon alpha  
IFNϒ: Interferon gamma  
IGRA: IFNϒ release assay  
IL-1: Interleukin 1  
IL-12: Interleukin 12  
IL-1β: Interleukin 1 beta  
IL-2:  Interleukin 2  
IL-6: Interleukin 6   
IL-8: Interleukin 8 
IQR: Interquartile range 
JNK: C-Jun-N-terminal kinases  
LAM: Lipoarabinomannan  
MAPK: Mitogen activated protein kinase  
MCP-1: Monocyte chemoattractant protein 1  
MDMs: Monocyte derived macrophages  
MDR-TB: Multidrug resistant TB  
MFI: Median fluorescence intensity  
MIG: Monokine induced by gamma interferon  
MIP-1α: Macrophage inflammatory protein 1 alpha  
MIP-1β:  Macrophage inflammatory protein 1 beta  
MMP: Matrix metalloproteinase 
MOI: Multiplicity of infection  
Mtb: Mycobacterium tuberculosis  
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MT-MMP: Membrane type matrix metalloproteinase 
N/A: Not applicable 
NF-ĸb: Nuclear factor kappa B  
NHBE: Normal human bronchial epithelial  
PBS: Phosphate buffered saline  
PCA: Principal Component Analysis  
PD: PD98059  
PE: Phycoerythrin  
PI: Propidium iodide  
PT: Pertussis toxin  
RD1: Region of difference 1  
ROC: Receiver operating characteristic  
RT-PCR: Real time polymerase chain reaction  
SB: SB203580 
SD: Standard Deviation 
siRNA: Small interfering RNA  
SP: SP600125  
STAT-3: Signal transducer and activator of transcription 3  
TB: Tuberculosis  
TGF beta: Transforming growth factor beta  
TH1: T helper 1   
TIMPs: Tissue Inhibitor of Metalloproteinases  
TLR-2: Toll-like receptor 2  
TNFα: Tumour necrosis factor alpha  
TST: Tuberculin skin test  
TTP: Time to positivity  
VEGF: Vascular endothelial growth factor VEGF 
XDR-TB: Extensively drug resistant TB  
 
